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Abstract  
 
     BRCA1 germ-line mutations predispose to hereditary breast and ovarian 
cancers. Cells lacking functional BRCA1 protein are deficient in the 
homologous recombination (HR) DNA repair pathway. Base excision 
repair (BER) is essential for processing base damage induced by 
endogenous and exogenous sources. Recently, BRCA1 was shown to 
transcriptionally regulate expression of genes involved in BER such as 
OGG1, NTH1, APE1 and XRCC1. The primary aim of the work described 
in this thesis was to investigate whether targeting the double-strand break 
(DSB) pathway in BRCA1-BER deficient cells using ATM or DNA-PKcs 
inhibitors would be synthetically lethal.  
Firstly, DNA repair gene and protein expression in BRCA1 deficient and 
BRCA1 proficient cells were investigated. Initially the RT² Profiler DNA 
Repair PCR Array was used to investigate the expression of 84 DNA repair 
genes. Data demonstrated down-regulation of several DNA repair mRNAs 
in BRCA1 mutant/knockdown cell lines as compared to BRCA1 proficient 
cell lines. Quantitative real time PCR (RT-qPCR) was performed for 
selected DNA repair genes (APE1, XRCC1, SMUG1, Pol ß, Lig3, ATM and 
DNA-PKcs) and confirmed statistically significant down-regulation of 
these genes in BRCA1 mutant/knockdown cell lines as compared to 
BRCA1 wild type/control cell lines. Protein expression of APE1, XRCC1, 
SMUG1, Pol ß, Lig3, ATM and DNA-PKcs was assessed by western blot 
analysis and showed down-regulation consistent with the results of mRNA 
expression. These results suggest that BRCA1 deficiency may be 
associated with a global defect in the BER pathway. 
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Secondly, as BRCA1 deficient cells demonstrated evidence of BER 
deficiency, these cells may be amenable to a synthetic lethality approach 
by targeting additional DSB repair targets. To examine this, BRCA1 
deficient cells were targeted by ATM inhibitors (KU55933 and KU60019). 
Data demonstrated that BRCA1 mutant/knockdown cell lines were 
significantly more sensitive to ATM inhibition than BRCA1 proficient cell 
lines. Functional studies were conducted to understand the mechanism 
behind this selective cytotoxicity of ATM inhibitors in BRCA1 deficient 
cells. BRCA1 deficient cells treated with ATM inhibitors showed 
significant increase in DSB formation compared to untreated BRCA1 
deficient cells. Cell cycle progression was arrested significantly at G2/M 
phase in treated BRCA1 HeLa cells as compared to untreated BRCA1 
HeLa cells. On the other hand, MDA-MB-436 cells showed a modest 
increase in G2/M arrest after 48 hours treatment which suggests disturbed 
cell cycle progression. BRCA1 deficient cell lines also demonstrated 
increased levels for apoptosis in response to ATM inhibition. This in vitro 
study suggests that a potential synthetic lethality relationship exists 
between BRCA1 deficiency and ATM inhibition.  
In light of the observed BRCA1/ATM synthetic lethality relationship, 
BRCA1 deficient cells were targeted with DNA-PKcs inhibitors (NU7441 
and NU7026) to investigate whether these drugs would also induce 
synthetic lethality. Data demonstrated that BRCA1 mutant/knockdown cell 
lines were significantly more sensitive to DNA-PKcs inhibition than 
BRCA1 proficient cell lines. Functional studies showed that BRCA1 
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deficient cells treated with DNA-PKcs inhibitors have a significant 
increase in DSB formation as compared to untreated BRCA1 deficient 
cells. The formation of DSBs was followed by a modest arrest at G1 phase 
and induction of apoptosis. This in vitro study suggests that a potential 
synthetic lethality relationship exists between BRCA1 deficiency and 
DNA-PKcs inhibition. 
Finally, BRCA1 deficient cells were targeted by ATM or DNA-PKcs 
inhibitor in combination with cisplatin to investigate whether it would 
enhance the observed synthetic lethality. The results of both combination 
treatments induced hypersensitivity in BRCA1 deficient cells compared to 
BRCA1 deficient cells treated with cisplatin alone. Significant increase in 
DSB formation was observed in BRCA1 mutant/knockdown cells treated 
with the combination of ATM inhibitor/cisplatin or DNA-PKcs 
inhibitor/cisplatin compared to each inhibitor alone. Cell cycle analysis 
showed significant G2/M arrest and induction of apoptosis in BRCA1 
deficient cells treated with the combination treatments compared to each 
inhibitor alone. These results support the hypothesis that cisplatin increases 
the efficacy of ATM and DNA-PKcs inhibition in BRCA1 deficient cells. 
Taken together, this study provides the pre-clinical evidence that ATM and 
DNA-PKcs could be alternative synthetic lethality targets in BRCA1 
deficient breast cancer. 
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1. Introduction 
 
     Cancer is a class of complex diseases caused by genetic, epigenetic or 
translational changes that force the transformation of normal cells into 
malignant cells (Baylin and Jones, 2011). The major limitations of existing 
anticancer agents are that their efficacy is restricted by specificity, toxicity and 
the development of drug resistance. The search for new targeted, less toxic 
treatments and methods to improve the specificity and effectiveness of existing 
therapies is a major focus of cancer research. 
 
,QWKHHDUO\V3DXO(KUOLFK*HUPDQFKHPLVWGHILQHG³&KHPRWKHUDS\´DV
the use of chemicals to treat disease; he was also the first to use animal models 
successfully in screening a series of chemicals for their potential activity 
against diseases. Ehrlich's accomplishment remains the cornerstone in cancer 
drug development (DeVita and Chu, 2008). Since then cancer research has 
produced a complex and rich foundation of information which has revealed 
that cancer is a disease involving dynamic changes in the genome. To provide 
an overview of the complex biological data about cancer, researchers identify 
six essential features to transform normal cells into cancer cells. These features 
were referred to aV³+DOOPDUNVRIFDQFHU´E\+DQDKDQDQG:HLQEHUJ (shown 
in Figure 1.1), and include; sustaining growth signals, insensitivity to 
antigrowth signals, resisting cell death, limitless replicative potential, inducing 
angiogenesis, activating invasion and metastasis (Hanahan and Weinberg, 
2000).  
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Almost ten years after that and with an increasing body of research, Hanahan 
and Weinberg suggested two additional hallmarks and two enabling 
characteristics. The new emerging hallmarks are; deregulating cellular 
energetics and avoiding immune destruction, while tumor-promoting 
inflammation and genome instability and mutation are enabling characteristics 
(Hanahan and Weinberg, 2011).  
 
 
Figure 1.1. Therapeutic Targeting of the Hallmarks of Cancer. 
Each µFKDUDFWHULVWLF¶ FDQ EH WDUJHWHG ZLWK D FODVV RI GUXJ ZKLFK LV
either in clinical trials or in some cases approved for clinical use in 
treating certain forms of human cancer.  Adapted from (Hanahan and 
Weinberg, 2011). Copyright© 2011 by Elsevier with permission 
conveyed through Copyright Clearance Center Inc. 
 
 
Genomic instability and mutation are GHVFULEHGDV³(QDEOLQJ&KDUDFWHULVWLFV´
as cells develop new ways to use different DNA repair pathways and damage 
signalling to avoid cell death. One novel approach in the treatment of cancer is 
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to potentiate the effect of the chemotherapy drug in damaging the DNA by 
targeting DNA repair mechanisms responsible for repairing this damage. In 
other words, this field is interested in combining a DNA repair inhibitor with 
the right DNA damaging agent.   
  One such novel target is Poly (ADP-ribose) polymerase 1 (PARP1). PARP1 
is an enzyme that plays an essential role in single strand break repair (SSBR), a 
pathway that is related to the base excision repair (BER) pathway. Inhibition of 
SSBR pathway is associated with accumulation of SSBs; without repair the 
SSB would be converted to a double strand break (DSB) lesion during DNA 
replication (Dantzer et al., 2000, Hoeijmakers, 2001, Schreiber et al., 2006).  
In 2005, two Nature papers reported that cells deficient in the Breast Cancer 
Susceptibility genes BRCA1 and BRCA2 were 100 to 1000 fold more sensitive 
to PARP inhibition than BRCA heterozygote or wild type control cell lines 
(Bryant et al., 2005, Farmer et al., 2005). Both of these studies were reported 
independently by two groups using deficient models of BRCA1 and BRCA2 
with different PARP inhibitors, which provide evidence that this sensitivity in 
BRCA mutant cells was due to PARP inhibition. The hypothesis was that with 
the mutation in BRCA genes cells are defective in the Homologous 
Recombination (HR) pathway and targeting PARP will inactivate the SSBR 
SDWKZD\LQGXFLQJµ6\QWKHWLF/HWKDOLW\¶ 
µSynthetic Lethality¶ is the process by which cancer cells are selectively 
targeted by the inactivation of two or more genes or pathways that causes cell 
death, whereas inactivation in only one of them is not lethal (Kaelin, 2005, 
Ashworth, 2008). Since then several studies have been conducted to 
investigate this hypothesis. Now there is evidence that cells with defects in the 
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HR pathway, or where the BRCA gene is silenced by epigenetic changes, are 
sensitive to PARP inhibitors (Ashworth, 2008), widening the therapeutic 
potential for these agents.   
Chapter one of this thesis sets out to provide the background information on 
DNA damage and repair pathways in mammalian cells, where mechanism of 
both base excision repair (BER) and double strand break (DSB) repair will be 
studied in some detail. Following that the progress to date in the development 
of inhibitors for DSB repair, and the biological role of ATM and DNA-PKcs 
will be presented8QGHUVWDQGLQJWKHFRQFHSWRI³V\QWKHWLFOHWKDOLW\´EHWZHHQ
BRCA and PARP in the treatment of cancers defective in HR DNA repair will 
follow. Finally, alternative synthetic lethality targets will be investigated.  
1.1. DNA damage 
 
 
     DNA is under constant attack from various destructive agents including 
endogenous, as well as exogenous sources summarised in Figure 1.2. 
Endogenous damage may result from spontaneous base loss or various types of 
base modification (for instance; cytosine deamination, converting it to uracil) 
caused by exposure to metabolic products such as reactive oxygen species, or 
mispairing errors introduced during replication (Lindahl, 1993, Gates, 2009). 
Exogenous damage has many sources including; UV light, X-rays or gamma 
radiation, thermal disruption or chemical exposure. DNA damage types can be 
broadly subdivided into base damage and backbone damage (Hoeijmakers, 
2001).  
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1.1.1. Base damage 
 
Deamination 
Cytosine residues in DNA can undergo hydrolytic deamination converting 
them to uracil residues. Up to 500 deamination of cytosine events take place in 
human cells per day. Other deamination reactions include conversion of 
adenine to hypoxanthine, 5-methylcytosine to thymine and guanine to xanthine 
Figure 1.2. Sources causing DNA damage and corresponding repair 
pathway. 
Specific DNA damage is categorized by possible endogenous or exogenous 
sources and the corresponding DNA repair pathway for each type of 
damage. Adapted from (Hoeijmakers, 2001). Copyright© 2001 by Nature 
Publishing Group with permission conveyed through Copyright Clearance 
Center Inc.  
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(Lindahl, 1993). Hydrolysis of the glycosidic bonds holding a base to the DNA 
backbone is also common (Gates, 2009).  
 
Oxidation 
One of the causes of DNA base damage is exposure to reactive oxygen species 
generated during either normal cellular oxygen metabolism, from exposure to 
UV light or a wide range of other exogenous sources. A frequent oxidative 
lesion is 8-hydroxyguanine (8-oxoG); this mutagenic lesion shows preference 
to pair with adenine rather than cytosine during replication. This lesion is 
estimated to occur at a rate of up to 500 events per day, the same rate as 
cytosine deamination (Tudek et al., 2003, Gates, 2009).  
 
Alkylation  
Another source of DNA base damage is where an alkyl group attaches to the 
DNA base giving alkylation products such as O2-alkylthymine, O4- 
alkylthymine, O6-methylguanine and O6- ethylguanine. This binding may 
prevent DNA replication causing mutation or cell death. Alkylation can be 
generated by both endogenous sources (for instance; oxidative by-product or 
cellular methyl donors such as S-adenosylmethionine) and exogenous sources 
(fuel combustion, tobacco exposure or anticancer therapies e.g. cisplatin) 
(Engelbergs et al., 2000, Fu et al., 2012). 
 
1.1.2. Backbone damage 
     The DNA backbone is under constant exposure to environmental and 
endogenous agents that create thousands of lesions per cell each day (Lindahl, 
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1993). While some of these lesions like abasic sites or SSB are considered to 
be toxic, DSB are considered to be the most harmful. There are three major 
classes of DSB structures that can be toxic if not repaired.  
(1) Two-ended DNA double-strand break, created by direct fracture of a DNA 
duplex. (2) One-ended DNA double-strand break, created when a replication 
fork encounters a DNA single-strand break. (3) Daughter strand gap, created 
when lagging or leading strand progression is inhibited by a DNA lesion 
(Helleday et al., 2007). 
1.2. DNA repair  
 
 
     The accurate and efficient repair of DNA damage is essential for normal 
cellular function and maintenance of genomic stability (Figure 1.2) 
(Hoeijmakers, 2001). Genomic instability in cancer cells is often related to 
deficiency in one or more of the DNA repair pathways, which can account for 
the development of a more malignant phenotype (Hoeijmakers, 2009).  
Cells have two strategies to use for damage recognition and to initiate DNA 
damage responses. Direct recognition is the simplest form of repair (one step) 
where particular DNA damage can be repaired by cognate proteins (usually an 
enzyme). The second DNA damage response is multi-step recognition, where 
several proteins are involved and each one has a particular job to do, starting 
from recognition of the damage and ending with sealing the new DNA strand. 
DNA repair pathways can be divided into five categories; direct repair, base 
excision repair (BER), nucleotide excision repair (NER), mismatch repair 
(MMR) and double strand break repair (DSB) which includes, homologous 
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recombination (HR) and non homologous end joining (NHEJ) pathways 
(Sancar et al., 2004).  
 
1.2.1. DNA repair pathways 
 
1.2.1.1. Direct repair 
     Several mechanisms exist to directly reverse certain DNA damaging 
lesions, for instance direct reversal of the O6-methyl group from O6-
methylguanine (O6-MeGua) by Methylguanine DNA Methyltransferase 
(MGMT). MGMT is a small enzyme of 20 kDa which forms a low stable 
complex with the DNA backbone at the damage site. It was believed that the 
enzyme flips-out the O6-MeGua base and the methyl group is transferred to an 
active site cysteine. However, O6-MeGua if not repaired can cause errors by 
mispairing with thymine during replication, causing G:C to A:T transitions or a 
strand break (Lindahl et al., 1988, Sancar et al., 2004, Luo et al., 2010).   
 
1.2.1.2. Base excision repair 
 
     BER is a complex pathway responsible for accurate removal of DNA bases 
that have been damaged by alkylation or oxidation, along with a variety of 
other lesions including base deamination and single strand breaks that could 
otherwise cause mutations during replication. BER in mammalian cells 
consists of two major sub-pathways that differ from each other in the length of 
the region they repair and in the subsets of enzymes involved (Figure 1.3). The 
short patch repair (SP-BER) pathway replaces single nucleotides, whereas the 
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long patch repair (LP-BER) pathway replaces 2-10 nucleotides. Initiation of 
BER is thought to be by the DNA glycosylase family proteins, which remove 
the damaged base creating an abasic site (apurinic/apyrimidinic, AP site). 
Apurinic/apyrimidinic endonuclease 1 (APE1) then cleaves the phosphodiester 
ERQG¶WRWKH$3VLWHOHDYLQJDQLFNZLWK¶GHR[\ULERVH-5-SKRVSKDWH¶G53
and ¶-hydroxyl group ¶2+ The second step of BER is adding the first 
QXFOHRWLGH WR WKH ¶-end of the AP site DQG UHPRYLQJ WKH ¶ WHUPLQDO VXJDU
residue (by the process of E-elimination) by DNA polymerase E (Pol E). 
Normally, this reaction continues through the SP-BER sub-pathway where 
DNA Ligase 3 and X-ray repair cross complementing gene 1 (XRCC1) 
complex then complete the repair.  
2Q WKH RWKHU KDQG ZKHQ WKH ¶-end is resistant to E-elimination the repair 
process proceeds through the LP-BER sub-pathway. In this sub-pathway, 
replication factor C (RF-C) recruits proliferating cell nuclear antigen (PCNA) 
onto the AP site. PCNA acts as a DNA sliding clamp for the DNA polymerase 
G and H (Poly G/H) which performs DNA synthesis to remove WKH¶ WHUPLQDO
sugar residue as part of a flap. As an alternative, Pol E and Rad9-Rad1-Hus1 
complex (9-1-1) was found to have a similar structure as PCNA. The flap is 
then removed by flap endonuclease (FEN1) and DNA Ligase 1 completes LP-
BER sub-pathway by ligating the DNA ends (Fortini and Dogliotti, 2007, 
Hegde et al., 2008, Abbotts and Madhusudan, 2010, Balakrishnan et al., 2009).     
 
     Poly(ADP-ribose) polymerases (PARPs) have been suggested to be 
involved in the regulation of the BER process, by binding to the AP site until 
the appropriate enzyme becomes available to process the repair (Khodyreva et 
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al., 2010, Yelamos et al., 2011). Once PARP1 is activated it catalyses the 
successive transfer of ADP-ribose units from the substrate nicotinamide 
adenine dinucleotide (NAD+) to a variety of acceptor nuclear proteins. This 
automodification attracts other DNA damage repair enzymes to the site such 
as, Pol ß, Ligase 3 and XRCC1 (Schreiber et al., 2006, Megnin-Chanet et al., 
2010). However, PARP1 does not play a major role in catalysis of DNA 
damage processing via either base excision repair pathway (Allinson et al., 
2003, Strom et al., 2011).     
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Figure 1.3. Base Excision Repair (BER) pathway.  
A damaged base is removed by a DNA glycosylase to generate an AP site. The repair 
patch may be a single nucleotide repair short patch (SP-BER) or a 2±10 nucleotide 
long patch (LP-BER). When the base damage is removed by one of the glycosylase 
family, APE1 (apurinic/apyrimidinic endonuclease 1) cleaves the 5¶ bond to the site 
and recruits DNA polymerase (Pol ȕ-į-İ) to fill in the gap that is ligated by Ligase 3 
(Lig3) /XRCC1 (X-ray cross-complementing protein 1) complex. When the AP site is 
generated by hydrolytic glycosylases, or by spontaneous hydrolysis, repair usually 
proceeds through the LP-BER sub-pathway. APE1 cleaves the 5¶ phosphodiester 
bond, and the RF-C/PCNA-Poly complex carries out repair synthesis and nick 
translation, displacing several nucleotides. The flap structure is cleaved off by FEN1 
(flap endonuclease) and the LP-BER is ligated by Ligase 1. PARP1/ poly(ADP-ribose) 
polymerase 1; PCNA/ proliferating cell nuclear antigen; OH/ hydroxyl group; dRP/ 
deoxyribose phosphate. Adapted from (Abbotts and Madhusudan, 2010).   
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1.2.1.3. Nucleotide excision repair 
 
     Nucleotide excision repair (NER) recognises and repairs base lesions 
associated with DNA helical distortion, including these produced by UV light 
or platinum chemotherapy. More than 25 proteins/complexes have been 
identified in eukaryotic cells which are required to complete NER. This 
pathway can be divided into two main sub pathways; global genome repair 
(GGR) and transcription-coupled repair (TCR), depending on the complexes 
that initiate repair. TCR removes lesions from the transcribed DNA strand of 
transcriptionally active genes when encountered by RNA polymerase II, 
restoring transcriptional activity and preventing apoptosis. GGR performs this 
process with poor efficiency, instead removing lesions on non-transcribed 
strands and transcriptionally inert genes to avoid replication fork stalling and 
chromosomal breakages. The key event in this pathway is incision of the 
damaged strand from each side of a lesion, releasing up to 32 nucleotides of 
the damaged DNA strand (Wood, 1997, Sugasawa, 2010).  
The clinical consequences of defective NER are demonstrated by three 
syndromes associated with defects of NER proteins; xeroderma pigmentosum 
(XP), cockayne syndrome (CS) and the photosensitive form of 
trichothiodystrophy (TTD). Individuals with inherited XP syndrome exhibit 
severe sun-sensitivity, freckling and a 1000-fold increase in skin cancer 
including squamous and basal cell cancers as well as melanomas. Mutations in 
XP genes (XPA, XPB, XPC, XPD, XPE, XPF or XPG) can be identified in 
these patients. 20% of all XP patients, those with more than one mutation in 
XP genes, exhibit neurological abnormalities in addition to their XP 
symptoms. These symptoms include deafness, speach and walking disability 
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because of primary neuronal degradation. CS patients with mutation in CSA 
and CSB genes may exhibit sun-sensitivity and skin cancer though less than 
XP patients. CS symptoms include growth retardation, cachexia, neurological 
and mental developmental delays, cataracts, retinopathy, deafness, dental 
caries, and characteristic facies with a thin face, flat cheeks, and prominent 
tapering nose. TTD patients with mutations in TTD-A, XPB and XPD genes 
also show sun-sensitivity though no increased skin cancer risk. TTD symptoms 
are erythema, ichthyosis-like skin changes, nail and other neuroectodermal 
dysplasias, and short, brittle sulphur-deficient hair (Robbins et al., 1991, 
Thoms et al., 2007, Kraemer et al., 2007).   
1.2.1.4. Mismatch repair 
 
     Mismatch repair (MMR) is the main pathway that recognises and repairs 
lesions/errors introduced during DNA replication. This pathway is initiated 
when a complex of MSH2 and MSH6 recognizes the mismatch. A range of 
combinations of MSH2 and either MSH6 or MSH3 are formed, which specify 
the type of mismatch recognized. After that, MSH proteins recruit MLH1 and 
its binding partners, post±meiotic-segregation increased 1 (PMS1) protein and 
post±meiotic-segregation increased 2 (PMS2) protein. An exonuclease 
removes the DNA lesion, a DNA polymerase synthesizes a new strand, and 
finally, a DNA Ligase completes the repair. A defect in MMR brings on a 
mutator phenotype, which causes a predisposition to cancer. MMR status also 
affects meiotic and mitotic recombination, DNA damage signalling and 
apoptosis (Jiricny, 2006, Li, 2008, Modrich and Lahue, 1996).  
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MMR deficiency is associated with three diseases, Hereditary Nonpolyposis 
Colorectal Cancer (HNPCC) syndrome, Muir ± Torre syndrome, and Turcot 
syndrome. HNPCC patients often develop colon cancer and other visceral 
tumours such as endometrial, ovarian, stomach, kidney, and small intestinal 
cancers. In 80% of all HNPCC patients mutations in the hMLH1, hMSH2, 
hMSH6, and hPMS2 MMR genes can be identified. Muir ± Torre syndrome 
patients present with sebaceous carcinomas, colon cancer, and other visceral 
tumours such as endometrial, ovarian, stomach, kidney, and small intestinal 
cancers. Mutations in hMSH1 and hMSH2 genes can be identified in these 
patients. Turcot syndrome is caused by mutations in hMSH1 and hPMS2 
genes. Turcot syndrome is associated with gliomas, lymphomas, colon cancer 
and other visceral tumours such as endometrial, ovarian, stomach, kidney, and 
small intestinal cancers (Peltomaki, 2003, Chung and Rustgi, 2003, Thoms et 
al., 2007).  
1.2.1.5. Double strand break repair 
 
     DNA double strand breaks (DSBs) are the most lethal class of damage in 
DNA. DSBs, if left unrepaired or inappropriately repaired, can lead to cell 
death or to a variety of genetic mutations, translocations and chromosome loss 
(Hoeijmakers, 2001). This kind of lesion could be generated directly, 
following exposure to ionizing radiation, or indirectly during the processing of 
other DNA adducts or at stalled replication forks. DSB damage is repaired by 
one of the DSB repair sub-pathways illustrated in Figure 1.4, homologous 
recombination (HR) which is error-free or Non-homologous end joining 
(NHEJ) which is error-prone. The balance between these two sub pathways 
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differs between cell types of a single species and also differs between different 
cell cycle phases within a single cell type (O'Driscoll and Jeggo, 2006, 
Brandsma and Gent, 2012). In addition to classical HR and NHEJ there is an 
alternative DSB repair pathway: 
Single Strand Annealing (SSA) pathway is activated when HR or NHEJ 
pathways cannot complete the repair. After resection of the break 
complementary stretches in the single strand DNA anneal, followed by the 
deletion of the intervening sequence and one of the repeat sequences. Some 
researchers categorize this pathway as an alternative for HR and others for 
NHEJ (Ivanov et al., 1996, Gottlich et al., 1998, Stark et al., 2004, Brandsma 
and Gent, 2012).  
Microhomology-mediated end joining (MMEJ) is a subset of Alternative Non-
homologous end joining (A-NHEJ). Repair by this pathway starts by resection 
RIWKH¶± ¶E\051FRPSOH[and then RPA binds to the DNA strand ends 
for protection. Where microhomologous regions are uncovered the DNA 
overhangs anneal, followed by DNA polymerase filling the gap and DNA 
Ligase sealing the strand. MMEJ is always associated with DNA deletions 
(McVey and Lee, 2008).      
Alternative Non-homologous end joining (A-NHEJ) is an error prone pathway 
considered as a major source of genetic instability. Like SSA, A-NHEJ is 
thought to be activated when HR or NHEJ pathways cannot complete the 
repair. This pathway is not fully understood yet, however several proteins have 
been found to play a role in A-NHEJ including; PARP1, MRN complex, 
Ligase 3, Ligase 1 and XRCC1 (Brandsma and Gent, 2012, Dueva and Iliakis, 
2013).     
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Figure 1.4. Double Strand Break (DSB) repair pathway.  
Homologous recombination (HR): (I) Following DSB, MRN complex and Rad51 
localises to DSB via BRCA2. (II) Rad51 and related proteins assemble the pre-
synaptic filament. (III) Rad51 and Rad54 identify homologous sequence of DNA 
and facilitate invasion into break site and new sequence of DNA is synthesised. (IV) 
Exchanged ends, (Holliday junctions), are rejoined by resolvases. Non-Homologous 
end joining (NHEJ): (V) Heterodimer of Ku70/Ku80 binds to exposed DNA 
initiating NHEJ. (VI) The active protein kinase DNA-PK complex (Ku70/Ku80 + 
DNA-PKcs) brings the ends of DSB for processing prior to religation. (VII) MRN 
complex, FEN1 and Artemis remove excess DNA ends. New DNA is synthesised by 
a DNA polymerase and ligation occurs via XRCC4 and DNA Ligase 4. DSB = 
double strand break, MRN = Mre11-Rad50-NBS1, XRCC2/3/4 = X-ray cross 
complementation group 2/3/4, V(D)J = Variable, diversity and joining, BRCA1/2 = 
breast cancer susceptibility 1/2. Adapted from (Hoeijmakers, 2001), Copyright© 
2001 by Nature Publishing Group with permission conveyed through Copyright 
Clearance Center Inc.  
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1.2.1.5.1. Homologous recombination 
 
     Homologous recombination (HR) pathway provides an error free repair of 
DSB. HR pathway takes place during late S phase and G2/M phase when 
homologous chromatids are available. HR involves multiple steps as presented 
in Figure 1.4, recognition of the DSB damage by the ataxia telangiectasia 
mutated (ATM) is the first sensor of DSB. ATM in turn activates multiple 
genes involved in HR repair, cell cycle arrest and apoptosis. Substrates for 
ATM phosphorylation include; BRCA1, p53, CHK2, histone H2AX and MRN 
complex (MRE11/RAD50/NBS1). The MRN complex then resects the DNA 
VWUDQG¶ WR¶ JHQHUDWLQJ¶ends of single stranded DNA (ssDNA) on either 
side of the DSB (Bakkenist and Kastan, 2004). The resulting SSB ends are 
then coated by Replication Protein A (RPA) protein which in turn recruits 
other proteins (including; Rad17/Rfc2-5, Rad9/Hus1/Rad1 and ATR/ATRIP) 
which form foci at the damaged site. RAD52 proteins then replace RPA 
proteins forming a ring to protect the SSB from exonucleolytic digestion.  
At this stage RAD52 competes with the KU complex of the NHEJ pathway 
and may determine sub-pathway selection between HR and NHEJ. RPA 
displacement is accomplished through the action of two proteins, BRCA1 and 
BRCA2. RAD51 and its related proteins (RAD51B, RAD51C, RAD51D, 
RAD54, XRCC2 and XRCC3) along with RPA, stimulate the activity of DNA 
strand exchange, with the complementary strand forming a heteroduplex while 
unpaired recipient DNA forms a D-loop. Conversely BRCA2 binds to RAD51, 
this complex binds to the exposed SSB and enables the loading of RAD51 to 
the SSB. Then DNA polymerases synthesize a new strand. The final step of the 
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HR repair is the sealing of the strands by DNA Ligase (Takata et al., 1998, 
Christmann et al., 2003, Li and Heyer, 2008).  
 
1.2.1.5.2. Non-homologous end joining   
 
     The Non-homologous end joining (NHEJ) pathway is more commonly used 
for DSB repair by mammalian cells (Figure 1.4). NHEJ functions in all phases 
of cell cycle, especially in the G1 phase. It is an error-prone pathway as it does 
not rely on sister chromatids (homologous template) for repair. This results in 
short deletions or insertion of incorrect base pairs. After DSB induction, the 
first step towards repair through NHEJ is the binding of a heterodimeric 
complex consisting of the proteins KU70 and KU80 to the DNA damaged ends 
forming a ring shaped structure to protect the DNA from exonuclease 
digestion. Following DNA binding, the KU heterodimer recruits the catalytic 
subunit of the DNA dependent protein kinase (DNA-PKcs) thereby forming 
the active DNA-PK complex. DNA-PKcs is activated by interaction with a 
ssDNA at the site of DSB. In the following step, DNA-PKcs recruits XRCC4 
which forms a stable complex with Ligase 4. The XRCC4/Ligase 4 complex 
binds to the ends of DNA molecules and brings both ends together with 
complementary but non- ligatable ends. This complex cannot directly re-ligate 
most of the DSBs before both ends are processed. Processing of DSBs is 
performed by the MRN complex, which has the role of removing the excess of 
'6%VWUDQGVDWWKH¶IOaps. While flap endonuclease 1 (FEN1) is responsible 
for UHPRYDO RI WKH ¶ RYHUKDQJV Another protein involved in processing 
overhangs is the protein Artemis, which acts in a complex with DNA-PK. 
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Artemis acquires endonuclease activity, degrading single-strand overhangs and 
KDLUSLQV ZKLFK VHHPV WR EH QHFHVVDU\ IRU SURFHVVLQJ ¶ DQG ¶ RYHUKDQJV
during NHEJ. This pathway is sometimes associated with gain or loss of a few 
nucleotides if internal microhomologies are used for annealing before sealing. 
This implies the involvement of DNA polymerases or Artemis to create 
compatible ends. Finally, ligation is achieved by the actions of XRCC4/Ligase 
4 complex (Takata et al., 1998, Christmann et al., 2003, Burma et al., 2006, 
Khanna and Jackson, 2001). 
1.3. Ataxia telangiectasia mutated (ATM) 
 
     The Ataxia Telangiectasia Mutated (ATM) gene product was identified in 
1995, based on its role in a rare, inherited disorder Ataxia Telangiectasia. The 
gene responsible for this disorder was mapped to chromosome 11q22-23. 
ATM protein is around 370 kDa and contains about 3056 amino acid residues. 
The 400 amino acids residues of its C-terminal region highly matched to the 
catalytic subunit of phosphatidylinositol-3 kinases (PI-3 kinases) (Savitsky et 
al., 1995, Rotman and Shiloh, 1998).  
The catalytic site of ATM is within the C-terminal PI-3 domain, although it is 
believed that the rest of this large protein is responsible for receiving signals 
(working as a DNA damaging sensor) to regulate downstream targets. Several 
proteins interact with ATM including CHK2 and p53 (Rotman and Shiloh, 
1998).    
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1.3.1. Role of ATM in the cellular response 
 
     ATM is a nuclear protein, the levels of which do not change when cells are 
exposed to ionizing radiation (IR). However, the protein kinase activity of 
ATM increases 2 to 3 fold following cellular exposure to IR, as determined by 
immunoprecipitation kinase assays (Canman et al., 1998, Banin et al., 1998, 
Chan et al., 1998). Bakkenist et al demonstrated that ATM containing a serine 
to alanine mutation at amino acid 1981 failed to support IR-induced 
phosphorylation of p53 or cell cycle arrest, suggesting that serine 1981 
phosphorylation is critical for the function of ATM. Moreover, serine 1981-
phosphorylated ATM localizes to nuclear foci in response to DNA damage 
(Bakkenist and Kastan, 2003).  
The ATM signalling pathway is activated following DSBs. ATM is recruited 
to the damaged sites, however it is not clear if ATM interacts with damaged 
DNA directly or indirectly.  
It was previously thought that ATM activation primarily requires direct 
binding to MRN complex. However recent studies has shown that PARP1 may 
control ATM phosphorylation and mediates the earliest recruitment of MRE11 
and NBS1 to DNA damage (Rupnik et al., 2008, Haince et al., 2008, Haince et 
al., 2007).  
 
Once ATM is activated, it may be released from the site of the DSB, enabling 
phosphorylation of several downstream substrates, such as chromatin bound 
histone H2AX and BRCA1 which lead to a variety of effects on DNA repair, 
cell cycle and apoptosis (Kurz and Lees-Miller, 2004). H2AX gets 
phosphorylated immediately after DNA damage by ATM on its C-terminal 
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serine residue 139 and is UHIHUUHG WRDV Ȗ+$;IRUPLQJIRFLZKLFKFDQEH
observed by using immunofluorescence (Rogakou et al., 1999). In 2001 Burma 
et al showed that once ATM is activated at a DSB, it immediately activates 
Ȗ+$; DW WKH GDPDJHG VLWH 7KLV YHU\ HDUO\ HYHQW FRXOG WKHQ LQLWLDWH WKH
recruitment of several DNA repair proteins (Burma et al., 2001). In terms of its 
role in cell cycle regulation, ATM interacts with a number of downstream 
substrates including proteins that activate the G1 (p53 and Nbs1), S (CHK2, 
BRCA1 and MRN) or G2/M (CHK1, CHK2 and Rad17) checkpoints. 
Activation of ATM-dependent cell cycle checkpoints would be expected to 
allow DNA repair, thereby enabling cells to survive. Studies proposed that 
considerable cross-talk exists between different ATM substrates and that 
several of them act in more than one cellular processes (Kurz and Lees-Miller, 
2004).  
 
Since ATM functions at the centre of a signalling network that controls 
different cellular responses, modulation of ATM function has become an area 
of interest for the treatment of cancer. Studies illustrated that ATM signalling 
pathways can be targeted in several ways to treat cancer. For instance, 
inhibition of ATM by the small molecule inhibitor (KU55933) increases the 
cytotoxicity of chemotherapeutic agents and IR in breast, colon and lung 
carcinoma cell lines (Crescenzi et al., 2008). Similarly, targeting p53 mutated 
cancer cells by inhibiting ATM increases cytotoxicity compared with 
proficient p53 cell lines (Smith et al., 2010).  
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1.4. DNA dependent protein kinase catalytic subunit (DNA-
PKcs) 
 
     The DNA-dependent protein kinase (DNA-PK) holoenzyme consists of two 
subunits: the first component is the heterodimer complex KU, comprising of 
two enzymes KU70 (approximately 70 kDa) and KU80 (80 kDa). The second 
component of DNA-PK is a large polypeptide that corresponds to DNA-PK 
catalytic subunit (DNA-PKcs) (Hartley et al., 1995). The DNA-PKcs gene was 
mapped to chromosome 8q11 (Connelly et al., 1998). DNA-PKcs protein is 
around 460 kDa with approximately 3500 amino acid residues. The carboxy-
terminal end of DNA-PKcs consists of 380 amino acid residues that fall into 
the phosphatidylinositol-3 kinase (PI-3 kinase) superfamily (Poltoratsky et al., 
1995, Hartley et al., 1995, Kurimasa et al., 1999). 
 
1.4.1. Role of DNA-PKcs in the cellular response 
 
     DNA-PKcs is a nuclear protein and recruitment to the DSB results in 
translocation of the heterodimer KU inward on the dsDNA allowing DNA-
PKcs to directly interact with DSB ends (Yoo and Dynan, 1999, Calsou et al., 
1999). DNA-PKcs was found to have unlimited kinase activity in the absence 
of KU heterodimer and DNA DSBs (Hammarsten and Chu, 1998, West et al., 
1998). The kinase activity of DNA-PKcs is essential for NHEJ and the DNA 
damage response. DNA-PKcs can phosphorylate several nuclear proteins 
including KU heterodimer (Chan et al., 1999), XRCC4 (Leber et al., 1998), 
Ligase 4 (Wang et al., 2004), Artemis (Weterings and Chen, 2008), H2AX 
(Stiff et al., 2004) and p53 (Shieh et al., 1997). Recently it was found that 
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DNA-PKcs phosphorylates NHEJ Werner syndrome protein (WRN) that is 
required for efficient DSB repair (Kusumoto-Matsuo et al., 2014).       
 
Following induction of a DSB, DNA-PKcs is phosphorylated at more than 40 
sites. The best characterized DNA-PKcs phosphorylation cluster is the 
threonine 2609. Phosphorylation of threonine 2609 cluster is important for 
NHEJ. Recently Zhang et al demonstrated that knock-in mutant mice with 
human DNA-PKcs lacking a functional threonine 2609 are highly sensitive to 
replication stress agents which confer early lethality. In addition, the threonine 
2609 phosphorylation cluster has been found to associate with other DNA 
repair proteins. For example, DNA-PKcs phosphorylation at the threonine 
2609 is important for the coordination between ATM and Artemis in DNA 
DSB repair (Zhang et al., 2011, Davis et al., 2014a).  
 
Regarding DNA-PKcs phosphorylations role in DNA repair, it is proposed that 
DNA-PK holoenzyme functions as a scaffolding protein to bring the broken 
DNA ends together and assists in the localisation of repair factors (Davis et al., 
2014a). Moreover, DNA-PKcs phosphorylation has a role in regulation of cell 
cycle arrest in response to DSB. Chen et al.¶V illustrated that DNA-PKcs 
functions primarily in the G1 phase (Chen et al., 2005). Conversely, DNA-
PKcs plays a direct role in the suppression of apoptosis. Le Romancer et al 
demonstrated that cleavage and inactivation of DNA-PK during apoptosis is 
expected to switch off the function of kinase in DNA repair. In mammalian 
cells, loss of DNA-PK due to mutations increases sensitivity to treatments that 
induce DSBs (Le Romancer et al., 1996).   
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1.5. The development of ATM and DNA-PKcs inhibitors 
 
     To date, several DSB repair inhibitors have been described. Wortmannin 
is a non-specific inhibitor of PI-3 kinase. It is known to block ATM as well as 
DNA-PKcs (Rosenzweig et al., 1997). In 2004, the first small molecule to 
target ATM kinase KU55933 (2-morpholin-4-yl-6- thianthren-1-yl-pyran-4-
one) was developed. KU55933 potentiates the cytotoxicity of IR and 
chemotherapeutic agents in cell lines (Hickson et al., 2004). In 2008 
CP466722, a specific inhibitor of ATM [2-(6, 7-dimethoxyquinazolin-4-yl)-5-
(pyridin- 2-yl)-2H-1, 2, 4-triazol-3-amine], was identified. CP466722 inhibited 
ATM dependent phosphorylation events and resulted in G2/M cell cycle arrest. 
CP466722 shows similarity to KU55933 inhibitor in rapidly and potently 
inhibiting ATM over a period of several hours and demonstrates reasonable 
stability in tissue culture (Rainey et al., 2008). In 2009, KU60019 (2-[(2R, 
6S)-2, 6-dimethylmorpholin- 4-yl]-N-[5-(6-morpholin-4-yl-4-oxo-4H-pyran-2-
yl)-9H-thioxanthen-2-yl]-acetamide), another specific inhibitor of ATM kinase 
was developed. KU60019 is an improved analogue of KU55933, and has been 
shown to be around 10 times more potent than KU55933 at radiosensitizing 
human glioma cells (Golding et al., 2009).  
 
     After initial use of Wortmannin for DNA-PKcs inhibition, LY294002 (2-
(4-morpholinyl)-8-phenylchromone) was developed. LY294002 is non-specific 
DNA-PKcs inhibitor and more toxic than Wortmannin (Vlahos et al., 1994, 
Davidson et al., 2013). A number of inhibitors have been generated using 
LY294002 as a template. NU7026 (2- (morpholin-4-yl)-benzo [h]chomen-4-
one), is over 50 fold more selective for DNA-PKcs than to other PI-3Ks 
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including ATM and ATR. NU7026 alone had no effect on cell cycle 
distribution although it increases DSB levels (Willmore et al., 2004). NU7441 
inhibitor (2-N-morpholino-8-dibenzothiophenyl-chromen-4-one) is more 
potent and specific to DNA-PKcs, (IC50 of only 14 nmol/L) and has at least 
100 fold selectivity for DNA-PKcs compared with other PI-3K family kinases. 
NU7441 inhibitor has proved to be not only a potent chemo- and radio-
sensitiser but also a powerful tool to study the biology of DNA-PKcs (Leahy et 
al., 2004, Zhao et al., 2006, Tavecchio et al., 2012, Davidson et al., 2013).  
 
1.6. Breast Cancer  
 
     Every day, thousands of women around the world are diagnosed with 
breast cancer. In 2008 almost 1.4 million women were diagnosed with breast 
cancer worldwide and around 459,000 deaths were recorded. Incidence rates 
were much higher in more developed countries with 71.7 per 100,000 
compared to 29.3 per 100,000 in less developed countries, whereas the 
corresponding mortality rates were 17.1 per 100,000 and 11.8 per 100,000 
respectively. The highest incidence rates were recorded in Western Europe, 
Australia/New Zealand and Northern Europe, whilst rates were lowest in 
Eastern Africa and Middle Africa (Youlden et al., 2012). There is a 0.5% 
overall increase in incidence annually. However, observed improvements in 
breast cancer survival especially in developed countries over recent decades 
have been attributed to the introduction of population-based screening using 
mammography, improved education and the systemic use of adjuvant therapies 
(Rosso et al., 2010, Gunsoy et al., 2014).  
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There are a number of factors that contribute to an increase risk of breast 
cancer, such as:  
(1) Age, about 2 out of 3 invasive breast cancers are found in women over the 
age of 50. (2) Diet, there is an increase in breast cancer risk by 13% with the 
higher level of fat intake. (3) Tobacco exposure in all its forms (smoking, and 
including second-hand smoke). (4) Alcohol consumption, alcohol has been 
described as being one of the most constant enhancers of breast cancer risk. (5) 
Body size, obesity if associated with an increased risk of breast cancer 
(Youlden et al., 2012, McCormack and Boffetta, 2011, Gunsoy et al., 2014). 
(6) Family history, having a first degree relative with breast cancer can 
LQFUHDVHDZRPDQ¶VULVNE\WZRIROG. This risk is greater if the relative has been 
diagnosed before the age of 50 (Pharoah et al., 1997). Family history accounts 
for 5-10% of the total number of cases of breast cancer and often involves 
germline mutations in breast cancer susceptibility genes such as BRCA1 and 
BRCA2, or others like p53, PTEN, ATM, CHK2 and RAD51 (Lose et al., 2006, 
Flanagan et al., 2010). 
 
     A wide variety of clinical and pathological factors are regularly used to 
categorize breast cancer patients in order to assess prognosis and determine the 
appropriate therapy. These factors include;  
(1) Age at diagnosis, women under the age of 40 often have a more aggressive 
cancer with higher mortality and recurrence rates in comparison with older 
women. Younger patients are more likely to have poor clinical characteristics, 
e.g. larger tumour size and higher histological grade, lymphatic vessel invasion 
and the involvement of lymph nodes. This is why this group is classified as 
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high risk and approximately 80% of these patients are offered adjuvant 
cytotoxic treatment (Kroman et al., 2000, van der Sangen et al., 2008, Schnitt, 
2010). (2) Tumour size, it has been established that the rate of distant 
recurrence increases in patients with large tumours as opposed to smaller 
tumours (Koscielny et al., 2009). However, tumour size alone is an unreliable 
prognostic factor in breast cancer (Foulkes et al., 2009). (3) Lymph node 
status, it is thought to be the second most prominent factor in gauging the 
probability of survival, after tumour size (Vorgias et al., 2001). (4) Hormone 
receptor expression, estrogen receptors (ER) and progesterone receptors (PR) 
located within the cell nucleus have prognostic value in breast cancer patients 
(Fisher et al., 1986, Garicochea et al., 2009). The prognostic and predictive 
importance of assessment of ER expression in breast cancer is well 
established; e.g. patients with ER-positive tumours have more favourable 
prognostic characteristics than patients with ER-negative tumours which 
relapse earlier. Patients with ER positive breast cancer will usually receive 
hormonal therapy; however the added value of PR assessment is controversial. 
PR status in ER- positive breast cancer might be used to help guide clinical 
management, as high levels of PR expression may identify a subset of ER- 
positive patients most likely to benefit from hormonal therapy (Hefti et al., 
2013). (5) Histological type, the histological type of invasive breast cancer 
presents valuable prognostic information. A few histologic types of invasive 
carcinoma have better prognostic value than others. Ductal carcinoma of no 
special type, accounting for up to 70% of all breast cancers, has the worst 
prognosis, whereas tubular breast cancer demonstrates the best prognosis 
(Martinez and Azzopardi, 1979, Fisher et al., 1975, Ellis et al., 1992, Rakha et 
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al., 2010). (6) Molecular classification, gene expression profiling has been 
used to define breast cancer subtypes based on the molecular characteristics 
and its association with clinical outcome. This classification groups tumours 
into five molecular subtypes; (a) Luminal A (breast cancer with the highest 
expression of ER receptor and expression of keratin 18 and 19 in luminal 
mammary cells, this class is the most common subtype, representing 50±60% 
of the total). (b) Luminal B (similar to luminal A but has moderate expression 
of ER receptor, luminal B molecular profile makes up between 10- 20% of all 
breast cancers). (c) Basal like (ER- negative and high expression of cytokeratin 
5, cytokeratin 17, the basal-like subtype represents 10±20% of all breast 
carcinomas). (d) Normal breast-like (expression of genes known to be 
expressed in normal mammary tissue, account for about 5±10% of all breast 
carcinomas). (e) HER2 positive (high expression of the HER2 gene and other 
genes associated with the HER2 pathway and/or HER2 amplicon located in the 
17q12 chromosome, 15-20% of all breast cancers correspond to this molecular 
subtype) (West et al., 2001, Eroles et al., 2012). 
 
1.7. The BRCA1 tumour suppressor gene 
 
     The Breast Cancer susceptibility 1 (BRCA1) gene was identified by Mary 
.LQJ¶V JURXS LQ  WKLV JHQH ZDV mapped to chromosome 17q21 then 
cloned by Mark Skolnick's group in 1994. BRCA1 gene contains 24 exons, 22 
coding exons and 2 non-coding exons. The identification of BRCA1 gene was a 
significant breakthrough in the management of breast and ovarian cancers 
(Hall et al., 1990, Miki et al., 1994). 
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BRCA1 protein is around 220 kDa and is a highly phosphorylated nuclear 
protein. BRCA1 contains nuclear import and export signals, allowing 
movement between the nucleus and cytoplasm to enable BRCA1 to perform its 
functions. BRCA1 contains about 1863 amino acid residues (Figure 1.5) 
including an N-terminal RING domain, two nuclear localization signals 
(NLSs), and two C-terminal BRCA1 Carboxyl Terminal (BRCT) domains of 
around 110 amino acid residues (Miki et al., 1994, Venkitaraman, 2002, Silver 
and Livingston, 2012). These domains interact with several proteins and 
contribute to multiple functions of BRCA1, including in DNA damage 
response and repair, cell cycle regulation, and transcriptional regulation.     
 
 
Figure 1.5. The Structure Domain of BRCA1. 
Two domains of BRCA1 that are frequently mutated in families with 
hereditary breast and ovarian cancer are the N-terminal RING domain and the 
C-terminal BRCT repeats. Both could contribute to tumour suppressing 
functions of BRCA1. NLS = nuclear localisation signal, BRCT = BRCA1 
carboxyl terminal. Adapted from (Silver and Livingston, 2012). Copyright© 
2012 by American Association for Cancer Research with permission 
conveyed through Copyright Clearance Center Inc.  
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1.7.1. Role of BRCA1 in DNA damage response and 
repair 
 
     One of the first links between BRCA1 and DNA repair was the functional 
interaction between BRCA1 and RAD51 suggesting a role for BRCA1 in 
genomic instability (Scully et al., 1997). Since then many studies have shown 
that BRCA1 plays a vital role in the HR pathway (Moynahan et al., 1999). In 
addition BRCA1 is also involved in the initial detection of DNA damage. 
Moreover, BRCA1 has roles in other DNA repair pathways such as: 
(1) NER: BRCA1 has shown direct control of global genomic repair (GGR) a 
sub-pathway of NER pathway through XPC, DDB2 and GADD45 genes, 
suggesting that deficiency in BRCA1 is followed by deficiency in GGR/NER 
(Hartman and Ford, 2002).  
(2) NHEJ: the role of BRCA1 in the NHEJ pathway is uncertain, although 
several studies suggest a major role of BRCA1 in NHEJ and the maintenance 
of genomic integrity (Zhong et al., 2002, Bau et al., 2004), while others did not 
(Moynahan et al., 1999, Merel et al., 2002).  
(3) BRCA1 has been suggested to stimulate the activity of three BER 
enzymes; OGG1 (8-oxoguanine DNA glycosylase), NTH1 (homolog of 
endonuclease III), and APE1. These enzymes mediate repair of three signature 
oxidative lesions, 8-oxoguanine, thymine glycol and abasic sites, respectively. 
BRCA1 regulation of BER enzymes was found to be through a transcriptional 
mechanism involving the transcription factor OCT1 (Octamer-binding 
transcription factor 1). The exact mechanism by which the BRCA1/OCT1 
complex regulates the BER pathway, and whether or not there is a 
physiologically important defect in BER that can be therapeutically targeted in 
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BRCA1 deficient cells, remains to be answered (Saha et al., 2010). A previous 
study has shown that BRCA1 in collaboration with APE1 down regulates 
levels of reactive oxygen species, oxidized DNA and nitrated proteins (Saha et 
al., 2009).   
1.7.2. Role of BRCA1 in cell cycle regulation 
 
     BRCA1 is involved in cell cycle regulation, a function that may allow 
adequate time for DNA repair to occur in cells. The phosphorylation of 
BRCA1 is required to activate cell cycle arrest after DNA damage. For 
instance, in response to ionizing irradiation, ATM phosphorylates BRCA1 on 
serine 1387 which is required to activate S phase arrest. On the other hand, 
BRCA1 phosphorylation on serine 1423 has a direct role in G2/M cell cycle 
arrest (Xu et al., 2002). Cell cycle regulation is controlled by a family of cyclin 
dependent kinases and their endogenous inhibitors acting at a variety of cell 
cycle checkpoints. For example, BRCA1 phosphorylation has been shown, 
through p53 dependent and independent pathways, to stimulate the 
transcription of the p21CIP1/WAF1 leading to G1/S cycle arrest (Chai et al., 1999, 
Mullan et al., 2006). BRCA1 participates in the G1/S checkpoint response 
indirectly through CHK2 and p53 phosphorylation (Foray et al., 2003). 
Recently, DNA-PKcs was shown to activate the CHK2±BRCA1 pathway 
during mitosis to ensure chromosomal stability (Shang et al., 2014).  
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1.7.3. Role of BRCA1 in transcriptional regulation 
 
     BRCA1 may regulate transcription by interacting with a core component of 
transcription RNA called polymerase II, BRCA1 is also a co-activator or co-
repressor of a number of known transcription factors (Irminger-Finger et al., 
1999). For example, BRCA1 has been reported to regulate the oestrogen 
receptor alpha ((5Į). The DELOLW\RI %5&$ WR LQGXFHH[SUHVVLRQRI(5Į is 
dependent on the transcription factor OCT1, which is required to recruit 
%5&$ WR WKH (5Į SURPRWHU (Gorski et al., 2009). In addition, BRCA1 has 
been shown to interact with the C-terminus of p53 and alter the transcriptional 
activity of p53 by re-directing it from activation of pro-apoptotic target genes 
to other genes involved in cell cycle arrest and DNA repair (Chai et al., 1999). 
Interestingly, mutations in p53 are common in BRCA mutated cancers and that 
this loss of p53 function may be important in tumourgenesis (Mullan et al., 
2006).  
 
1.8. BRCA1 and cancer  
 
     Germ-line mutations in BRCA1 predispose to breast and ovarian cancer 
development. BRCA1 mutation carriers have an 80% lifetime risk of 
developing breast cancer and 40-50% risk of developing ovarian cancer (Risch 
et al., 2001). In addition, BRCA1 mutations increase the risk of other types of 
cancer, such as pancreatic and prostate cancers. Children (both male and 
female) of a carrier have a 50% chance of inheriting the mutation in their 
germline, where one defective allele is sufficient to predispose to cancer 
(Thompson and Easton, 2002). If there is somatic loss of function of the 
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second allele then a tumour is likely to develop. This is known as the Knudson 
two hit hypothesis for tumour suppressor genes (Knudson, 1971).   
 
1.9. Synthetic lethality  
 
     Synthetic lethality is defined as a genetic combination of mutations in two 
or more genes/pathways that leads to cell death, whereas a mutation in only 
one of them does not (Figure 1.6). Synthetic is used here for its ancient Greek 
meaning: the combination of two entities to form something new. This 
phenomenon was first discovered from the investigation of fruit flies in 1922 
by Calvin Bridge. Sturtevant replicated these results in Drosophila 
pseudoobscura in 1956 (Rehman et al., 2010, Kaelin, 2005, Nijman, 2011). 
Synthetic lethality represents a new approach of targeting DNA repair 
pathways with cancer therapies based on the genetic background of the 
tumour.  
 
 
 
  
Figure 1.6. Synthetic Lethality. 
Deletion of either gene A or gene B does not affect cell viability 
whereas inactivation of both at the same time is synthetically lethal. 
Adapted from (Nijman, 2011).  
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1.9.1. Synthetic lethality between BRCA and PARP 
 
     The well known synthetic lethality relationship to date is targeting BRCA 
mutation with PARP1 inhibitors (Farmer et al., 2005, Bryant et al., 2005). 
PARP1 plays a role in single strand break repair (SSBR), a pathway related to 
BER. Inhibition of SSBR is associated with accumulation of DSBs, which can 
be exploited in a subset of cancers possessing defects in DSB repair. BRCA 
gene products have a role in the HR pathway (Venkitaraman, 2002). BRCA 
deficient cells have impaired HR repair (Moynahan et al., 1999). The 
PARP1/BRCA synthetic lethality model proposes that targeting BRCA 
deficient tumours, which are HR deficient, with PARP inhibitor leads to 
accumulation of SSBs. This is followed by the formation of DSBs during DNA 
replication, leading to cell death (Farmer et al., 2005, Bryant et al., 2005). A 
study by Farmer et al demonstrated reduced survival of BRCA1 and BRCA2 
deficient cell lines after treatment with PARP1 inhibitors (KU0058684 and 
KU0058948). Both treated BRCA deficient cell lines showed G2/M cell cycle 
arrest and apoptosis. In addition, Bryant et al, demonstrated that PARP1 
inhibitors (NU1025 and AG14361) were more effective in BRCA2 deficient 
cell lines as compared to BRCA2 proficient cell lines. Treatment of BRCA2 
GHILFLHQWFHOOOLQHVUHVXOWHGLQLQGXFWLRQRIȖ+$;IRFLIRUPDWLRQUHSUHVHQWLQJ
DNA DSBs). Both of these studies were reported independently and concluded 
that BRCA deficient cells were selectively sensitive to PARP1 inhibition. 
 
The PARP1/BRCA synthetic lethality model was then translated into clinical 
trials. A Phase I clinical trial of PARP inhibitor was conducted with Olaparib 
(known previously as AZD2281 and then KU0059436) in a cohort of patients 
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with BRCA deficient tumours. The study demonstrated that Olaparib has 
antitumor activity in BRCA mutation carriers. In addition, a Phase II clinical 
trial of Olaparib in BRCA deficient tumours showed positive proof of the 
PARP1/BRCA synthetic lethality concept (Fong et al., 2010, Balmana et al., 
2011, Audeh et al., 2010, Tutt et al., 2010). The outcomes of both Phase I and 
II clinical trials provided evidence that PARP inhibitors could be used as a new 
treatment in BRCA deficient tumours (Chan and Mok, 2010, Balmana et al., 
2011).  
 
     Recent studies have, however, illustrated some problems with PARP 
inhibition, including a lack of specificity. The PARP family of enzymes 
consists of at least 17 members and each one of them has a different structure 
and function (Rouleau et al., 2010, Mangerich and Burkle, 2011, Underhill et 
al., 2011). PARP1 for instance is involved in: telomere length, organizing the 
spindle apparatus, localization and activation of p53 and also the SSBR 
pathway (Mangerich and Burkle, 2011). Recent studies have evaluated a series 
of 185 inhibitors of PARP, including the best-known inhibitors being tested 
clinically such as Olaparib, ABT-888 and Rucaparib, for the specificity to bind 
to the catalytic domains of 13 of the 17 human PARP family members. In this 
study they determined that majority of the inhibitors bind to multiple targets 
and are therefore not specific (Wahlberg et al., 2012). Resistance to PARP 
inhibition is also an emerging problem. Potential resistance mechanisms 
include: altered NHEJ capacity and restoration of, or increase in, HR capacity 
(Montoni et al., 2013). Moreover, although BRCA1 deficient tumours are 
sensitive to PARP1, BRCA1 hypomorphic mutant tumours can restore BRCA1 
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expression and are therefore insensitive to PARP inhibition (Drost et al., 
2011). Another potential resistance mechanism involves Tumor Suppressor 
p53 Binding Protein 1 (53BP1), which binds to the central DNA-binding 
domain of p53. Bunting et al, demonstrated that loss of 53BP1 can restore the 
HR pathway in BRCA1 deficient cells. The mechanism for this is the 
promotion of ATM function and therefore this may be overcome by the use of 
ATM inhibitors (Bunting et al., 2010). On the other hand, because most agents 
that would be combined with a PARP inhibitor are already administered at or 
near a maximum dose, the addition of another potentiating agent is likely to 
increase toxicity as well as efficacy. For instance, a phase II trial was 
conducted involving 40 patients with metastatic malignant melanoma treated 
with PARP inhibitor (AG014699) in combination with temozolomide. Results 
showed that 18% of the study subjects demonstrated partial responses, with 
notable side effects such as, temozolomide-related myelosuppression and one 
toxic death (Plummer et al., 2006, Pacher and Szabo, 2007). More recently a 
phase I trial was terminated; this study was designed to determine the 
maximum tolerated dose and safety profile of Olaparib in combination with 
topotecan in solid tumours. The most common side effects reported were 
fatigue and gastrointestinal adverse events similar to the ones previously 
reported in Olaparib monotherapy studies. However, unexpected high 
haematological toxicities were observed even with substantially lower doses of 
both agents (Samol et al., 2012).   
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1.9.2. Alternative synthetic lethality targets  
 
     The discovery of the synthetic lethality (SL) relationship between BRCA 
and PARP has become the paradigm for a new class of rational cancer 
therapies. Several novel SL candidates have also been recently investigated. 
For instance, RAD51D deficiency showed sensitivity to PARP inhibitor 
suggesting a possible SL target (Loveday et al., 2011). Similarly, Mantle Cell 
Lymphoma (MCL) deficient in both ATM and p53 are more sensitive to the 
PARP inhibitor (Olaparib) than cells lacking ATM function alone. Suggesting 
that inhibition of both ATM and PARP may have efficacy in targeting p53 
deficient malignancies (Williamson et al., 2012). Similar sensitivity is 
observed in MRE11 deficient cells with PARP1 inhibitor (ABT-888) treatment 
(Vilar et al., 2011).  
 
The emerging problems with PARP inhibition led our group to investigate 
alternative SL targets. For example, we have shown that targeting 
Apurinic/apyrimidinic endonuclease (APE1), a central component of the BER 
pathway, with a small molecule inhibitor induces SL in HR deficient cell lines 
(Mohammed et al., 2011, Sultana et al., 2012). Similarly, targeting APE1 in 
Phosphatase and tensin homolog (PTEN) deficient melanoma cell lines 
induces SL (Abbotts et al., 2014a). In addition, targeting X-ray repair cross 
complementing gene 1 (XRCC1) deficient cell lines with DSB repair inhibitors 
(ATM or DNA-PKcs) or SSB break repair inhibitor (ATR) results in SL 
(Sultana et al., 2013a, Sultana et al., 2013b).   
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1.10. Hypothesis and Aims  
 
      
     The base excision repair (BER) pathway is critical for processing DNA 
damage caused by alkylation, oxidation, single strand breaks and base 
deamination (Dianov and Hubscher, 2013). The well known synthetic lethality 
relationship to date is targeting BRCA mutated tumours (HR deficient) with 
PARP1 inhibitors. However with the emerging problems using PARP 
inhibition, several novel synthetic lethality candidates have been recently 
investigated within the BER pathway. On the other hand, studies suggest a 
cross talk between BRCA1 and BER (Alli et al., 2009). In a more recent study, 
a functional interaction between Pol ß and BRCA1 was demonstrated 
(Masaoka et al., 2013), implying a potential role for Pol ß in BRCA1 mediated 
DSB repair. In addition, BRCA1 has also been shown to be involved in the 
transcriptional regulation of BER factor such as OGG1, NTH1 and APE1 
(Saha et al., 2010). As a result, the hypothesis of this study is that with the 
essential role of BRCA1 in regulating several BER factors, such as APE1, Pol 
ß, OGG1 and NTH1, then BRCA1 deficient cell lines may have impaired BER 
factors which leads to accumulation of SSBs followed by the formation of 
DSBs during the DNA replication process. Therefore, it is suggested that 
BRCA1 deficient cells are reliant on the DSB pathway for cellular survival. 
Accordingly targeting the DSB pathway by ATM or DNA-PKcs inhibition in 
BRCA1-BER deficient cell lines may induce synthetic lethality (Figure 1.7). 
The aims of this research project are as follows: 
1. To investigate DNA repair mRNA and protein expression in BRCA1 
deficient and proficient cell lines.  
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2. To investigate if targeting BRCA1 deficiency by ATM inhibitors 
(KU55933 & KU60019) is synthetically lethal.  
3. To investigate if targeting BRCA1 deficiency by DNA-PKcs inhibitors 
(NU7441 & NU7026) is synthetically lethal. 
4. To investigate if targeting BRCA1 deficiency by ATM or DNA-PKcs 
inhibitor in combination with cisplatin is synthetically lethal. 
 
 
 
 
 
Figure 1.7. Hypothetical synthetic lethality in BRCA1/ BER deficient 
cells, by ATM or DNA-PKcs inhibitors. 
Impaired BER factors in BRCA1 deficient cell lines leads to accumulation 
of SSBs followed by the formation of DSBs during the DNA replication 
process. Therefore, it is suggested that cells are reliant on the DSB 
pathway for cellular survival. Targeting the DSB pathway by ATM or 
DNA-PKcs inhibition may induce synthetic lethality leading to cell death. 
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2. Materials and Methods 
2.1. Materials 
 
 
   KU55933 [2-(4-Morpholinyl)-6-(1-thianthrenyl)-4H-pyran-4-one], KU60019 
[(2R,6S-rel)-2,6-Dimethyl-N-[5-[6-(4-morpholinyl)-4-oxo-4H-pyran-2-yl]-9H-
thioxanthen-2-yl-4-morpholineacetamide], NU7441 [8-(4-Dibenzothienyl)-2-
(4-morpholinyl)-4H-1-benzopyran-4-one], NU7026 [2-(4-Morpholinyl)-4H-
naphthol[1,2-b]pyran-4-one], and NU1025 [8-Hydroxy-2-methyl-4(3H)-
quinazolinone] were purchased from Tocris Bioscience (UK), while (3-AB) 3-
aminobenzamide was purchased from Sigma (UK). All compounds were 
dissolved in 100 % v/v dimethyl sulphoxide (DMSO) to give 5 or 10 mM stock 
solutions, and stored at -20°C. Cisplatin solution was obtained from Pharmacy, 
Nottingham City Hospital, UK and stored at room temperature. 
 
2.2. Cell lines and culture media 
 
 
2.2.1. HeLa SilenciX® cells 
 
 
     Human cervical adenocarcinoma adherent cell lines, BRCA1 HeLa 
SilenciX (Adherent HeLa cells silenced for BRCA1 (Accession Number: 
NM_007295)) and Control HeLa SilenciX (Adherent HeLa cells transfect with 
control shRNA), were purchased from Tebu-Bio (www.tebu-bio.com) and 
were grown in DMEM medium (with L-Glutamine 580mg/L, 4500 mg/L D-
Glucose, with 110mg/L Sodium Pyruvate) (Invitrogen,UK) supplemented with 
10% FBS, 1% penicillin/streptomycin and 125 ȝg/ml Hygromycin B 
(Invitrogen,UK). BRCA1 HeLa SilenciX cells were used between passage 20 
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and 34; Control HeLa SilenciX cells were used between passage 48 and 60. All 
materials were obtained from (Sigma/PAA, UK) unless otherwise stated. To 
make it easier for discussion of the results, BRCA1 deficient HeLa SilenciX 
cells are referred to as BRCA1 HeLa and Control BRCA1 proficient HeLa 
SilenciX cells are referred to as Control HeLa.  
 
2.2.2. Breast cancer cells 
 
  
     Human breast adenocarcinoma adherent cell lines, MCF7 (hemizygous for 
BRCA1 wild type used between passage 25 and 38), and MDA-MB-436 
(BRCA1 mutated used between passage 17 and 29), were used in this study. 
MDA-MB-436 cells are homozygous for a 5396 + 1G>A mutation in the splice 
donor site of exon 20 resulting in loss of the wild-type BRCA1 allele. Analysis 
has identified two BRCA1 transcript lengths; one transcript had skipped exon 
20 (predicting an in-frame deletion of 28 amino acids in the encoded BRCA1 
proteins) and the second transcript had spliced at a cryptic splice site in intron 
20 (5396 + 88/89) (predicting an insertion of 7 amino acids encoded by intron 
sequences followed by a termination codon) (Merajver et al., 1995, Elstrodt et 
al., 2006). 
MCF7 cells were obtained from ATCC® and were maintained with RPMI-
1640 supplemented with 10% FBS and 1% penicillin/streptomycin. MDA-
MB-436 cells were obtained from CLS and were grown in DMEM: Ham¶s F12 
supplemented with 2 mM L-glutamine, 10% FBS and 1% 
penicillin/streptomycin. All materials were obtained from Sigma/PAA (UK). 
2.3. Methods 
 
63 
 
 
2.3.1. Subculture of cell lines 
 
 
     All cell lines were cultured at 37ºC in a humidified incubator with 5% CO2 
and 95% air. To subculture, all cells were handled separately with their own 
reagents and under sterile conditions. Medium was removed and cells washed 
twice with phosphate buffered saline (PBS) (without Ca2+ and Mg2+). Cells 
were detached from the flask by adding 5 ml or less of 0.5mg/ml trypsin-
EDTA (Sigma/PAA, UK) and incubated for 5 minutes at 37ºC. Medium was 
used to deactivate the trypsin and the suspension was centrifuged at 1000 rpm 
for 5 minutes to remove residual trypsin. The pellet was resuspended in 
medium, mixed well and split into a new tissue culture flask. All cell lines 
were routinely confirmed to be mycoplasma negative. 
 
2.3.2. Cryopreservation of cell lines 
 
 
     Cells were cryopreserved at a low passage number for future use. Prior to 
freezing cells were trypsinised and counted using a haemocytometer. 1 x 106 
cells were resuspended in 1 ml of freezing medium, stored in a cryovial at -
80ºC overnight, and then transferred to liquid nitrogen for long term storage. 
Freezing medium consisted of complete medium for the cell line + 10% 
DMSO, with the exception of HeLa cells where the freezing medium was 50% 
FBS + 40% PBS +10% DMSO. Cells were recovered from liquid nitrogen by 
thawing rapidly in a water bath at 37°C. The cells were then resuspended in 9 
ml fully supplemented culture medium and centrifuged at 1000 rpm for 5 
minutes in order to remove traces of DMSO. The medium was then removed 
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and the pellets were resuspended in medium and transferred to tissue culture 
flasks. 
2.3.3. AQueous non-radioactive cell proliferation assay 
(MTS assay) 
 
2.3.3.1. Background principles 
 
 
     MTS assay (Promega, UK) is frequently used for screening different 
compounds to determine if they have effects on cell proliferation or show 
direct cytotoxic effects that eventually lead to cell death. 
MTS solution is composed of a tetrazolium compound [3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS] and an electron coupling reagent phenazine 
methosulfate (PMS). Cells reduce MTS into a formazan product that is soluble 
in tissue culture medium; formazan is produced by dehydrogenase enzymes 
that are only found in metabolically active cells (Riss et al., 2011, Cory et al., 
1991). 
2.3.3.2. Assay 
 
 
     To evaluate the cytotoxicity of varying doses of inhibitors (KU55933, 
NU7441 or NU1025), MTS assays were performed according to the 
PDQXIDFWXUHU¶VUHFRPPHQGDWLRQ500 - 2000 cells, in 200 µl of medium, were 
seeded into each well of a 96-well plate. Cells were allowed to adhere for 24 
hours, followed by incubation with varying concentrations of inhibitors. The 
MTS assay was performed on day 6. 
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2.3.3.3. Data analysis 
 
 
     On day 6, 20 µl of MTS reagent was added to each well, and the plate was 
incubated for 3-4 hours at 37ºC in the dark. Formazan absorbance was 
measured at 490 nm using a plate reader (FLUOstar OPTIMA, UK/ Infinite® 
F50, UK). Percentage of the absorbance was determined by comparison to a 
control population of untreated cells. 
This assay was performed three times, each time in triplicate. Graphs were 
produced and statistical analysis performed using the Microsoft Excel 2010 
and GraphPad prism software version 6.02. 
 
2.3.4. Clonogenic survival assay  
 
2.3.4.1. Background principles 
 
 
     The clonogenic survival assay allows a determination of cell survival after 
exposure to potentially cytotoxic agents. The assay measures viable cells that 
have undergone at least 5-6 rounds of replication to produce a colony and have 
therefore survived the drug exposure (Munshi et al., 2005). 
2.3.4.2. Plating efficiency  
 
     Cell lines were plated into 6-well plates at varying densities. Plates were 
incubated for 12-14 days under normal incubator conditions, then media was 
removed and wells were fixed (with methanol and acetic acid mixture) for 10 
minutes. Plates were stained with crystal violet and colonies counted manually. 
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2.3.4.3.  Clonogenic assay 
 
 
     HeLa SilenciX cells (200-500 cells/well) and Breast cancer cells (300-900 
cells/well) where seeded in a 6-well plate. Cells were allowed to adhere for 24 
hours. Compounds (KU55933, KU60019, NU7441, NU7026 or 3-
Aminobenzamide) were added at the indicated concentrations, with a control 
for each cell line that did not receive drug. The plates were left in the incubator 
for 14 days. After incubation, the media was discarded, cells were fixed (with 
methanol and acetic acid mixture) and colonies stained with crystal violet and 
counted manually. 
To evaluate cisplatin chemopotentiation cells were seeded as above and after 
24 hours cells were exposed to cisplatin for 16 hours. Plates were then washed 
twice with PBS, fresh media added and plates placed in an incubator with or 
without inhibitors 14 days then they were fixed and stained as above. All 
assays were performed in duplicate and repeated three times. 
A second clonogenic survival assay method was also employed to determine 
validity of the previously described protocol. In this method, cells lines were 
plated as previously described, cells were allowed to adhere for 24 hours, after 
which inhibitory compound was added at varying concentrations. Cells were 
incubated for 24 hours, after which the plates were gently washed with PBS 
and the medium replaced without inhibitor. Plates were again incubated for 14 
days prior to staining as previously described.  
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2.3.4.4. Data analysis 
 
 
     Blue stained visible colonies ZLWK  50 cells were counted manually and 
surviving fraction was calculated as follows: 
Surviving Fraction (SF) = [No. of colonies formed / (No. of cells seeded x 
Plating efficiency)]. 
Plating efficiency was calculated by: 
Plating Efficiency (PE) = (No. of colonies formed / No. of cells seeded) x 100. 
When comparing between the two clonogenic protocols, and in the clonogenic 
combination study, the inhibitory concentration of an inhibitor that result in the 
death of 50% of the cell population (IC50) was calculated using curve fitting 
with nonlinear regression analysis. This assay was performed three times. 
Graphs were produced and statistical analysis performed using the Microsoft 
Excel 2010 and GraphPad prism software version 6.02. 
 
2.3.5. Ȗ+$;immunofluorescence microscopy assay 
 
2.3.5.1. Background principles 
 
 
     The histone protein H2AX is one of three types of histone H2A found in 
eukaryotic cells and has been shown to be involved in DNA repair and is a 
central component of signalling pathways activated in response to DNA double 
strand breaks. Within minutes of a DNA double strand break, H2AX becomes 
rapidly phosphorylated by ATM, ATR or DNA-PK, on a serine 139 residue 
IRUPLQJȖ+$;IRFLHDFKIRFLLVWKRXJKWWRFRUUHVSRQGWRRQHGRXEOH strand 
break within the nucleus (Rogakou et al., 1998, Rogakou et al., 1999, Paull et 
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al., 2000). This focus can be detected using antibody staining and fluorescence 
microscopy. 
2.3.5.2. Assay 
 
 
     100,000 cells per well were seeded onto sterile coverslips in 6-well plates. 
Cells were allowed to adhere for 24 hours, and then cells were incubated in 
medium containing ATM inhibitors (KU55933/KU60019) or DNA-PKcs
 
inhibitors (NU7441/NU7026). After 24 and 48 hours treatment, cells were 
washed with PBS and fixed with ice-cold 100% methanol for 10 minutes. 
After rehydrating in PBS, cells were permeabilized in blocking buffer [KCM 
buffer (120mM potassium chloride, 20mM sodium chloride, 10mM Tris-HCl, 
1mM EDTA, 0.1% Triton X-100) with 2% bovine serum albumin, 10% milk 
powder, and 10% normal goat serum] for one hour. Cells were incubated 
with primary anti phospho-histone H2AX (Ser139) antibody (mouse 
monoclonal antibody, Millipore Corp., dilution 1:200) in blocking buffer at 
room temperature for 1 hour. After incubation, the cells were washed in 
KCM buffer and incubated with secondary anti-mouse antibody (polyclonal 
goat anti-mouse immunoglobulins, DAKO, dilution 1:200) at room 
temperature for 1 hour in the dark, followed by 2-3 washes in KCM buffer. 
Coverslips were air dried at room temperature, stained with DAPI 
(Vectashield Hard Set, Vector Laboratories Inc., Burlingame, USA) and 
stored overnight at 4°C before analyses.  
To evaluate cisplatin chemopotentiation, cells were seeded as above and after 
24 hours cells were exposed to cisplatin for 16 hours. Plates were then 
washed twice with PBS, fresh media added and plates placed in an incubator 
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with or without inhibitors for 24 and 48 hours then washed and fixed as 
above. Immunofluorescence microscopy was then performed as described 
below. 
2.3.5.3. Data analysis 
 
 
     Images were obtained using Olympus BX40 microscope and the images 
captured by cellSens (Vers 1.4) Imaging Software and camera (Olympus). 
&HOOVFRQWDLQLQJȖ+$;IRFLZHUHGHWHUPLQHG LQFHOOVSHU VOLGH LQ WKUHH
VHSDUDWH H[SHULPHQWV 1XFOHL FRQWDLQLQJ PRUH WKDQ VL[ Ȗ+$X foci were 
considered positive. 7KLVPHWKRG!Ȗ+$;IRFLRITXDQWLILFDWLon has been 
VKRZQWREHUHOLDEOH0RUHRYHUWKHEDVDOOHYHORIȖ+$;IRFLIRUWKHFHOOOLQHV
used in the present study (Breast cancer and HeLa cell lines) has previously 
been shown to be a maximum of 6 (Farmer et al., 2005, Bryant et al., 2005, 
Sultana et al., 2012). The student t-test was used to calculate if there is a 
significant difference in sensitivity between mutant/knockdown cells before 
and after treatment with inhibitors. A p-value 0.05 was defined as a 
significant relationship. Graphs were produced and statistical analysis 
performed using the Microsoft Excel 2010 and GraphPad prism software 
version 6.02. 
 
2.3.6. Flow cytometric analyses for cell cycle 
 
2.3.6.1. Background principles 
 
     Distribution of cell cycle by flow cytometry is a widely used procedure. 
This assay is based on analysis of the cellular DNA content after stainingcells 
with the fluorescent DNA binding dye, propidium iodide (PI). This method 
70 
 
 
reveals distribution of cells in three major phases of the cycle (G1, S and 
G2/M) (Ormerod and Kubbies, 1992, Pozarowski and Darzynkiewicz, 2004). 
 
2.3.6.2. Assay 
 
     100,000 cells were plated in to T25 flasks, and were allowed to adhere for 
24 hours. Inhibitory compound was added and after 48 hours treatment, cells 
were collected by trypsinization and centrifugation (1000 rpm for 5 minutes). 
The cell pellets were fixed in 70% ethanol in PBS, incubated at 4oC overnight 
to allow fixation and then stored under these conditions until FACS analyses. 
Prior to FACS analysis, fixed cells were centrifuged and the pellet was 
resuspended in 500 µl PBS containing propidium iodide (PI) (2 µg/ml) and 
DNAse-free RNase A (10 µg/ml). After incubation at 37oC for 1 hour, samples 
then were analysed. 
To evaluate cisplatin chemopotentiation cells were seeded as above and after 
24 hours cells were exposed to cisplatin for 16 hours. Plates were then washed 
twice with PBS, fresh media added and placed in an incubator with or without 
inhibitors 48 hours. Cell cycle analysis was then performed.  
 
2.3.6.3. Data analysis 
 
     Samples were analysed on a Cytomics F500 flow cytometer (Beckman 
Coulter, USA) using a 488nm laser for excitation and a 620nm bandpass filter 
for collection of data. Data was analysed using FlowJo 7.6.1 (Tree Star, 
Ashland, USA). At least 50,000 cells from each cell suspension were analysed. 
This assay was performed three times; the student t-test was used to calculate 
if there is a significant difference in sensitivity between mutant/knockdown 
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cells before and after treatment with inhibitors. A p-value 0.05 was defined as 
a significant relationship. Graphs were produced and statistical analysis 
performed using the Microsoft Excel 2010 and GraphPad prism software 
version 6.02. 
 
2.3.7. Annexin V flow cytometric analyses for Apoptosis 
 
2.3.7.1. Background principles 
 
     Programmed cell death (Apoptosis), is a common form of cell death in 
eukaryotes and during embryonic development. It is characterized by 
chromatin condensation, altering in cell volume and translocation of membrane 
phosphatidylserine (PS) from the inner side of the plasma membrane to the 
surface (Figure 2.1). Annexin V is a Ca2+-dependent phospholipid-binding 
protein with a high affinity for PS. Staining with Annexin V is used in 
conjunction with a second dye such as propidium iodide (PI) for identification 
of early and late apoptotic cells (Figure 2.2). Viable cells with intact 
membranes are negative (reject) to PI, whereas dead cells with damaged 
membranes are positive (permeable) to PI. Therefore, viable cells are both 
Annexin V and PI negative, early apoptotic cells are Annexin V positive and 
PI negative, late apoptotic cells are Annexin V and PI positive, finally necrotic 
cells are Annexin V negative and PI positive (Koopman et al., 1994, Riccardi 
and Nicoletti, 2006). 
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Figure 2.1. Annexin V flow cytometry mechanism (V-FITC). 
In early apoptosis, phosphatidylserine, which is located inside the 
plasma membrane, transposes to the cell outer surface. Annexin V is a 
human vascular anticoagulant, with high affinity for PS. Annexin V-
FITC/PI staining method is widely used in the detection of early 
apoptosis. Adapted from (www.flow-cytometry.us). 
 
 
 
Figure 2.2. Annexin V and PI Staining.  
Viable cells are both Annexin V and PI negative, early apoptosis cells 
are Annexin V positive and PI negative, late apoptosis cells are 
Annexin V and PI positive, finally necrotic are Annexin V negative 
and PI positive. 
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2.3.7.2. Assay 
 
 
     Cells were grown to sub-confluence (70-80 %) and harvested. 100,000 cells 
were plated in to T25 flasks and were allowed to adhere for 24 hours. 
Inhibitory compound was added and cells were collected after 24 and 48 hours 
exposure. Cells were trypsinized and centrifuged at 1000 rpm for 5 minutes. 
The cell pellets were washed twice with ice-cold PBS and then resuspend in 
Binding buffer (BioLegend, UK) at a concentration of 1x106 cell/ml. 5 µl of 
FITC Annexin V (ImmunoTools, Germany) and 5 µl PI were added to 100 µl 
of the cell solution and incubated for 15 minutes at room temperature in the 
dark. 400 µl of the Binding buffer was then added and the sample analysed by 
FACS. 
To evaluate cisplatin chemopotentiation cells were seeded as above and after 
24 hours cells were exposed to cisplatin for 16 hours. Plates were then washed 
twice with PBS, fresh media added and placed in an incubator with or without 
inhibitors for 24 and 48 hours. Cell cycle analysis was then performed.  
2.3.7.3. Data analysis 
 
 
     Samples were analysed on a Cytomics F500 flow cytometer (Beckman 
Coulter, USA) using a 488nm laser for excitation and a 575nm bandpass filter 
for collection of data. Data was analysed using FlowJo 7.6.1 (Tree Star, 
Ashland, USA). At least 20,000 cells from each cell suspension were analysed. 
This assay was performed three times; the student t-test was used to calculate 
if there is a significant difference in sensitivity between mutant/knockdown 
cells before and after treatment with inhibitors. Percentage of the absorbance 
was determined by comparison to a control population of untreated cells. A p-
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value 0.05 was defined as a significant relationship. Graphs were produced 
and statistical analysis performed using Microsoft Excel 2010 and GraphPad 
prism software version 6.02. 
 
2.3.8. DNA repair gene expression profiling 
 
2.3.8.1. Background principles 
 
 
     To determine the human DNA repair gene profile in BRCA1 deficient cell 
lines, RT-T3&5 DUUD\ ZDV SHUIRUPHG XVLQJ WKH '1$ UHSDLU 57ð 3URILOHU
PCR Array (Qiagen, UK). This array represents 84 key genes involved in the 
Base excision, Nucleotide excision, Mismatch, Double-strand break, and other 
DNA repair pathways. Additionally, quantitative real time PCR (RT-qPCR) 
using QuantiTect® Primers (Qiagen, UK) was performed to confirm up/down 
gene expression.   
2.3.8.2. RNA extraction 
 
 
     Total cellular RNA was isolated using the RNeasy mini kit (Cat No; 74104, 
Qiagen) aFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV%ULHIO\ ȝORI%XIIHU
RLT was added to the 2 x 106 pelleted cells, and then vortexed. 350 ȝORI
ethanol was mixed with the lysate and then 700 ȝORIWKHO\VDWHZDVWUDQVIHUUHG
to an RNeasy spin column. The sample was then centrifuged for 15 seconds at 
10,000 rpm. The flow through was discarded and 350 ȝORI%XIIHU5:ZDV
added to the RNeasy spin column to wash the membrane. The sample was 
centrifuged for 15 seconds at 10,000 rpm, and the flow through was discarded. 
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DNA digestion was performed to eliminate genomic DNA contamination 
using the DNase digestion kit (Cat No; 79254, Qiagen). 70 ȝORI%XIIHU5''
and 10 ȝORI'1DVH,VWRFNVROXWLRQZDVDGGHGLQWRD ml eppendorf. This 
DNase I incubation mix was centrifuged for 15 seconds at 10,000 rpm. 80 ȝORI
the DNase I mix was then added directly to the RNeasy spin column 
membrane, and incubated at room temperature for 15 minutes. 350 ȝORI%XIIHU
RW1 was added to the RNeasy spin column, and the sample was centrifuged 
for 15 seconds at 10,000 rpm. The flow through was discarded and 500 ȝORI
Buffer RPE was added to the RNeasy spin column to wash the membrane. The 
sample was centrifuged for 15 seconds at 10,000 rpm. 500 ȝORI%XIIHU53(
was added to the RNeasy spin column to wash the membrane, and the sample 
was centrifuged for 2 minutes at 10,000 rpm. Following centrifugation, the 
RNeasy spin column was carefully placed in a new 1.5 ml eppendorf, and 40 
ȝORI51DVH-free water was added directly to the spin column membrane. The 
sample was centrifuged for 1 minute at 10,000 rpm to elute the RNA.  
The concentration (µg/µl) of the eluted RNA was performed by measuring 
absorbance ratio at 260:280 nm using a spectrophotometer system (Nanodrop 
2000c, Thermo Scientific, USA) and RNA aliquots were then stored at -80ºC.  
2.3.8.3. cDNA Synthesis 
 
 
     Equal amounts of RNA (0.5 µg) were reverse transcribed to form cDNA 
using RT² First Strand Kit (Cat No; 79254330401, Qiagen). For each RNA 
sample 2 ȝO*('1$elimination buffer) and nuclease-free water was added 
to bring the total volume of genomic DNA elimination mixture to 10 ȝO7KH
genomic DNA elimination mixture was centrifuged for 10 seconds at 10,000 
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rpm. The mixture was incubated at 42°C for 5 minutes. Following incubation, 
the genomic DNA elimination mixture was chilled on ice for at least one 
minute. For preparation of the room temperature cocktail, 4 ȝO RI ; 57
Buffer 3 (BC3), 1 ȝORI3ULPHU	([WHUQDO&RQWURO0L[3 ȝORI5(57
Enzyme Mix 3), and 3 ȝORI nuclease free water were added to a sterile 1.5 mL 
eppendorf. The 10 ȝO RI 57 FRFNWDLO was added to the genomic DNA 
elimination mixture. The reaction was incubated at 42°C for 15 minutes and 
the reaction was stopped by heating at 95°C for 5 minutes. Following heating, 
91 ȝORIQXFOHDVHIUHHZDWHUZDVDGGHGWRWKHF'1$DQG held on ice until the 
array was prepared or the cDNA was stored at -80ºC. 
2.3.8.4. 57ð3URILOHU'1$5HSDLU3&5$UUD\ 
 
 
     To evaluate the expression of 84 DNA repair genes, cDNA samples were 
mixed with RT2 SYBR Green Mastermix (Qiagen) according to the VXSSOLHU¶V
instructions. Briefly, the PCR component mix was prepared as follow; 
Table 2.15HDFWLRQPL[IRU57ð3URILOHU'1$5HSDLU3CR Array 
Reagent Volume 
RT2 SYBR Green Mastermix  
cDNA synthesis reaction  
RNase-free water  
1350 ȝO 
102 ȝO 
1248 ȝO  
Total 2700 ȝO 
 
 
25 ȝO RI the mix was added to each well of the PCR array plate (Cat No: 
PAHS-042ZC). The plate was sealed using optical adhesive film and 
centrifuged for 1 minute to remove bubbles. RT PCR was performed on an 
Applied Biosystems 7500 FAST cycler, the cycler conditions were; initial 1:10 
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minutes at 95ºC; followed by 2-41:15 seconds at 95ºC, then 1 minute at 60ºC. 
Quality controls included within the array plates confirmed the lack of DNA 
contamination and successfully tested for RNA quality and PCR performance. 
2.3.8.5. Quantitative real time PCR (RT-qPCR) 
 
  
     To confirm up/down regulation of gene expression as shown by RT² 
3URILOHU '1$ 5HSDLU 3&5 $UUD\ TXDQWLWDWLYH UHDO WLPH 3&5 57-qPCR) 
using QuantiTect® Primers (Qiagen, UK) was performed according to the 
VXSSOLHU¶V LQVWUXFWLRQV %ULHIO\ WKH 3&5 FRPSRQHQW PL[ ZDV SUHSDUHG DV
follow; 
Table 2.2. Reaction mix for Quantitative real time PCR (RT-qPCR). 
 
Reagent Volume 
cDNA from RT2 First Strand synthesis 
10x QuantiTect primer 
SYBR Green Mastermix 
RNase-free water 
2 ȝO 
1 ȝO 
5 ȝO 
2 ȝO 
Total 10 ȝO 
 
PCR mix was added to each well of the PCR plate (Applied Biosystems®, 
UK). The plate was sealed using optical adhesive film and centrifuged for 1 
minute to remove bubbles. RT qPCR was performed on an ABI prism 7700 
(Applied Biosystems) using SYBR green detection (Applied Biosystems®, 
UK). Thermal cycler conditions included incubation at 95ºC for 10 minutes 
followed by 40 cycles of 95ºC for 15 seconds and 60ºC for 1 minute. 
Following the 40 cycles, the products were heated from 60ºC to 95ºC over 20 
minutes to allow melting curve analysis to be done. This allowed the 
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specificity of the products to be determined (single melting peak) and 
confirmed the absence of primer-dimers. The housekeeping gene GAPDH was 
used to standardise the samples and the relative expression of BRCA1, XRCC1, 
APE1, SMUG1, Pol ß, Lig3, ATM and DNA-PKcs were therefore calculated as 
the ratio between the expression of test gene and the expression of 
housekeeping gene. Positive and negative controls (no template) were included 
in each experiment and all reactions were performed three times. 
Table 2.3. QuantiTect® Primers used in RT-qPCR analysis.   
Gene Symbol Source Catalog  no. 
APE1 Qiagen QT00012474 
XRCC1 Qiagen QT00016688 
SMUG1 Qiagen QT00002317 
Pol ß Qiagen QT00088655 
Lig3 Qiagen QT00017115 
ATM Qiagen QT00061593 
DNA-PKcs Qiagen QT00086828 
BRCA1 Qiagen QT00039305 
GAPDH Qiagen QT00079247 
ß2M Applied Biosystems Forward /GAGTATGCCTGCCGTGTG 
Reverse /AATCCAAATGCGGCATCT 
 
 
2.3.8.6. Data analysis 
 
     Raw data from both real-time PCR methods were uploaded using a PCR 
array data analysis template available at 
http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php. The integrated 
Web-based software package for the PCR array system automatically 
performed all comparative threshold F\FOH ǻǻ&t)±based fold-change 
calculations from the uploaded data. For these calculations, GAPDH was used 
for normalization of the data. After normalization, the relative expression of 
each gene was averaged for the two samples in each cell line. Fold changes in 
average gene expression were expressed as the difference in expression of 
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BRCA1 deficient cells compared with BRCA1 proficient cells (control). 
Statistical significance determined IRU WKH 57ð 3URILOHU $UUD\ using the 
Bonferroni correction for multiple testing, with p values less than 0.05 
(threshold p < 0.000595 = 0.05/84). RT-qPCR statistical significance 
determined using t test, with p values less than 0.05. Analysis performed using 
GraphPad prism software version 6.02. 
2.3.9. Western Blot analysis  
 
2.3.9.1. Background principles 
 
 
     Western blot is a method developed more than 30 years ago (Burnette, 
1981). This process involves separation of specific proteins in given cells or 
tissue extract on a sodium dodecyl sulphate (SDS)-polyacrylamide gel, 
followed by electrophoresis transfer to a nitrocellulose membrane and detected 
using specific antibodies (primary antibodies) that bind to the target protein. 
Horseradish peroxidise (HRP) enzyme conjugated secondary antibodies were 
used to bind with their specific primary antibodies which can be detected using 
ECLTM chemiluminescent system. Visualisation of the immune complex was 
performed using X-ray film.    
2.3.9.2. Preparation of cell lysate 
 
     70-80% confluent cells were washed with PBS, trypsinised and counted 
using a haemocytometer. The cell pellet was resuspended in media, 1 x 106 or 
2 x 106 cells were lysed using 100 µl of RIPA buffer (20 mM Tris, 150 mM 
NaCl, 1% Nonidet p-40, 0.5% sodium deoxycholate, 1 mM EDTA, 0.1% SDS; 
Sigma) containing 10% of protease inhibitor (Sigma) and 1% of phosphatase 
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inhibitor cocktails 2 and 3 (Sigma). The lysate was incubated on ice for 1 hour, 
then repeatedly aspirated with a fine-gauge needle and incubated overnight at -
20°C. Next day lysates were centrifuged at 13000 rpm for 20 minutes at 4°C 
and the supernatant was stored at -20°C. 
2.3.9.3. Protein quantification (Bradford assay) 
 
     Bradford assay (Bio-Rad, UK) is a method based on binding Coomassie 
dye to protein (Bradford, 1976). Differential colour change occurs in response 
to the protein concentration. Briefly, 10 µl of protein were mixed with 250 µl 
assay solution in 96-well plate. The absorbance value was measured at 595 nm 
by plate reader (FLUOstar OPTIMA, UK/ Infinite® F50, UK) with in 1 hour. A 
protein standard curve was generated using bovine serum albumin (BSA) 
against corresponding protein concentrations. The determination of the protein 
concentration, in respective cell lysates, was carried out to ensure equal 
loading of protein in the wells of western blot gel.  
2.3.9.4. Preparation of cell lysates for electrophoresis 
 
 
     Equal volumes (20 ± 50 µg) of protein were mixed with 5 µl lithium 
dodecyl sulphate (LDS) sample buffer (Expedeon, UK), 1 µl Dithiothreitol 
(DTT) (Invitrogen, UK) and dH2O. The mix was incubated at 70ºC for 10 
minutes, and then placed on ice. 
2.3.9.5. Polyacrylamide gel electrophoresis and Protein 
transfer 
 
 
     Samples were loaded onto precast SDS 4-12% gels (Expedeon, UK) and 
were run in 3-(N-morpholino) propanesulphonic acid-sodium dodecyl sulphate 
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(MOPS-SDS) running buffer (Expedeon), at a constant voltage of 125-200 V 
for 60-120 minutes. 
Using the Xcell II Blot Module (Invitrogen), proteins were transferred to a 
nitrocellulose membrane (Whatman, GE Healthcare) in transfer buffer [20% 
(v/v) methanol, 50 mM Tris-HCl, and 380 mM glycine] by application of a 
25V current for 60-120 minutes. 
2.3.9.6. Immunoblotting  
 
 
     Membranes were blocked by incubation with PBS-T (PBS, 0.05% Tween 
20) containing 5% non-fat milk for 60 minutes at room temperature. 
Membranes were incubated with primary antibody diluted in blocking buffer 
for 60 minutes at 37ºC or overnight at 4oC. The membranes were washed 3 
times (5 minutes each) with PBS-T. Protein expression was examined by 
application of HRP-labelled secondary antibody (Dako, Denmark) at 1:1000 
dilution in blocking buffer for 60 minutes at room temperature. The 
membranes were washed 3 times (5 minutes each) with PBS-T and detected on 
photographic film using ECL reagent (GE Healthcare).  
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2.3.9.7. Primary antibodies 
 
 
Table 2.4. Primary antibodies used in Western blot.  
Antigen Antibody MW Source Catalog no. Dilution 
APE1 Rabbit  37   kDa Novus NB 100-101 1:1000 
XRCC1 Mouse 85   kDa Neomarkers MS-434-PO 1:150 
SMUG1 Goat 37   kDa Acris APO884PU-N 1:1000 
Pol ß Rabbit 38   kDa Abcam Ab26343 1:1000 
Lig3 Rabbit 113 kDa Abcam Ab96576 1:1000 
BRCA1 Rabbit 220 kDa Santa Cruz  Sc-642 1:150 
ATM  Goat 350 kDa Abcam  ab2631 1:1000 
DNA-PKcs Rabbit 460 kDa Abcam ab32566 1:1000 
ß -actin Mouse  42   kDa Sigma A2228 1:10000 
 
 
 
2.3.9.8. Data analysis 
 
     Photographic films were scanned and analysed using Image Studio Lite 
(Ver 3.1) (Li-Cor, USA). ȕ-actin was used for normalization of the data. This 
assay was performed in two or three independent experiments; the student t-
test was used to calculate the significant difference between control cells and 
mutant/knockdown cells. A p-value 0.05 was defined as significant. Graphs 
were produced and statistical analysis performed using the GraphPad prism 
software version 6.02.  
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Chapter 3 
DNA repair profiling in BRCA1 deficient 
and proficient cells 
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3. DNA repair profiling in BRCA1 deficient and 
proficient cells  
3.1. Introduction 
 
     Germ-line mutations in the BRCA1 gene are one of the most common 
causes of hereditary forms of breast and ovarian cancers. BRCA1 mutation 
carriers have 80% lifetime risk of developing breast cancer, and 40-50% risk of 
developing ovarian cancer (Risch et al., 2001). In addition, BRCA1 mutations 
increase the risk of other types of cancer, such as pancreatic and prostate 
cancers (Thompson and Easton, 2002). Moreover, in sporadic breast cancer, 
epigenetic mechanisms of gene inactivation are now well recognized as a 
potential alternative to genetic mutation in the silencing of the BRCA1 
promoter in up to 11-14% of tumours (Turner et al., 2004). Dysfunctional 
%5&$SDWKZD\PD\DOVRFRQWULEXWHWRDµ%5&$QHVV¶SKHQRW\SHLQDERXW
of cancers (Turner et al., 2004), where breast cancers do not harbour germline 
BRCA mutations but display similar phenotypes including HR deficiency. The 
term µ%5&$QHVV¶ is a phenotype which refers to molecular and 
histopathological characteristics observed in a subset of breast cancers that 
H[KLELWVLPLODULW\WR%5&$GHILFLHQWWXPRXUVLQFOXGLQJµEDVDOSKHQRW\SH¶and 
µWULSOH QHJDWLYH¶ RHVWURJHQ UHFHSWRU SURJHVWHURQH UHFHptor and HER2 
negative) cancers (Turner et al., 2004, Matros et al., 2005). This chapter 
investigated, whether BRCA1 deficient cells compared to BRCA1 proficient 
cells exhibit altered profile of DNA repair expression.  
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3.1.1. BRCA1 mutation in breast cancer cell lines 
 
     Four established breast cancer cell lines with BRCA1 mutation have been 
reported, HCC1937 was the first BRCA1 deficient cell line reported in 1998. 
HCC1937 was derived from a germline BRCA1 mutation carrier (Tomlinson et 
al., 1998). In 2006 Elstrodt and colleagues screened 41 human breast cancer 
cell lines and found three to be BRCA1 mutant (summarised in Table 3.1), the 
same results were confirmed by analysis of 51 human breast cancer cell lines 
in 2013 (Elstrodt et al., 2006, Riaz et al., 2013).     
 
 
Cell line 
BRCA1 
Mutation 
status 
BRCA1 
transcript 
expression 
 
Exon 
 
ER 
 
PGR 
 
P53 
 
EGFR 
 
MDA-MB-436 
 
5396 + 1G>A 
 
++* 
 
20 
 
- 
 
- 
 
- 
 
+ 
 
SUM1315M02 
 
185delAG 
 
+ 
 
2 
 
- 
 
- 
 
- 
 
+ 
 
SUM149PT 
 
2288delT 
 
+ 
 
11 
 
- 
 
- 
 
- 
 
+ 
 
HCC1937 
 
5382insC 
 
++ 
 
20 
 
- 
 
- 
 
- 
 
+ 
 
Table 3.1. BRCA1 mutations in breast cancer cell lines. 
ER, estrogen receptor; EGFR, epidermal growth factor receptor; PGR, progesterone 
receptor. For transcript expression: (+, low transcript levels); (++, normal transcript levels); 
(++*, Two transcript lengths that both differ from the wild type sequence). For protein 
expression: (+, expression) and (-, no expression) (Tomlinson et al., 1998, Elstrodt et al., 
2006, Riaz et al., 2013). 
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3.1.2. Rationale for the study 
 
     As discussed previously (section 1.7.1) BRCA1 plays a role in many DNA 
repair pathways including, BER, NER, MMR, HR and NHEJ. Therefore in this 
chapter, a comprehensive analysis of the DNA repair pathway genes in 
BRCA1 deficient cells compared to proficient cells will be described using the 
57ð3URILOHU'1$5HSDLU3&5$UUD\DVGHVFULEHGLQVHFWLRQ7KH
RT² Profiler PCR Array has the advantage of combining RT-PCR performance 
with the ability of microarrays to detect the expression of 84 DNA repair genes 
simultaneously.  
BRCA1 has been suggested to stimulate the activity of three BER enzymes 
(see section 1.7.1); OGG1, NTH1 and APE1. These enzymes mediate repair of 
three signature oxidative lesions; 8-oxoguanine, thymine glycol and abasic 
sites, respectively (Saha et al., 2010). A more recent study supports these 
findings and has confirmed down-regulation of the same enzymes in BRCA1 
deficient cells, it also suggested XRCC1 to be regulated by BRCA1 (De 
Summa et al., 2014). XRCC1 protein associates with Pol ß, and Lig3, to form a 
complex that repairs the single strand DNA breaks generated during the BER 
process. In addition, recent studies suggest a cross talk between BRCA1 and 
other BER genes. For instance, a functional interaction between Pol ß and 
BRCA1 (Masaoka et al., 2013) has been described, and an association between 
low SMUG1 protein expression and loss of BRCA1 expression (Abdel-Fatah 
et al., 2013). For this reason in the current study BER genes (APE1, XRCC1, 
SMUG1, Pol ß and Lig3) will be investigated for a potential link with BRCA1 
deficiency. In addition, as the main aim of this study is to investigate synthetic 
lethality in a BRCA1 deficient system by targeting the DSB pathway, ATM (a 
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key enzyme in HR) and DNA-PKcs (a key enzyme in NHEJ) genes will be 
investigated as well. Therefore, the selected genes (BRCA1, APE1, XRCC1, 
SMUG1, Pol ß, Lig3, ATM and DNA-PKcs) will be investigated using the RT² 
3URILOHU$UUD\DQGWKHQIXUWKHUDVVHVVPHQWRIWKHUHVXOWVZLOOEHFDUULHGRXW
by quantitative real time PCR (RT-qPCR) using QuantiTect® Primers (as 
described in section 2.3.8.5.). Finally, the mRNA expression of the selected 
genes will be compared with protein expression using western blot analysis.  
 
3.1.2.1. Aims  
 
The aims of this chapter were as follows: 
1. To explore DNA repair expression in BRCA1 proficient and deficient 
cell lines using 57ð3URILOHU'1$5HSDLU3&5$UUD\ 
2. To confirm up or down regulation of selected DNA repair genes in a 
panel of BRCA1 proficient and deficient cell lines using Quantitative 
real time PCR (RT-qPCR). 
3. To investigate alteration in protein expression of selected DNA repair 
factors in BRCA1 proficient and deficient cell lines using western blot 
analysis. 
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3.2. Materials and Methods 
 
Materials and methods for the assays listed are described in full in Chapter 2.  
BRCA1 deficient MDA-MB-436 breast cancer cells and BRCA1 proficient 
MCF7 breast cancer cells were used in this study (Table 3.2). A second set of 
BRCA1 proficient and deficient cell line model was also used; BRCA1 
deficient HeLa SilenciX cells and Control BRCA1 proficient HeLa 
SilenciX cells.  
To make it easier for discussion of the results, BRCA1 deficient HeLa 
SilenciX cells are referred to as BRCA1 HeLa and Control BRCA1 proficient 
HeLa SilenciX cells are referred to as Control HeLa.  
 
 
Cell line 
BRCA1 
Mutation  
status 
BRCA1 
transcript 
expression 
 
ER 
 
PGR 
 
P53 
 
EGFR 
 
MDA-MB-436 
 
5396 + 1G>A 
 
+* 
 
- 
 
- 
 
- 
 
+ 
 
MCF7 
 
Wild type 
 
+ 
 
+ 
 
+ 
 
+ 
 
- 
 
Table 3.2. Breast cancer cell lines used in this project. 
ER, estrogen receptor; EGFR, epidermal growth factor receptor; PGR, 
progesterone receptor.  For transcript expression: (+, normal transcript 
levels); (+*, Two transcript lengths that both differ from the wild type 
sequence). For protein expression: (+, expression) and (-, no expression) 
(Elstrodt et al., 2006, Riaz et al., 2013). 
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3.3. Results 
3.3.1. Determination of BRCA1 expression in cell lines 
3.3.1.1. Western blot analysis demonstrates reduced BRCA1 
protein expression  
     The protein expression of BRCA1 was determined in all cell lines by 
western blotting. Briefly, cell lysates were prepared from 70-80% confluent 
cells and loaded onto polyacrylamide gels as described in section 2.3.9. 
BRCA1 was resolved on precast SDS 4-12% gels. Following electrophoresis, 
proteins were electrotransferred onto nitrocellulose and probed for target 
protein using specific antibody (Table 2.4). Recombinant BRCA1 protein 
(Sigma/UK, 0.02µl) was also run as control on the gel, moreover as a loading 
control; ȕ-actin antibody was used.   
 
  
Figure 3.1. BRCA1 protein expression in the cell lines studied by western 
blot  
Whole cell protein lysates were collected for each cell line and 50 µg 
samples were separated by electrophoresis on denaturing polyacrylamide 
gels as described in section 2.3.9. Recombinant BRCA1 protein was also 
run as control on the gel. Blot was probed using specific BRCA1 antibody 
with predicted molecular weight 220 kDa $V D ORDGLQJ FRQWURO ȕ-actin 
antibody (42 kDa) was used.   
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     As expected, MDA-MB-436 and BRCA1 HeLa cell lines are BRCA1 
deficient (Figure 3.1), when compared to MCF7 and Control HeLa cell lines. 
Quantification of protein expression is shown in Figure 3.2. Significant under-
expression of BRCA1 protein was confirmed in BRCA1 HeLa (fold change 
mean = 0.09, p < 0.0001) and MDA-MB-436 cells (fold change mean = 0.07, p 
= 0.0001) compared to Control HeLa and MCF7 cells respectively.     
 
 
3.3.1.2. RT- qPCR demonstrate reduced BRCA1 mRNA 
expression  
     After confirming low expression of BRCA1 protein in BRCA1 HeLa and 
MDA-MB-436 cells, mRNA expression was determined by RT-qPCR as 
described in section 2.3.8.5. Relative expression were calculated for each cell 
line and compared to their respective control cell lines. The mRNA expression 
Figure 3.2. Quantification of BRCA1 protein expression  
(A) Relative BRCA1 expression in BRCA1 HeLa cells was calculated in 
comparison to Control HeLa cells. (B) Relative BRCA1 expression in 
MDA-MB-436 cells was calculated in comparison to MCF7 cells. Values 
plotted are means ± SD of the fold-change (ratio of protein/ß-actin 
normalized to control) *** p<0.001 and **** p<0.0001.  
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of housekeeping genes ß2-microglobulin (ß2M) and GAPDH (primer details in 
Table 2.3) were used to standardise the samples. The relative expression of 
BRCA1 mRNA was calculated as the ratio between the expression of BRCA1 
gene and the expression of the housekeeping gene. Negative control was 
included in each experiment. As both housekeeping genes showed similar 
results, GAPDH was used for all subsequent experiments. Data as expected 
(Figure 3.3) demonstrated low mRNA expression of BRCA1 in BRCA1 HeLa 
cells compared to Control HeLa (mean fold change = 0.16; p = 0.0015). Low 
BRCA1 mRNA expression was also seen in MDA-MB-436 cells compared to 
MCF7 cells (mean fold change = 0.09; p = 0.0026).  
  
 
Figure 3.3. Quantification of BRCA1 mRNA expression  
(A) Relative BRCA1 expression in BRCA1 HeLa cells was calculated in 
comparison to Control HeLa cells. (B) Relative BRCA1 expression in MDA-MB-
436 cells was calculated in comparison to MCF7 cells. The housekeeping gene 
GAPDH was used to standardise the samples and the relative expression level of 
BRCA1 was therefore calculated as the ratio between the level of gene of interest 
and the level of housekeeping gene. Negative control (no template) was included 
in each experiment and all reactions were run in triplicate ** p<0.01.  
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3.3.2. RT2 Profiler DNA Repair PCR Array 
 
     Real-time (RT-PCR) is a highly sensitive and reliable method for gene 
expression analysis. RT2 Profiler PCR Arrays has the advantage of combining 
RT-PCR performance and the ability of microarrays to detect the expression of 
many genes simultaneously. RT2 Profiler PCR array from Qiagen is a high 
throughput assay which allows analysis of the gene expression profiles in 
chosen cell populations. It consists of two step reverse transcription RT-PCR 
reaction: firstly isolated RNA and then converted to cDNA. Secondly the 
cDNA in combination with gene specific primers and a PCR master mix which 
contains a SYBR Green (which fluoresces when bound to double-stranded 
DNA (dsDNA)), subjected to thermal cycling. 
Baseline fluorescence represents thH EDFNJURXQG µQRLVH¶ fluorescence, which 
refers to the signal level during the initial cycles and it is automatically 
determined by the PCR cycler software. RT-PCR phases can be broken up into 
three sections; Exponential phase; each PCR cycle results in a doubling of 
dsDNA product which increases fluorescent signal until a pre-specified 
threshold is reached. This threshold cycle (Ct) is the cycle number at which 
fluorescent signal of the reaction crosses the baseline threshold, and is 
dependent upon the initial concentration of the primer target within the sample. 
Linear phase; the reaction components are being consumed, gradually reducing 
reaction efficiency and products are starting to degrade. Plateau phase; the 
reaction has stopped, no more products are being made and if left long enough, 
the PCR products will begin to degrade. Graphical representation of Ct can be 
observed using amplification plots (Figure 3.4). By normalising the Ct of the 
gene of interest against the Ct of a housekeeping gene XVLQJ ǻǻ&t method 
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ǻǻ&t calculation method listed in APPENDIX A), gene expression can be 
compared in different samples (lifetechnologies, 2012, Qiagen, 2011).  
     The Qiagen RT2 Profiler PCR array is performed in a 96-well format 
(Figure 3.5), allowing analysis of 84 genes simultaneously. In addition to 5 
housekeeping genes, the genomic DNA control (GDC) that specifically detects 
non-transcribed genomic DNA contamination with a high level of sensitivity. 
The reverse-transcription control (RTC) that tests the efficiency of the reverse-
transcription reaction performed with the RT2 First Strand Kit by detecting a 
WHPSODWHV\QWKHVL]HGIURPWKHNLW¶VEXLOW-in external RNA control. The positive 
PCR control (PPC) consists of a pre-dispensed artificial DNA sequence and 
the assay that detects it. This control tests the efficiency of the polymerase 
chain reaction itself. Genes assessed in the RT2 Profiler DNA PCR Array are 
listed in APPENDIX B.  
 
Figure 3.4. Illustration of qRT-PCR amplification plot.  
Plot represents the accumulation of product over the duration of the qRT-
PCR. The samples used to create the plots are a dilution series of the target 
DNA sequence.  Adapted from (lifetechnologies, 2012). 
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     Fluorescent reference dye (Rn), in this case SYBR Green, is normalised 
against ROX which is a passive reference dye contained within the PCR 
PDVWHU PL[ ,Q DPSOLILFDWLRQ SORWV ǻ5Q VFDOH ZKLFK LV SORWWHG DJDLQVW F\FOH
number on a Log10, is a subtraction of baseline fluorescence from Rn. To 
demonstrate if the amplification was successful, post-amplification melting 
curve analysis can be performed. After thermo-cycling is completed, 
fluorescence of the PCR product is recorded while temperature is increased.  
When the melting point (Tm) is reached it is followed by a sudden decrease in 
fluorescent signal. Tm may be affected by multiple factors like (DNA length, 
and the presence of base mismatches); therefore different PCR products 
display different melting characteristics. By plotting change in Fluorescence 
Figure 3.5. RT2 Profiler PCR Array plate layout. 
Wells A1 to G12 each contain a real-time PCR assay for a DNA repair pathways 
related gene. Wells H1 to H5 contain a housekeeping genes panel to normalize array 
data (HK1-5). Well H6 contains a genomic DNA control (GDC). Wells H7 to H9 
contain replicate reverse-transcription controls (RTC). Wells H10 to H12 contain 
replicate positive PCR controls (PPC). Adapted from (Qiagen, 2011). 
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against change in Temperature (±ǻ)ǻ7 WR JLYH D PHOWLQJ SURILOH LW LV
SRVVLEOH WR GHWHFW WKH SUHVHQFH RI QRQVSHFLILF SURGXFW RU µSULPHU-GLPHUV¶
(binding of homologous primers to self rather than template) as additional 
peaks on the melting curve. To avoid presence of non-specific product, 
optimise the concentration of RNA was needed to find the concentration that 
gives successful amplification with less background noise (lifetechnologies, 
2012, Qiagen, 2011).    
3.3.3. Optimisation of the purified RNA for RT-PCR 
 
     High-quality RNA is essential for obtaining good, RT-PCR results. The 
most important prerequisite for any gene expression analysis experiment is 
consistently high-quality RNA from every experimental sample. So the 
concentration (µg/µl) of the purified RNA was performed by measuring 
absorbance ratio at 260 : 280 nm using a spectrophotometer system (Nanodrop 
2000c, Thermo Scientific, USA) before every assay. 
Optimisation of purified RNA for RT-PCR was carried out at different 
concentrations; starting with 1 µg total RNA per array. Amplification plot for 
the RT2 Profiler array demonstrated successful amplification (Figure 3.6), 
however some background noise were detected. Melting curve analysis for 
both HeLa cell lines is summarised in Figure 3.7. Three nonspecific products 
(melting peaks) detected in Control HeLa cells, and one nonspecific product 
was detected with BRCA1 HeLa cells.  
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Figure 3.6. Optimisation of RNA concentration for RT2 PCR. 
Amplification plot for RT2 Profiler DNA Repair Array, using 1 µg total RNA 
per array. Product is indicated by exponential fluorescence accumulation with 
increasing cycle number. Plot demonstrates successful amplification, though 
some background noise is detected.  
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     As mentioned above, using 1 µg total RNA per array showed successful 
amplification, however some background noise in amplification plot along 
with nonspecific product detected in melting curves. Therefore the total RNA 
was reduced using 0.5 µg which shows successful amplification of all 84 
primers for each of the cell lines (see Figure 3.8). Successful melting curve 
analysis for all the cell lines is summarised in Figure 3.9 with every specific 
product for all the 84 target genes.  
Figure 3.7. Melting curve analysis for HeLa cells with 1 µg total RNA per 
array. 
The presence of nonspecific product is observed as additional peaks to the left 
of the melting curve. Three nonspecific products (melting peaks) are seen in 
Control HeLa cells, and one nonspecific product was seen with BRCA1 HeLa.  
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Figure 3.8. Amplification plots for RT2 Profiler DNA Repair Array. 
Amplification of PCR product is indicated by exponential fluorescence 
accumulation with increasing cycle number.  
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Figure 3.9. Melting curves for RT2 Profiler PCR Array. 
Single melting peaks are observed for all the 84 primers assayed with all 
the cell lines, indicating high specificity. 
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3.3.4. BRCA1 deficiency is associated with multiple altered DNA 
repair gene expression profile 
 
     To investigate whether BRCA1 deficiency is associated with an altered 
DNA repair gene expression, both breast cancer (MDA-MB-436 and MCF7) 
and HeLa cell lines (BRCA1 HeLa deficient cells and Control HeLa proficient 
cells) were used to investigate mRNA expression by using RT2 PCR DNA 
repair profile assay as described in section 2.3.8.4. Data analysis as described 
in section 2.3.8.6 was performed by importing the raw RT2 PCR DNA repair 
profile assay data into a Qiagen analysis template that can compare multiple 
experimental replicates for one cell line against multiple experimental 
replicates of the control cells. The integrated Web-based software package for 
the PCR array system automatically performed all comparative threshold cycle 
ǻǻ&t)±based fold-change calculations from the uploaded data. For these 
calculations, GAPDH was used for normalization of the data. Scatter plots 
were charted to compare gene expression in BRCA1 wild type MCF7 cells to 
MDA-MB-436 and Control HeLa cells to BRCA1 HeLa cells as illustrated in 
Figure 3.10 and Figure 3.11. 
 
     A number of genes were initially observed to be under-expressed in 
BRCA1 deficient cell lines compared to BRCA1 proficient cells (though not 
statistically significant), including: BER factors (Table 3.3) such as (APE1, Pol 
ß, SMUG1, NTHL1, UNG, FEN1, OGG1, NEIL1 and XRCC1); HR factors 
(Table 3.4) such as (RAD21, RAD51, RAD54L and ATM); NHEJ factors (Table 
3.5) such as (DNA-PKcs, LIG4, XRCC5 and XRCC6); NER factors (Table 3.6) 
such as (ERCC1, ERCC2, ERCC3, ERCC4 and ERCC5) and MMR factors 
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(Table 3.7) such as (MLH1, MSH2, MLH3, MSH3, MSH4 and MSH5). Other 
related DNA repair gene expressions results are shown in APPENDIX C.   
 
 
 
 
 
Figure 3.10. Scatter plot comparing DNA repair gene expression in 
BRCA1 HeLa deficient cells against Control HeLa BRCA1 proficient cells.  
The area outside the grey lines indicates two-fold change in gene expression 
in BRCA1 HeLa deficient cells compared to Control HeLa proficient cells. 
Green circles indicate gene under-expression. Data are from 4 independent 
experiments. 
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Figure 3.11. Scatter plot comparing DNA repair gene expression in 
BRCA1 deficient MDA-MB-436 cells against Control BRCA1 proficient 
MCF7 cells. 
The area outside the grey lines indicates two-fold change in gene expression 
in BRCA1 deficient MDA-MB-436 cells compared to Control BRCA1 
proficient MCF7 cells. Green circles indicate gene under-expression. Data 
are from 3 independent experiments. 
103 
 
 
 
 
 
 
Table 3.3. Base excision repair genes under-expressed in BRCA1 deficient 
cell lines compared to BRCA1 proficient cell lines.  
Statistical significance determined using the Bonferroni correction for 
multiple testing, with p values less than 0.05 (threshold p < 0.000595 = 
0.05/84).  
 Fold Change P Value Fold Change P Value 
Base Excision Repair pathway 
 BRCA1 HeLa cells compared to 
Control HeLa cells. 
MDA-MB-436 cells compared 
to MCF7 cells 
APE1  0.9409 0.884684 0.3727 0.129971 
APE2  1.3159 0.513565 0.4227 0.186305 
PARP1  0.867 0.734063 0.3466 0.104084 
PARP2  0.5142 0.113767 0.4542 0.225598 
PARP3  0.6157 0.24867 0.74 0.643637 
Pol ß  0.4801 0.081162 0.3508 0.108061 
SMUG1  0.8477 0.694167 0.3244 0.084292 
NTHL1 0.7368 0.467355 0.1743 0.007565 
UNG 0.6014 0.2264 0.1367 0.002386 
FEN1 0.9652 0.932845 0.3687 0.125779 
OGG1 0.8994 0.800667 0.2696 0.044589 
NEIL1 0.1794 4.97E-05 0.1284 0.001735 
NEIL2 1.0452 0.916272 0.4597 0.232758 
NEIL3 0.7661 0.525954 0.172 0.007128 
XRCC1 0.46 0.065009 0.2161 0.019016 
CCNO 0.6362 0.281997 0.5398 0.343677 
LIG3 0.5202 0.120232 0.2258 0.022699 
MUTYH 0.5441 0.147802 0.3013 0.065909 
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 Fold Change P Value Fold Change P Value 
Homologous recombination pathway 
 BRCA1 HeLa cells compared 
to Control HeLa cells. 
MDA-MB-436 cells compared 
to MCF7 cells 
BRCA1 0.2858 0.002997 0.1102 0.000774 
BRCA2 0.8036 0.602818 0.1888 0.010779 
RAD21  0.7465 0.486529 0.3336 0.092238 
RAD50  0.598 0.221385 0.4154 0.177557 
RAD51  0.4348 0.047867 0.1967 0.01287 
RAD51B 0.5634 0.17243 0.0035 1.35E-16 
RAD51C  0.6507 0.306534 0.0366 6.01E-07 
RAD51D  0.2415 0.000771 0.2555 0.036586 
RAD54L 0.569 0.179889 0.1526 0.004084 
RAD52 0.4867 0.086983 0.5749 0.395073 
XRCC2 0.6684 0.337792 0.1455 0.003244 
XRCC3 0.6135 0.245154 0.2486 0.033003 
ATM 0.6491 0.30388 0.2646 0.04166 
DMC1 0.1552 1.12E-05 0.1049 0.000592 
Table 3.4. Homologous recombination genes under-expressed in BRCA1 
deficient cell lines compared to BRCA1 proficient cell lines.  
Statistical significance determined using the Bonferroni correction for 
multiple testing, with p values less than 0.05 (threshold p < 0.000595 = 
0.05/84).  
 
 
 Fold Change P Value Fold Change P Value 
Non-homologous end joining pathway 
 BRCA1 HeLa cells compared 
to Control HeLa cells. 
MDA-MB-436 cells compared 
to MCF7 cells 
DNA-PKcs 0.3941 0.027044 0.1417 0.00285167 
XRCC4 0.7831 0.560666 0.1958 0.0126124 
XRCC5 0.9085 0.819398 0.2602 0.0391621 
XRCC6 0.966 0.934363 0.3028 0.0670124 
XRCC6BP1  1.2011 0.662691 0.1237 0.00143637 
LIG4 0.8472 0.692972 0.225 0.0223933 
Table 3.5. Non-homologous end joining genes under-expressed in 
BRCA1 deficient cell lines compared to BRCA1 proficient cell lines.  
Statistical significance determined using the Bonferroni correction for 
multiple testing, with p values less than 0.05 (threshold p < 0.000595 = 
0.05/84).  
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 Fold Change P Value Fold Change P Value 
Nucleotide Excision repair pathway 
 BRCA1 HeLa cells compared 
to Control HeLa cells. 
MDA-MB-436 cells compared 
to MCF7 cells 
BRIP1  0.6094 0.238695 0.0207 6.21E-09 
LIG1 0.8041 0.603755 0.138 0.002504 
ATXN3 0.5322 0.133711 0.167 0.006227 
RAD23A  0.3338 0.009237 0.3472 0.104664 
RAD23B 1.1663 0.71429 0.3608 0.117858 
RPA1 0.8723 0.745059 0.3048 0.068525 
CCNH 0.8436 0.685694 0.3193 0.079999 
CDK7 0.9395 0.881941 0.3411 0.099029 
DDB1 0.9989 0.997897 0.4437 0.212276 
DDB2 0.6038 0.230168 0.0931 0.000303 
PNKP 0.513 0.112515 0.2365 0.027241 
POLL 0.3423 0.010967 0.331 0.089917 
RPA3 0.3167 0.006392 0.2927 0.059662 
SLK 0.6866 0.37098 0.4019 0.161845 
ERCC1 0.4388 0.050344 0.3989 0.15841 
ERCC2 0.5797 0.19469 0.4072 0.167956 
ERCC3 0.8955 0.792752 0.2168 0.019293 
ERCC4 0.677 0.353311 0.1761 0.00792 
ERCC5 0.7557 0.505017 0.7899 0.717002 
ERCC6 0.7167 0.428061 0.314 0.075715 
ERCC8 0.6865 0.370706 0.2744 0.047489 
XAB2 0.7547 0.503003 0.4005 0.160214 
XPA  0.8541 0.707449 0.2709 0.045366 
XPC 0.6286 0.269452 0.348 0.105382 
Table 3.6. Nucleotide excision repair genes under-expressed in BRCA1 
deficient cell lines compared to BRCA1 proficient cell lines.  
Statistical significance determined using the Bonferroni correction for 
multiple testing, with p values less than 0.05 (threshold p < 0.000595 = 
0.05/84).  
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 Fold Change P Value Fold Change P Value 
Mismatch repair pathway 
 BRCA1 HeLa cells compared to 
Control HeLa cells. 
MDA-MB-436 cells compared 
to MCF7 cells 
POLD3 0.6115 0.24197 0.2132 0.018015 
PMS1 0.4435 0.053395 0.266 0.04247 
PMS2 0.7229 0.439965 0.3196 0.080299 
MLH1 0.7251 0.444321 0.2236 0.021839 
MSH2 0.8477 0.694213 0.3276 0.086968 
MLH3 0.6227 0.259804 0.2389 0.028331 
MSH3  0.7749 0.543888 0.2801 0.051116 
MSH4  0.3285 0.00828 0.6991 0.582307 
MSH5  0.3414 0.010783 0.1551 0.004409 
MSH6  0.6342 0.27871 0.3555 0.112648 
MPG 0.7868 0.568232 0.2445 0.031002 
TREX1 0.8607 0.721094 0.7439 0.649341 
Table 3.7. Mismatch repair genes under-expressed in BRCA1 deficient 
cell lines compared to BRCA1 proficient cell lines.  
Statistical significance determined using the Bonferroni correction for 
multiple testing, with p values less than 0.05 (threshold p < 0.000595 = 
0.05/84).  
 
 
3.3.5. DNA repair protein expression is down-regulated in BRCA1 
deficient cell lines compared to BRCA1 proficient cell lines.  
 
     The 57ð3URILOHU$UUD\suggested reduced expression of several mRNAs 
involved in BER, HR, NHEJ, NER and MMR in BRCA1 deficient cell lines as 
compared to BRCA1 proficient cell lines. As discussed previously (section 
3.1.2.) selected DNA repair factors (APE1, XRCC1, SMUG1, Pol ß, Lig3, 
ATM and DNA-PKcs) will be investigated. To determine the protein 
expression of these factors, western blots were performed as described in 
section 2.3.9. Western blots results of BER, HR and NHEJ factors are shown 
in Figure 3.12 and Figure 3.13. Reduced expression of XRCC1, APE1, 
SMUG1, Pol ß and lig3, along with both ATM and DNA-PKcs proteins were 
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observed in BRCA1 deficient cell lines as compared to BRCA1 proficient cell 
lines.   
 
 
Figure 3.12. Representative western blot analysis of Base Excision Repair 
proteins in BRCA1 deficient and proficient cell lines.  
BER Proteins (XRCC1, APE1, SMUG1, Pol ß and Lig3) expression shows down-
regulation in BRCA1 deficient cell lines (BRCA1 HeLa and MDA-MB-436) 
compared to BRCA1 proficient cell lines (Control HeLa and MCF7). Whole cell 
protein lysates were collected for each cell line and 25 or 50 µg samples were 
separated by electrophoresis on denaturing polyacrylamide gels as described in 
section 2.3.9. Blot was probed using specific antibodies with predicted molecular 
weight (XRCC1, 80 kDa; APE1, 37 kDa; SMUG1, 37 kDa; Pol ß, 38 kDa and Lig3, 
113 kDa)$VDORDGLQJFRQWUROȕ-actin antibody (42 kDa) was used.   
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3.3.6. Quantitative real time PCR (RT-qPCR) in BRCA1 deficient 
and BRCA1 proficient cells. 
 
     Quantitative real time PCR (RT-qPCR) using QuantiTect® Primers (Qiagen, 
UK) was performed as described in section 2.3.8.5 for the selected DNA repair 
factors; BRCA1, APE1, XRCC1, SMUG1, Pol ß, Lig3, ATM and DNA-PKcs 
(discussed previously section 3.1.2.). mRNA expression is shown in Table 3.8 
Figure 3.13. Representative western blot analysis of ATM and DNA-PKcs 
expression.  
ATM and DNA-PKcs are down-regulated in BRCA1 deficient cell lines 
(BRCA1 HeLa and MDA-MB-436) compared to BRCA1 proficient cell lines 
(Control HeLa and MCF7). Whole cell protein lysates were collected for each 
cell line and 25 or 50 µg samples were separated by electrophoresis on 
denaturing polyacrylamide gels as described in section 2.3.9. Blot was probed 
using specific antibodies with predicted molecular weight (ATM, 350 kDa and 
DNA-3.FV  N'D $V D ORDGLQJ FRQWURO ȕ-actin antibody (42 kDa) was 
used.   
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for breast cancer cell lines and mRNA expression for HeLa cell lines is shown 
in Table 3.9.  
 
 Fold Change P Value 
APE1 0.0716 0.0057 
XRCC1 0.0406 0.0007 
SMUG1 0.0533 0.0029 
Pol ß 0.2487 0.0.033 
Lig3 0.2720 0.0257 
ATM 0.0165 0.0002 
DNA-PKcs 0.0584 0.0019 
BRCA1 0.0938 0.0026 
Table 3.8. Quantitative real time PCR (RT-qPCR) for multiple DNA 
repair genes in BRCA1 deficient cells. 
DNA repair mRNA expression in MDA-MB-436 compared to MCF7 cells.  
Statistical significance determined using t test, with p values less than 0.05.  
 
 
 Fold Change P Value 
APE1 0.3622 0.0081 
XRCC1 0.3150 0.0151 
SMUG1 0.5100 0.0469 
Pol ß 0.3100 0.0166 
Lig3 0.5678 0.0004 
ATM 0.2750 0.0285 
DNA-PKcs 0.2300 0.0454 
BRCA1 0.1627 0.0015 
Table 3.9. Quantitative real time PCR (RT-qPCR) for multiple DNA 
repair genes in BRCA1 deficient cells. 
DNA repair mRNA expression in BRCA1 HeLa cells compared to Control 
HeLa cells. Statistical significance determined using t test, with p values 
less than 0.05. 
 
 
 
 
110 
 
 
3.3.7. Quantification of DNA repair mRNA and protein 
expression in BRCA1 deficient and BRCA1 proficient cells. 
 
     Relative quantification of mRNA and protein expression for XRCC1, 
APE1, SMUG1, Pol ß, Lig3, ATM and DNA-PKcs was performed. BRCA1 
HeLa cells, expressed relatively low DNA repair factors compared to Control 
HeLa cells, as demonstrated in Figure 3.14 and Figure 3.16. MDA-MB-436 
cells expressed relatively low DNA repair factors compared to MCF7 cells, as 
demonstrated in Figure 3.15 and Figure 3.17.      
Western blot results were analysed using Image Studio (Li-Cor, Lincoln, USA) 
as described in section 2.3.9.8. RT-qPCR results were analysed as described in 
section 2.3.8.6. These assays were performed in two or more independent 
experiments. The student t-test was used to investigate the difference in 
expression of DNA repair proteins between BRCA1 proficient and BRCA1 
deficient cell lines.  
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Figure 3.14. Quantification of Base Excision Repair proteins expression 
(left) and quantitative real time PCR (RT-qPCR) showing mRNA 
expression (right) in BRCA1 deficient and proficient HeLa cell lines. 
(A) Showing protein expression, values plotted are means ± SD of the fold-
change (ratio of protein/ß-actin normalized to control) and (B) mRNA 
expression, values plotted are means ± SD of the fold-change (ratio of 
mRNA/GAPDH normalized to control). * p<0.05, ** p<0.01 and *** 
p<0.001, p value was assessed by t-test compared to Control HeLa cell line. 
Graphs were produced and statistical analysis performed using 
GraphPad prism. 
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Figure 3.15. Quantification of Base Excision Repair proteins expression 
(left) and quantitative real time PCR (RT-qPCR) showing mRNA 
expression (right) in BRCA1 deficient and proficient breast cancer cell 
lines.  
(A) Showing protein expression, values plotted are means ± SD of the fold-
change (ratio of protein/ß-actin normalized to control) and (B) mRNA 
expression, values plotted are means ± SD of the fold-change (ratio of 
mRNA/GAPDH normalized to control). * p<0.05, ** p<0.01 and *** 
p<0.001, p value was assessed by t-test compared to MCF7 cell line. 
Graphs were produced and statistical analysis performed using 
GraphPad prism.  
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Figure 3.16. Quantification of ATM and DNA-PKcs protein (left) and 
quantitative real time PCR (RT-qPCR) showing mRNA expression 
(right) in BRCA1 deficient and proficient HeLa cell lines.  
(A) Showing protein expression, values plotted are means ± SD of the fold-
change (ratio of protein/ß-actin normalized to control) and (B) mRNA 
expression, values plotted are means ± SD of the fold-change (ratio of 
mRNA/GAPDH normalized to control). * p<0.05, p value was assessed by 
t-test compared to Control HeLa cell line. Graphs were produced and 
statistical analysis performed using GraphPad prism.  
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Figure 3.17. Quantification of ATM and DNA-PKcs protein expression 
(left) and quantitative real time PCR (RT-qPCR) showing mRNA 
expression (right) in BRCA1 deficient and proficient breast cancer cell 
lines.  
(A) Showing protein expression, values plotted are means ± SD of the fold-
change (ratio of protein/ß-actin normalized to control) and (B) mRNA 
expression, values plotted are means ± SD of the fold-change (ratio of 
mRNA/GAPDH normalized to control). * p<0.05, ** p<0.01 and *** 
p<0.001, p value was assessed by t-test compared to MCF7 cell line. 
Graphs were produced and statistical analysis performed using GraphPad 
prism. 
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3.3.8. Growth inhibition MTS assay in response to MMS 
 
     BRCA1 deficient cells demonstrate low BER factors as shown. To test 
whether low BER expression confers phenotypic consequence, MMS 
(alkylating agent) in BRCA1 proficient and deficient cells was investigated. 
MTS assay was used to determine cell growth inhibition in response to MMS 
treatment (0.00 µM to 800 µM) for 72 hours in BRCA1 mutated MDA-MB-
436 cells and control MCF7 cells. As shown in Figure 3.18, BRCA1 mutated 
MDA-MB-436 cells were more sensitive to MMS than control MCF7 cells. 
The data concurs with a previous study by Masaoka et al, who demonstrated 
similar MMS sensitivity in BRCA1 deficient cells (Masaoka et al., 2013). 
  
Figure 3.18. MMS treatment in BRCA1 deficient and proficient cells. 
BRCA1 deficient cells exhibited decreased cell growth after exposure for 
72 hours to MMS, compared to BRCA1 proficient cell line. Data are 
shown as the mean and SD values for each concentration from 2 
independent experiments. 
118 
 
 
3.4. Discussion and conclusions 
3.4.1. Loss of BRCA1 expression links to a global reduction in 
mRNA and proteins involved in Base excision repair pathway 
 
     In a recent publication, BRCA1 has been suggested to stimulate the activity 
of three BER enzymes; OGG1 (8-oxoguanine DNA glycosylase), NTH1 
(homolog of endonuclease III), and APE1 (apex nuclease 1). These enzymes 
mediate repair of three signature oxidative lesions; 8-oxoguanine, thymine 
glycol and abasic sites, respectively (Saha et al., 2010). A more recent study 
supports these findings, and has confirmed down-regulation of APE1, NTH1, 
OGG1 as well as XRCC1 in BRCA1 mutated and sporadic breast cancers (De 
Summa et al., 2014). XRCC1 protein associates with Pol ß, and Lig3, to form a 
complex that repairs the single strand DNA breaks generated during the BER 
process (Saha et al., 2010). Other studies suggest a cross talk between BRCA1 
and other BER genes e.g. Pol ß and SMUG1 (Masaoka et al., 2013, Abdel-
Fatah et al., 2013), highlighting additional BER factors that may be associated 
with BRCA1 expression. For these reasons in the current study BER factors; 
APE1, XRCC1, SMUG1, Pol ß and Lig3 were investigated. To achieve this, 
the 57ð 3URILOHU $UUD\ was conducted first to investigate 84 DNA repair 
genes in BRCA1 deficient cell lines as compared to BRCA1 proficient cell 
lines. However, the establishment of a statistical significance threshold that 
adequately controls the proportion of false-positive findings is not a trivial 
issue. Therefore, due to the sample size and number of arrays statistical 
significance was determined using a Bonferroni correction to adjust for 
multiple testing, with corrected p values set at less than 0.05 (threshold p < 
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0.000595 = 0.05/84). Thus, the current RT² Profiler array results did not 
always reach statistical significance and further independent replicates are 
required. Further assessment of the results was carried out using quantitative 
real time PCR (RT-qPCR) for the selected DNA repair genes as discussed 
above. Finally, the mRNA expression of the selected genes was compared with 
protein expression using western blot. 
In the current study, expression of several BER mRNAs were found to be 
down-regulated in both BRCA1 mutant/knockdown cell lines (see Table 3.3); 
low mRNA expression was demonstrated for APE1, OGG1 and NTHL1 genes 
which was consistent with the results published by Saha et al. mRNAs of the 
selected BER genes also showed down-regulation. Interestingly many other 
BER mRNAs showed down-regulation including; PARP1, PARP2, PARP3, 
NEIL1, NEIL3, UNG, FEN1, MUTYH and CCNO. Targeted assessment in 
individual primer assays may be useful to further assess these genes. 
Conversely, individual RT-qPCR analysis for XRCC1, APE1, LIG3, SMUG1 
and Pol ß mRNA expression demonstrated significant reduction in both 
mutant/knockdown BRCA1 cell lines as compared to proficient BRCA1 cell 
lines (see Table 3.8 and Table 3.9). This reduction was linked to reduction in 
protein expression (see Figure 3.14 and Figure 3.15). These results suggest that 
there may be impairment in key BER factors in BRCA1 deficient cells, which 
may cause different types of unrepaired single strand breaks.  
3.4.1.1. BRCA1 deficient cell lines are hypersensitive to 
MMS  
     In this section of the study the efficacy of the alkylating agent in DNA 
damage formation in BRCA1 deficient and proficient cells was investigated. 
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Methyl methane sulphonate (MMS) is an alkylating agent, damage induced by 
MMS is repaired by BER pathway. MMS acts by methylating DNA on N7-
deoxyguanosine and N3-deoxyadenosine, creating adducts that are substrates 
for BER. At high concentrations of MMS, the frequency of methylation events 
overwhelms BER capacity and induce replication fork stalling, resulting in 
cytotoxic levels of DSB formation (Stevnsner et al., 1993, Masaoka et al., 
2013). A number of studies have shown that BRCA1/BER deficient cell lines 
were hypersensitive to MMS compared to their wild type matched controls 
(Bridge et al., 2005, Masaoka et al., 2013). In this study MMS was confirmed 
to be selectively toxic to BRCA1/BER mutated human cancer cell line (MDA-
MB-436) compared to MCF7 proficient cell line by using MTS assay. This 
result suggests impairment in BER. However, measuring BER efficiency 
should be conducted in BRCA1 deficient cell lines in the future studies.  
3.4.2. Loss of BRCA1 expression is associated with reduction in 
expression of Homologous recombination factors 
 
     The first report of a role for BRCA1 in genomic stability and double strand 
break repair, by Scully and colleagues, suggested a functional interaction 
between BRCA1 and RAD51 in both the meiotic and mitotic cell cycles. This 
in turn suggests an important role for BRCA1 in controlling genomic stability 
(Scully et al., 1997). This association was corroborated by a later report by 
Chen and colleagues, who observed the presence of both BRCA1 and RAD51 
on the damaged DNA site in meiotic cells (Chen et al., 1998). This finding was 
followed by the first functional evidence for the role of BRCA1 in HR repair 
pathway through its direct interaction with RAD51 (Moynahan et al., 1999). 
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Subsequent observations that agents causing recombinogenic lesions like 
cisplatinum and ionizing radiation, do not induce formation of RAD51 foci in 
BRCA1 deficient cells, suggesting that disruption of BRCA1 was associated 
with markedly reduced expression of RAD51 (Bhattacharyya et al., 2000, 
Bindra et al., 2004). In the current study, reduced BRCA1 expression in 
mutant/knockdown cell lines was associated with a reduction in RAD51 
expression at mRNA (see Table 3.4) in both mutant/knockdown cell lines. 
Several other HR mRNA expressions were also observed to be down-regulated 
in both mutant/knockdown cell lines; low mRNA expression was demonstrated 
for RAD51 related family (RAD51B, RAD51C and RAD51D), RAD50, RAD52, 
XRCC3, BRCA2 and DMC1. In addition, RAD54L and XRCC2 were also 
down-regulated in both mutant/knockdown cell lines. Recently, RAD21 has 
been suggested as a potential BRCA1 mutation status dependent predictive and 
prognostic marker in familial breast cancer (Yan et al., 2012). In the present 
study low mRNA expression of RAD21 in both mutant/knockdown cell lines 
was demonstrated. ATM is believed to be the first sensor in DSB and a key 
player in HR pathway. ATM activates multiple genes involved in HR repair, 
cell cycle arrest and apoptosis. Substrates for ATM phosphorylation include; 
BRCA1, p53, CHK2, histone H2AX and MRN complex (Bakkenist and 
Kastan, 2004). In this study low mRNA expression of ATM in BRCA1 
mutant/knockdown cell lines was demonstrated using RT2-PCR array. Then 
ATM was assessed in individual RT-qPCR which showed significant mRNA 
reduction in both mutant/knockdown BRCA1 cell lines compared to proficient 
BRCA1 cell lines (see Table 3.8 and Table 3.9). Gene expression was 
associated with protein expression for ATM (see Figure 3.16 and Figure 3.17). 
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Taken together, these results suggest that BRCA1 deficiency may associate 
with a global defect in HR repair expression. However, individual primer 
assays may be useful to further assess these genes.  
 
3.4.3. Loss of BRCA1 expression is associated with reduction in 
expression of Non-homologous end joining factors 
 
     BRCA1 interacts with the Rad50/Mre11/Nbs1 complex that occupies a 
central role in DNA double-strand break repair mediated by HR and NHEJ. 
Zhong and colleagues suggested a BRCA1 role in NHEJ. They investigated 
Brca1-deficient mouse embryonic fibroblasts cell extracts and found that it 
exhibit reduced end-joining activity independent of the endogenous protein 
amounts of DNA LIG4, KU80 (known as XRCC5), and KU70 (known as 
XRCC6) (Zhong et al., 2002). In the current study, reduced BRCA1 expression 
in mutant/knockdown cell lines was associated with a reduction in LIG4, 
XRCC5 and XRCC6 expression at mRNA confirming Zhong et al results (see 
Table 3.5). In addition, XRCC4 show down-regulation at the mRNA 
expression in mutant/knockdown cell lines. DNA-PKcs is known to have a 
critical role in NHEJ pathway. Recently, Shang and colleagues reported that 
DNA-PKcs is the upstream regulator of the CHK2±BRCA1 pathway (Shang et 
al., 2014). In this study low mRNA expression of DNA-PKcs was 
demonstrated in mutant/knockdown cell lines by RT2-PCR array (see Table 
3.5). Then DNA-PKcs was assessed in individual RT-qPCR which showed 
significant mRNA reduction in both mutant/knockdown BRCA1 cell lines 
compared to proficient BRCA1 cell lines (see Table 3.8 and Table 3.9). Also, 
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gene expression was consistent with protein expression in DNA-PKcs (see 
Figure 3.16 and Figure 3.17). Taken together, these results suggest that 
BRCA1 deficiency is associated with impairment in NHEJ expression.  
 
3.4.4. Loss of BRCA1 expression is associated with reduction in 
expression of other DNA repair factors 
 
     BRCA1 has been suggested to control Nucleotide excision repair (NER), 
through the p53 protein which regulates NER by transcriptional regulation of 
genes involved in the recognition of adducts in genomic DNA. Loss of p53 
function results in deficient global genomic repair (GGR), a subset of NER 
that targets and removes lesions from the whole genome. BRCA1 specifically 
enhances the GGR pathway, independent of p53, and can induce p53-
independent expression of the NER genes XPC, DDB2, and GADD45 
(Hartman and Ford, 2002). In the current study, reduced BRCA1 expression in 
mutant/knockdown cell lines was associated with a reduction in XPC and 
DDB2 expression at mRNA consistent with the data published by Hartman and 
Ford (see Tabel 3.6). In addition, a panel of NER factors also shows down-
regulation at the mRNA expression. For instance; CCNH, RPA3, ERCC1, 
ERCC4, ERCC6, ERCC8, BRIP1, LIG1, ATXN3, RAD23A, RPA1, CDK7, 
DDB1, DDB2, PNKP, POLL, SLK, ERCC2, ERCC3, ERCC5, XAB2 and XPA.   
 
The role of BRCA1 in MMR pathway is still not understood, however recently 
a report by Song and colleagues demonstrated that mutation in BRCA1 was 
followed by mutation in MSH6 and MSH2 (Song et al., 2014). In the current 
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study, reduced BRCA1 expression in mutant/knockdown cell lines was 
associated with a reduction in MSH6 and MSH2 expression at mRNA 
supporting Song et al results (see Table 3.7). Moreover, a panel of MMR 
mRNA expressions were observed to be down-regulated in both 
mutant/knockdown cell lines including; POLD3, PMS1, PMS2, MLH1, MLH3, 
MSH3, MSH4, MSH5, MPG and TREX1. These results suggest that BRCA1 
deficiency may associate with a global defect in NER and MMR expression. 
However, further investigation is needed to measure the efficiency of these 
pathways.   
 
Taken together, the main aim of this chapter was to investigate a potential 
impairment in DNA repair pathways within BRCA1 deficient cells. To achieve 
this, 57ð 3URILOHU $UUD\ was conducted first to investigate 84 DNA repair 
genes in BRCA1 deficient cell lines compared to BRCA1 proficient cell lines. 
Data demonstrated down-regulation in several DNA repair mRNAs however; 
the results did not always give statistical significance. Further assessment of 
the results was carried out using quantitative real time PCR (RT-qPCR) for 
selected DNA repair genes (APE1, XRCC1, SMUG1, Pol ß, Lig3, ATM and 
DNA-PKcs) which had previously been shown to have a potential link with  
BRCA1 (Abdel-Fatah et al., 2013, Masaoka et al., 2013, De Summa et al., 
2014). Data for individual primers demonstrated statistically significant down-
regulation of the selected DNA repair genes. This highlights the difference 
between the two PCR methods, where both showed consistent down-regulation 
but data was not statistically significant with the 57ð 3URILOHU $UUD\ 7KLV
can have two explanations. Firstly the efficiency, specificity and sensitivity of 
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primers can differ. Secondly, and more importantly, the average threshold 
cycle (Ct) should be in the range of 15 to 35 which is considered as a strong 
positive reaction. Ct values greater than 35 are considered as a weak reaction. 
Ct value is negatively associated with the concentration of nucleic acids 
detected. Ct values are classified in subsequent categories of Ct < 25, Ct 25-35 
and Ct 35-40. In the present study both Ct values for both PCR methods were 
in the range of 18 to 33. However the percentage distributions of Ct values 
were different. In the 57ð3URILOHU$UUD\RI&WYDOXHVZHUHDQG
34% between 25 and 35, whereas by RT-qPCR around 90% of Ct values were 
25-35 and 10% were < 25. This suggests that the reason for having consistent 
but not statistically significant results in 57ð3URILOHU$UUD\ZDVEHFDXVHRI
the distribution of the Ct values. It is worth mentioning that a previous study 
demonstrated similar results when they compared a quantitative RT-PCR array 
(qPCR-array) with an oligonucleotide microchip (microarray) (Chen et al., 
2009). For future work this problem can be avoided by further dilution of the 
cDNA. 
3.4.5. Conclusions 
     These in vitro studies suggested that BRCA1 has been linked to a possible 
defect in BER, HR, NHEJ, NER and MMR, via mechanisms that are not fully 
understood. This chapter described the assessment of DNA repair factors 
expressions in BRCA1 mutant/knockdown cell lines. Selected DNA repair 
factors (APE1, XRCC1, SMUG1, Pol ß, Lig3, ATM and DNA-PKcs) were 
observed to be down-regulated at the mRNA and/or protein expression. Taken 
together, these results suggest that BRCA1 deficiency may be associated with 
a global defect in DNA repair.  
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4. Targeting BRCA1 deficiency in breast cancer for 
personalized therapy using ATM inhibitors 
(KU55933 & KU60019) 
4.1. Introduction 
 
 
     BRCA1 facilitates the efficient resolution of DNA double-strand breaks 
(DSBs) through homologous recombination (HR) (Huen et al., 2010, 
Caestecker and Van de Walle, 2013). Cells lacking functional BRCA1 protein 
have impaired HR, and thus are suggested to depend on the more error-prone 
non-homologous end joining (NHEJ) pathway leading to chromosomal 
instability that drive breast cancer development (Huen et al., 2010). BER 
pathway is critical for processing DNA damage caused by alkylation, 
oxidation, ring saturation, single strand breaks and base deamination (Dianov 
and Hubscher, 2013).  
PARP1 (poly [ADP-ribose] polymerase 1) plays a role in single strand break 
repair (SSBR), a BER related pathway (Langelier and Pascal, 2013). The DNA 
repair intermediates generated during SSBR/BER, if unrepaired, may get 
converted to toxic DSBs (Dianov and Hubscher, 2013). PARP1 inhibition is 
synthetically lethal in BRCA deficient cells (Farmer et al., 2005, Bryant et al., 
2005). Although it should be noted that recent studies illustrated some 
problems with PARP inhibition (Edwards et al., 2008, Montoni et al., 2013, 
Fojo and Bates, 2013). For instance, PARP family of enzymes consist of at 
least 17 members, each one of them has a different structure and function 
(Rouleau et al., 2010, Mangerich and Burkle, 2011, Underhill et al., 2011). So 
there are issues with specificity of current inhibitions under development. 
Moreover, a recent study evaluated a series of 185 inhibitors of PARP, 
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including the best-known inhibitors being tested clinically such as Olaparib, 
ABT-888 and Rucaparib, for the specificity to bind to the catalytic domains of 
13 of 17 human PARP family members. In this study they determined that the 
majority of the inhibitors bind to multiple targets (Wahlberg et al., 2012).        
Emerging studies suggest a cross talk between BRCA1 and BER factors. 
BRCA1 mutated and basal-like breast cancer cells were found to be sensitive 
to oxidative DNA damage induced by hydrogen peroxide (H2O2) treatment. 
The increased sensitivity was associated with defective BER as assessed by 
cell based BER assay in BRCA1 deficient cells (Alli et al., 2009). In a more 
recent study, BRCA1 deficient cells were sensitive to alkylating agent Methyl 
methane sulphonate (MMS) and functional interaction between Pol ß and 
BRCA1 was demonstrated in that study (Masaoka et al., 2013) implying a 
potential role for Pol ß in BRCA1 mediated DSB repair. In addition, BRCA1 
has also been shown to be involved in the transcriptional regulation of BER 
factor such as OGG1, NTH1, XRCC1 and APE1 (Saha et al., 2010, De Summa 
et al., 2014). 
Ataxia telangiectasia mutated (ATM) is a key component of HR pathway. 
ATM is a serine/threonine kinase that activates over a hundred proteins 
involved in DNA damage response, DNA repair, cell cycle regulation, 
apoptosis and other pathways (Kurz and Lees-Miller, 2004, Chaudhary and Al-
Baradie, 2014). The ATM signalling pathway is activated following DSBs. 
ATM is recruited to the damaged sites, however it is not clear if ATM interacts 
with damaged DNA directly or indirectly. It was previously thought that ATM 
activation primarily requires direct binding to MRN complex which is a sensor 
of DSBs (Chaudhary and Al-Baradie, 2014). However recent studies have 
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shown that PARP1 may control ATM phosphorylation and mediates the 
earliest recruitment of MRE11 and NBS1 to DNA damage (Rupnik et al., 
2008, Haince et al., 2008, Haince et al., 2007).  
4.1.1. Rationale for study 
     Data presented in Chapter 3 of this thesis suggested that BRCA1 deficiency 
is associated with reduced expression of several factors involved in BER. In 
this chapter it was investigated if such BRCA1-BER deficient cells could be 
targeted by blockade of ATM for personalized therapy.  
4.2. Aims 
The aims of this study were as follows: 
1. To investigate the effect of ATM inhibitors (KU55933 and KU60019) 
on cell viability and growth using clonogenic cell survival and MTS 
assays.  
2. To confirm the effect of PARP inhibitors (NU1025 and 3-
Aminobenzamide) on cell viability and growth using clonogenic cell 
survival and MTS assays. 
3. To test the hypothesis that DNA double strand breaks accumulate in 
cells after exposure to ATM inhibitors in BRCA1 deficient cells.  
4. To determine the effect of ATM inhibitors on cell cycle in BRCA1 
deficient cells.  
5. To explore induction of apoptosis in BRCA1 deficient cells after 
treatment with ATM inhibitors.   
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4.3. Results 
 
4.3.1. Clonogenic cell survival and Growth inhibition in response 
to ATM inhibitors (KU55933 & KU60019)  
 
     The plating efficiencies (which is a measure of a cells ability to form 
colonies) of the HeLa cell lines were around 60% to 98% in this study, this is 
consistent with the previous published literature which showed the high plating 
efficiency of HeLa cells (Puck and Fisher, 1956, Rafferty, 1985). On the other 
hand, previous studies showed plating efficiency of breast cancer cell lines 
around 29% to 55% (Mukherjee et al., 2005, Mukherjee and Martin, 2006, 
Ware et al., 2007, Zhang et al., 2014, Karasawa et al., 2014, Duangmano et al., 
2012). In this present study plating efficiencies for MCF7 and MDA-MB-436 
cells in clonogenic assay were around (45% to 58%) and (24% to 54%), 
respectively. It is possible that one of the reasons for this slight 
increase/decrease in plating efficiencies is due to the specific culture 
conditions (e.g. cell culture media and FBS concentrations) and cell seeding 
number in different studies.    
 
Clonogenic survival assays were performed to test whether BRCA1 deficient 
cells are sensitive to ATM inhibition. BRCA1 mutated (MDA-MB-436) and 
knockdown cell lines (BRCA1 HeLa cells) along with BRCA1 proficient 
MCF7 cells and Control HeLa cell lines were treated with increasing 
concentrations of KU55933 (C21H17NO3S2) which is a potent, selective and 
competitive ATM kinase inhibitor. Results are shown in Figure 4.1.   
IC50 values were calculated using nonlinear regression, with the proviso that in 
BRCA1 proficient cell lines (Control HeLa and MCF7) cytotoxicity did not 
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approach 50% in some cases, thus impairing extrapolation. Clonogenic assay 
demonstrated that BRCA1 HeLa cells, are more sensitive to KU55933 
compared to Control HeLa cells (mean IC50= 2.911 ± 0.21 vs. mean IC50= 
9.160 ± 1.6). Similarly, increased sensitivity was also demonstrated in BRCA1 
mutated MDA-MB-436 cells compared to control MCF7 cells (mean IC50= 
6.39 ± 0.43 vs. mean IC50= 9.23 ± 0.48).      
In general, increasing concentrations of KU55933 inhibitor reduced the colony 
forming ability in BRCA1 deficient cells compared to the BRCA1 proficient 
cells. To validate further, an alternative clonogenic assay protocol was 
performed, where cells were treated with ATM inhibitor for 24 hours then 
 
Figure 4.1. Clonogenic survival assay of ATM inhibitor (KU55933).  
Cell lines with reduced BRCA1 expression exhibited decreased colony 
forming ability after treatment with KU55933 inhibitor for 14 days, compared 
to BRCA1 proficient cell lines. (A) BRCA1 HeLa cells compared to Control 
HeLa cells. (B) MDA-MB-436 cells compared to MCF7 cells. Plating 
efficiencies of cell lines with standard error were as follows: (A) Control 
HeLa- 85.83% ± 3.433%; BRCA1 HeLa- 74.10% ± 4.054% (B) MCF7- 
45.71% ± 4.69%; MDA-MB-436- 36.73% ± 3.67%. Clonogenic data are 
shown as the mean and SD YDOXHVIRUHDFKFRQFHQWUDWLRQIURPLQGHSHQGHQW
experiments. 
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culture media was replaced with fresh media and the remaining assay was 
conducted as described in 2.3.4.3. Results are illustrated in Figure 4.2.  
 
The alternative clonogenic assay results demonstrated that BRCA1 HeLa cells 
are more sensitive to KU55933 than Control HeLa cells (mean IC50= 5 ± 0.24 
vs. IC50 above the maximum level tested). Similarly, sensitivity was 
demonstrated in BRCA1 mutated MDA-MB-436 cells compared to control 
MCF7 cells (mean IC50= 4.45 ± 0.23 vs. IC50 above the maximum level 
tested). Both the 24 hour KU55933 treatment protocol and the 14 day 
treatment protocol, provide evidence that increasing concentration of KU55933 
  
Figure 4.2. Clonogenic survival assay of inhibitor KU55933 (24 hours 
treatment protocol). 
Cell lines with reduced BRCA1 expression exhibited decreased colony 
forming ability after treatment with KU55933 inhibitor for 24 hours. (A) 
BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-436 
cells compared to MCF7 cells. Plating efficiencies of cell lines with 
standard error were as follows: (A) Control HeLa- 83.30% ± 3.30%; 
BRCA1 HeLa- 86.80% ± 6.80% (B) MCF7- 48.78% ± 4.33%; MDA-
MB-436- 53.62% ± 1.94%. Clonogenic data are shown as the mean and 
SD values for each concentration from 2 independent experiments.  
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inhibitor reduces the colony forming ability of BRCA1 deficient cell lines 
compared to the BRCA1 proficient cell lines. The 14 day treatment protocol 
was used for all further clonogenic assays described in the rest of the thesis.  
 
 
     For additional validation, the proliferation assay (MTS assay) was used to 
determine cell growth in response to KU55933. As shown in Figure 4.3, 
BRCA1 deficient HeLa cells were more sensitive to KU55933 than the Control 
HeLa cells. Similar sensitivity was demonstrated in BRCA1 mutated MDA-
MB-436 cells compared to control MCF7 cells. 
 
 
 
 
Figure 4.3. MTS cell growth inhibition assays of ATM inhibitor (KU55933).  
Cell lines with reduced BRCA1 expression exhibited decreased cell growth after 
treatment with KU55933 inhibitor for 6 days, compared to BRCA1 proficient cell 
lines. (A) BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-436 
cells compared to MCF7 cells. Data are shown as the mean and SD values for each 
FRQFHQWUDWLRQIURP2 independent experiments. 
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     For further validation, KU60019 (C30H33N3O5S), another ATM potent 
kinase inhibitor, was investigated (Golding et al., 2009). As shown in Figure 
4.4 clonogenic cell survival assays, BRCA1 HeLa cells are more sensitive to 
KU60019 than Control HeLa cells. Similar sensitivity was also demonstrated 
in BRCA1 mutated MDA-MB-436 cells compared to control MCF7 cells. 
Taken together, these data provide strong evidence that BRCA1 deficient cells 
are sensitive to ATM inhibition.   
    
 
Figure 4.4. Clonogenic survival assay of ATM inhibitor (KU60019). 
Cell lines with reduced BRCA1 expression exhibited decreased colony forming 
ability after treatment with KU60019 inhibitor for 14 days, compared to BRCA1 
proficient cell lines. (A) BRCA1 HeLa cells compared to Control HeLa cells. 
(B) MDA-MB-436 cells compared to MCF7 cells. Plating efficiencies of cell 
lines with standard error were as follows: (A) Control HeLa- 87.75% ± 5.75%; 
BRCA1 HeLa- 67.00% ± 17.00% (B) MCF7- 61.36% ± 4.21%; MDA-MB-436- 
46.00% ± 4.25%. Clonogenic data are shown as the mean and SD values for 
HDFKFRQFHQWUDWLRQIURP2 independent experiments.   
135 
 
 
4.3.2. Growth inhibition and clonogenic cell survival in response 
to PARP inhibitors 
 
     MTS cell growth assays were performed using NU1025 (C9H8N2O2) a well 
characterised inhibitor of PARP (Bowman et al., 1998, Griffin et al., 1998, 
Sultana et al., 2012), as a positive control drug to induce lethality in this model 
system. Figure 4.5 demonstrates that BRCA1 HeLa cells were more sensitive 
to NU1025 than the Control HeLa cells. Similar sensitivity was also 
demonstrated in BRCA1 mutated MDA-MB-436 cells compared to control 
MCF7 cells. This result is consistent with previous studies that demonstrated 
similar sensitivity in BRCA1 deficient cells to NU1025 (Bryant et al., 2005, 
Sultana et al., 2012). 
 
 
 
Figure 4.5. MTS cell growth inhibition assays of PARP inhibitor (NU1025). 
Cell lines with reduced BRCA1 expression exhibited decreased cell growth after 
treatment with NU1025 inhibitor for 6 days, compared to BRCA1 proficient cell 
lines. (A) BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-
436 cells compared to MCF7 cells. Data are shown as the mean and SD values 
IRUHDFKFRQFHQWUDWLRQIURP2 experiments. 
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      For additional validation, 3-Aminobenzamide (C7H8N2O) another PARP 
inhibitor, was investigated (Purnell and Whish, 1980). As shown in Figure 4.6, 
BRCA1 HeLa cells are more sensitive to 3-Aminobenzamide compared to 
Control HeLa cells. Similar sensitivity was also demonstrated in BRCA1 
mutated MDA-MB-436 cells compared to control MCF7 cells. This result is 
consistent with a previous study that showed sensitivity in BRCA1 deficient 
cells to 3- Aminobenzamide (Bryant et al., 2005). Functional analyses in cells 
were then carried out to investigate ATM inhibition in BRCA1 deficient cells.   
 
 
  
 
Figure 4.6. Clonogenic survival assay of PARP inhibitor (3-Aminobenzamide). 
Cell lines with reduced BRCA1 expression exhibited significantly decreased 
colony forming ability after treatment with 3-Aminobenzamide inhibitor for 14 
days, compared to BRCA1 proficient cell lines. (A) BRCA1 HeLa cell line 
compared to Control HeLa. (B) MDA-MB-436 compared to MCF7. Plating 
efficiencies of cell lines with standard error were as follows: (A) Control HeLa- 
98.17% ± 1.83%; BRCA1 HeLa- 98.33% ± 0.33% (B) MCF7- 64.06% ± 0.94%; 
MDA-MB-436- 64.61% ± 0.72%. Clonogenic data are shown as the mean and SD 
YDOXHVIRUHDFKFRQFHQWUDWLRQIURPLQGHSHQGHQWH[SHULPHQWV 
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4.3.3. Ȗ+$;IRFXVLPPXQRIOXRUHVFHQFHPLFURVFRS\DVVD\  
 
     To determine whether DSBs accumulate after treatment with KU55933, 
'6%V ZHUH PHDVXUHG XVLQJ WKH Ȗ+$; LPPXnofluorescence microscopy 
assay. As described in Chapter 2 section 2.3.5, cells were treated with 10 µM 
of KU55933 for 24 hours and 48 hours. As shown in Figure 4.7, after 48 hours 
of treatment, a significant increase in foci formation was observed in BRCA1 
deficient cells. Cells were then treated with 5 µM of KU55933 for 48 hours as 
shown in Figure 4.8, but no VLJQLILFDQW DFFXPXODWLRQ RI Ȗ+$; IRFL LQ
BRCA1 deficient cells was observed. The data support a dose response effect 
of ATM inhibition in BRCA1 deficient cells.  
  
Figure 4.7. Representative photomicrographic of Immunofluorescence 
microscopy assay following KU55933 treatment for 24 hours and 48 hours.  
BRCA1 HeLa cells and Control HeLa cells, were treated with 10 µM for 24 and 
 KRXUV WKHQ IL[HG DQG VWDLQHG ZLWK Ȗ+$; SULPDU\ DQG ),7&-conjugated 
secondary antibodies. DAPI was used as a nuclear stained showing in blue and 
Ȗ+$;IRFLGHWHFWHGIOXRUHVFHLQJUHHQ 
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4.3.3.1. Ȗ+$;IRUPDWLRQLQUHVSRQVHWRATM inhibitors 
 
     BRCA1 proficient and BRCA1 deficient cell lines following treatment with 
10 µM of KU55933 for 48 hours are shown in Figure 4.9. The data 
demonstrates a statistically significant increase in the accumulation of Ȗ+$;
foci in treated BRCA1 HeLa cells compared to untreated BRCA1 HeLa cells 
(mean 66.50% ± 6.5 vs. mean 20.50% ± 3.5; p = 0.02) and compared to 
corresponding treated Control HeLa cells (mean 8.00% ± 3.00; p = 0.014). 
Figure 4.8. Representative photomicrographic of Immunofluorescence 
microscopy assay following KU55933 treatment 5 µM and 10 µM for 48 
hours.  
BRCA1 HeLa cells and Control HeLa cells, were treated with 5 µM and 10 µM 
IRUKRXUV WKHQIL[HGDQGVWDLQHGZLWKȖ+$;SULPDU\DQG),7&-conjugated 
secondary antibodies. DAPI was used as a nuclear stained showing in blue and 
Ȗ+$;IRFLGHWHFWHGIOXRUHVFHLQJUHHQ 
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Similar results were also observed in treated MDA-MB-436 cells in which 
DFFXPXODWLRQRIȖ+$;IRFLZHUHsignificantly higher compared to untreated 
MDA-MB-436 cells (mean 88.00% ± 4.0 vs. 5.50% ± 0.50; p = 0.002) and 
compared to corresponding treated MCF7 cells (mean 4.50% ± 1.50; p = 
0.0026). 
 
     For further validation KU60019, another ATM inhibitor, was investigated. 
Treatment with 1µM of KU60019 produced similar results as with KU55933. 
As shown in Figure 4.10, a statistically significant increase in the accumulation 
of Ȗ+$;IRFL LQ treated BRCA1 HeLa cells compared to untreated BRCA1 
HeLa cells (mean 41.50% ± 4.5 vs. 10% ± 1.0; p = 0.02), and compared to 
corresponding treated Control HeLa cells (mean 5.00% ± 1.00; p = 0.015) 
Figure 4.9,PPXQRIOXRUHVFHQFHPLFURVFRS\VWDLQLQJIRUȖ+$;IRFL
formation   following KU55933 treatment for 48 hours.  
(A) BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-
436 cells compared to MCF7 cells. Data are shown as the mean and SD 
YDOXHVIRUHDFKFRQFHQWUDWLRQIURPLQGHSHQGHQWH[SHULPHQWVS
and ** p<0.01, p value was assessed by a t-test comparing BRCA1 
deficient cell lines to BRCA1 proficient cell lines. Graphs were produced 
and statistical analysis performed using GraphPad prism. 
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were observed. Similar results were also observed in treated MDA-MB-436 
FHOOVLQZKLFKDFFXPXODWLRQRIȖ+$;IRFLwas significantly higher compared 
to untreated MDA-MB-436 cells (mean 71.50% ± 2.5 vs. 17.50% ± 1.5; p = 
0.002), and compared to the corresponding treated MCF7 cells (mean 37.50% 
± 1.5; p = 0.007). Although MDA-MB-436 cells were more sensitive to 
KU60019 inhibitor, MCF7 cells showed a similar change (from 10% to 
37.50%). This result infers that KU60019 inhibitor maybe toxic to MCF7.   
 
 
 
 
Figure 4.10,PPXQRIOXRUHVFHQFHPLFURVFRS\VWDLQLQJIRUȖ+$;IRFL
formation   following KU60019 treatment for 48 hours.  
(A) BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-
436 cells compared to MCF7 cells. Data are shown as the mean and SD 
YDOXHVIRUHDFKFRQFHQWUDWLRQIURP2 independent experiments. * p<0.05 
and ** p<0.01, p value was assessed by a t-test comparing BRCA1 
deficient cell lines to BRCA1 proficient cell lines. Graphs were produced 
and statistical analysis performed using GraphPad prism. 
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4.3.4. Cell cycle analysis by propidium iodide flow cytometry after 
treatment with ATM inhibitors 
 
 
     DSB formation induces cell cycle checkpoint activation to trigger cell cycle 
arrest to allow DNA repair, if the damage is extensive then this process can 
initiate apoptosis (Kurz and Lees-Miller, 2004). To evaluate cell cycle 
progression, Propidium iodide (PI) flow cytometry was used as described in 
Chapter 2, section 2.3.6.  
 
Cells were treated for 24 hours and 48 hours with 10 µM or 20 µM of 
KU55933 (Figure 4.11). Although no significant difference was observed after 
24 hours, at 48 hours in BRCA1 deficient cells treated with 10 µM KU55933 
exhibited a significant increase in G2/M phase arrest compared to control cells 
was observed. On the other hand, at 20 µM concentration conducts apoptosis 
was evident, illustrated by the loss of cells count.    
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     Results for BRCA1 proficient and BRCA1 deficient cells following 
treatment with 10 µM (KU55933) for 48 hours are shown in Figure 4.12. The 
data demonstrate a statistically significant G2/M arrest in treated BRCA1 
HeLa cells compared with untreated BRCA1 HeLa cells (mean 26.60% ± 0.40 
vs. 20.50% ± 1.50; p = 0.05), and compared to corresponding treated Control 
Figure 4.11. Representative graphs of flow cytometric cell cycle analysis 
following KU55933 treatment.  
BRCA1 HeLa cells and Control HeLa cells were treated with 10 µM and 
20 µM for 24 hours and 48 hours. Y axis represents cell count and 
propidium iodides detected fluorescence is shown on the X axis. 
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HeLa cells (mean 21.50% ± 0.50; p = 0.0154). Results of treated MDA-MB-
436 cells demonstrate an increase in G2/M arrest compared to MDA-MB-436 
untreated cells, though this is not significant (mean 32.45% ± 2.75 vs. mean 
27.60% ± 2.9; p = 0.3). The observed G2/M arrest was significantly higher in 
treated MDA-MB-436 cells compared to treated MCF7 cells (mean 20.30% ± 
0.50; p = 0.0491). Conversely, Control HeLa and MCF7 cells did not show the 
same increase (i.e. ~5%) as with BRCA1 deficient cells. (Control HeLa and 
MCF7 cells, G2/M arrest mean 21.50% to 22.55% and 19% to 20.30%, 
respectively). 
     
      For further validation KU60019, another ATM inhibitor, was investigated. 
Treatment with 1µM of KU60019 produced similar results as with KU55933. 
Figure 4.12. Flow cytometric cell cycle analysis following KU55933 
treatment for 48 hours.  
(A) BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-436 
cells compared to MCF7 cells. Data are shown as the mean and SD values 
IRUHDFKFRQFHQWUDWLRQIURP3 independent experiments. SS value 
was assessed by a t-test comparing BRCA1 deficient cell lines to BRCA1 
proficient cell lines. Graphs were produced and statistical analysis 
performed using GraphPad prism. 
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As shown in Figure 4.13, a statistically significant G2/M arrest in treated 
BRCA1 HeLa cells was demonstrated as compared to untreated BRCA1 HeLa 
cells (mean 31.55% ± 0.55 vs. 26.9% ± 0.2; p = 0.015), and as compared to the 
corresponding treated Control HeLa cells (mean 23.80% ± 0.10; p = 0.005). A 
similar, although not statistically significant, G2/M arrest was also observed in 
treated MDA-MB-436 cells compared to untreated MDA-MB-436 cells (mean 
34.60% ± 0.40 vs. 28.30% ± 1.7; p = 0.06). A statistically significant G2/M 
was observed in treated MDA-MB-436 cells as compared to treated MCF7 
cells (mean 25.15% ± 1.15; p = 0.0162). In contrast, Control HeLa cells and 
MCF7 did not show the same increase (G2/M arrest mean 19.5% to 23.8% and 
25.70% to 25.15%, respectively). 
Figure 4.13. Flow cytometric cell cycle analysis following KU60019 
treatment for 48 hours.  
(A) BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-
436 cells compared to MCF7 cells. Data are shown as the mean and SD 
YDOXHVIRUHDFKFRQFHQWUDWLRQIURP2 independent experiments. * p<0.05 
and ** p<0.01, p value was assessed by a t-test comparing BRCA1 
deficient cell lines to BRCA1 proficient cell lines. Graphs were produced 
and statistical analysis performed using GraphPad prism. 
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4.3.5. Apoptosis detection by annexin V-FITC flow cytometry 
after treatment with ATM inhibitors 
 
 
     Annexin V was used in conjunction with a propidium iodide (PI) for 
identification of late apoptotic cells as described in Chapter 2, section 2.3.7. 
Viable cells with intact membranes are negative (reject) to PI, whereas dead 
cells with damaged membranes are positive (permeable) to PI. Therefore, 
viable cells are both Annexin V and PI negative, early apoptosis cells are 
Annexin V positive and PI negative, late apoptosis cells are Annexin V and PI 
positive, necrotic cells are Annexin V negative and PI positive (Koopman et 
al., 1994, Riccardi and Nicoletti, 2006).  
 
Cells were treated for 24 hours and 48 hours with 10 µM of KU55933. As 
shown in Figure 4.14, although no significant increase in apoptosis after 24 
hours was evident, at 48 hours in BRCA1 deficient cells treated with 10 µM of 
KU55933 showed significant increase in apoptosis compared to control cells 
was observed.   
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     Results for BRCA1 proficient and BRCA1 deficient cells following 
treatment with 10 µM (KU55933) for 48 hours are shown in Figure 4.15, data 
were normalised against baseline apoptotic fraction (untreated cells) to 
determine the percentage increase in apoptosis. The data demonstrate a 
statistically significant increase in apoptosis with treated BRCA1 HeLa cells 
compared to untreated BRCA1 HeLa cells (mean 11.12% vs. 3.6%; p = 
Figure 4.14. Representative graphs of flow cytometry images for apoptosis 
assay following KU55933 treatment.  
Cells were treated with 10 µM of KU55933 for 24 hours or 48 hours, then 
stained with annexin V-FITC and propidium iodide (PI), and analysed by two-
colour flow cytometry. Viable cells are both Annexin V and PI negative [bottom 
left quadrant], early apoptosis cells are Annexin V positive and PI negative 
[bottom right quadrant], late apoptosis cells are Annexin V and PI positive [top 
right quadrant], necrotic cells are Annexin V negative and PI positive [top left 
quadrant].  
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0.0014). Similar results were also observed in treated MDA-MB-436 cells, in 
which a significant increase in apoptosis as compared to untreated MDA-MB-
436 cells was observed (mean 13.1% vs. 4.8%; p < 0.0001). On the other hand, 
Control HeLa and MCF7 cells did not show the same rate of increase (mean 
3.9% to 5.7% and 3.17% to 7.5%, respectively). 
     For further validation KU60019, another ATM inhibitor, was investigated. 
Treatment with 1µM of KU60019 produced similar results as with KU55933. 
As shown in Figure 4.16, the data demonstrates a statistically significant 
increase in apoptosis in treated BRCA1 HeLa cells compared to the 
 
 
 
Figure 4.15. Apoptosis detection by annexin V-FITC flow cytometry in 
KU55933 treated cells.  
Treatment with KU55933 inhibitor was associated with a significant 
increase in apoptotic cells. Data were normalised against baseline apoptotic 
fraction to determine the percentage increase in apoptosis. (A) BRCA1 
HeLa cells compared to Control HeLa cells. (B) MDA-MB-436 cells 
compared to MCF7 cells. Data are shown as the mean and SD values for 
HDFKFRQFHQWUDWLRQIURP3 experiments. * p<0.05 and ** p<0.01, p value 
was assessed by a t-test comparing BRCA1 deficient cell lines to BRCA1 
proficient cell lines. Graphs were produced and statistical analysis 
performed using GraphPad prism.   
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corresponding untreated BRCA1 HeLa cells (mean 9.56% vs. 5.53%; p = 
0.037). A similar increase was also observed in treated MDA-MB-436 cells as 
compared to untreated MDA-MB-436 cells (mean 8.99% vs. 4.68%; though 
was not significant). Conversely, Control HeLa and MCF7 cells did not show 
the same rate of increase (mean 4% to 3.8% and 3.97% to 5.9%, respectively).  
  
 
 
Figure 4.16. Apoptosis detection by annexin V-FITC flow cytometry in 
KU60019 treated cells.  
Treatment with KU60019 inhibitor was associated with an increase in 
apoptotic cells. Data were normalised against baseline apoptotic fraction to 
determine the percentage increase in apoptosis. (A) BRCA1 HeLa cells 
compared to Control HeLa cells. (A) BRCA1 HeLa cells compared to 
Control HeLa cells. (B) MDA-MB-436 cells compared to MCF7 cells. Data 
are shown as the mean DQG 6' YDOXHV IRU HDFK FRQFHQWUDWLRQ IURP  3 
experiments. ** p<0.01, p value was assessed by a t-test comparing BRCA1 
deficient cell lines to BRCA1 proficient cell lines. Graphs were produced 
and statistical analysis performed using GraphPad prism.   
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4.4. Discussion and conclusions 
 
 
     BER is a highly conserved pathway, responsible for repairing the vast 
majority of endogenous DNA damage including alkylation, oxidation, ring 
saturation, single strand breaks and base deamination. Defects in BER have 
been genetically linked to cancer risk. For instance, Pol ß was found to play an 
important role in suppressing carcinogenesis since 30% of human tumors 
investigated to date carry Pol ß mutations (Sobol et al., 2002, Starcevic et al., 
2004, Wallace, 2014). More recently in our group, a study was undertaken in 
breast cancer and found that low Pol ß is associated with poor survival (Abdel-
Fatah et al., 2014). In addition, XRCC1 another key factor in BER, recently 
shown that loss of XRCC1 was associated with poor survival in breast cancer. 
Moreover, XRCC1 deficiency was highly associated with loss of other DNA 
repair factors, such as BRCA1 and p53 (Sultana et al., 2013a). Recent data 
indicate a cross talk between BRCA1 and BER factors. Saha et al study for 
instance showed that BRCA1 is involved in the transcriptional regulation of 
OGG1, NTH1, XRCC1 and APE1 (Saha et al., 2010). In agreement with this 
data, Chapter 3 of this thesis has shown that reduced BRCA1 expression in 
mutant/knockdown cell lines was associated with a significant reduction in 
several BER genes at the mRNA and protein expression. As BRCA1 deficient 
cells were shown to be BER deficient, cells may be more reliant on backup 
DSB repair pathways to maintain cellular survival. Blocking DSB repair 
should cause selective toxicity in BRCA1-BER deficient cells. The aim of this 
chapter was to investigate if targeting BRCA1 deficiency by ATM inhibitors 
(KU55933 or KU60019) is synthetically lethal. 
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Clonogenic survival assays (inhibitor exposure for total assay period) were 
conducted first to evaluate the cytotoxicity of ATM inhibitors against BRCA1 
knockdown HeLa cells and BRCA1 mutated MDA-MB-436 cells, using 
Control HeLa and MCF7 cells as BRCA1 proficient controls, respectively. 
Then an alternative clonogenic assay protocol was performed (inhibitor 
exposure for 24 hours of assay period). For additional validation, the 
proliferation assay (MTS assay) was used to determine cell growth in response 
to ATM inhibitor. Results of all assays showed both KU55933 and KU60019 
inhibitors induced significant cytotoxicity in BRCA1 deficient cells compared 
to BRCA1 proficient cells. These data suggest that BRCA1 deficient cells are 
reliant on ATM to maintain cellular survival. 
To validate the cell line system used in the current study, clonogenic survival 
assay and MTS assay using PARP inhibitors (NU1025 and 3-
Aminobenzamide) against BRCA1 deficient and proficient cell lines were 
performed. As predicted, both inhibitors induced significant cytotoxicity in 
BRCA1 deficient cells. These results support previously published data 
showing selective sensitivity to PARP inhibitors (in particular; NU1025 and 3-
Aminobenzamide) in BRCA1 deficient models (Bryant et al., 2005, Sultana et 
al., 2012). Several functional studies were conducted to understand the 
mechanism behind this selective cytotoxicity of ATM inhibitors to BRCA1 
deficient system. BRCA1 deficient cell lines were previously demonstrated to 
express reduced expression of several DSB repair factors (Chapter 3). The 
baseline level of DSBs damage present in these cells was assessed using 
Ȗ+$; LPPXQRIOXRUHVFHQFH PLFURVFRS\ DVVD\ ZKLFK LV D ZHOO YDOLGDWHG
marker of DSBs. BRCA1 deficient cell lines treated with ATM inhibitors 
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(KU55933 or KU60019) for 48 hours were associated with a statistically 
significant increase in the accumulation of Ȗ+$;IRFLcompared to untreated 
BRCA1 deficient cells. Interestingly MCF7 cells showed a slight increase after 
KU60019 inhibitor treatment but not with KU55933, this result infers that 
KU60019 may be toxic to MCF7 (Figure 4.10B); this could be linked to the 
slight increase in apoptosis as well (Figure 4.16B).   
These results support the hypothesis that ATM inhibition in BRCA1-BER 
deficient cells causes DSB accumulation which cannot be repaired due to an 
actual defect in DSB pathway. Moreover accumulation of Ȗ+$;IRFLLQFHOOV
treated with ATM inhibitors has been reported in previous publications 
(Shaheen et al., 2011, Sultana et al., 2013a). Although phosphorylation of 
H2AX is ATM dependent, accumulation of Ȗ+$;IRFL LQ%5&$GHILFLHQW
cells was observed. One possible explanation for this finding is that other 
factors such as ATR or DNA-PKcs may be involved. Further mechanistic 
studies are required to clarify additional pathways. 
DSB formation induces cell cycle checkpoint activation to trigger cell cycle 
arrest to allow DNA repair, or if the DNA damage is extensive can initiate 
apoptosis (Kurz and Lees-Miller, 2004). Cell cycle progression was arrested 
significantly at G2/M phase in treated BRCA1 HeLa cells compared to 
untreated BRCA1 HeLa cells (after treatment with ATM inhibitors for 48 
hours). BRCA1 mutated MDA-MB-436 cells showed a modest increase in 
G2/M arrest, though it was not significant (Figure 4.12 and 4.13). It should be 
noted that the flow cytometry assay was conducted after 24 and 48 hours, and 
to confirm G2/M arrest in MDA-MB-436 cells different time points should be 
tested in the future. 
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These increases in G2/M arrest support previously published data showing 
G2/M arrest after ATM inhibition (Sultana et al., 2013a, Lee et al., 2013, 
Nadkarni et al., 2012, Jazayeri et al., 2006). ATM phosphorylates Ser1423 of 
BRCA1 which is required for G2/M checkpoint activation (Cortez et al., 1999, 
Xu et al., 2001, Wu et al., 2010); in agreement with previous studies the 
current study shows that in the absence of BRCA1 and ATM, cells arrest in 
G2/M phase giving the cell time to repair. This could explain the survival data 
since the arrest in G2 would allow more NHEJ repair in BRCA1 deficient after 
blocking HR. Though it is interesting that ATM inhibition leads to G2/M 
arrest, one possible explanation is the overlapping function between 
ATM/CHK2 and ATR/CHK1 pathways which share many substrates (Smith et 
al., 2010). This overlapping function was seen in p53 deficient cells which rely 
on ATM and ATR to control the checkpoint signalling to survive after DNA 
damage (Reinhardt et al., 2007). G2/M arrest could then be followed by 
apoptosis. A flow cytometry-based apoptosis detection assay was performed. 
Results demonstrated that BRCA1 deficient cell lines treated with ATM 
inhibitors for 48 hours exhibited an increase in apoptosis rate compared to 
untreated BRCA1 deficient cell lines. These results support those previously 
published showing ATM inhibitor KU55933 treatment triggers apoptosis in 
different cancer cell lines (Sultana et al., 2013a, Li and Yang, 2010, Korwek et 
al., 2012) which again highlighted the importance of ATM in DNA repair and 
cell survival. 
The data presented here support that ATM maybe a promising alternative 
synthetic lethality target. This study suggests that ATM inhibition is 
responsible for the synthetic lethality in BRCA1 deficient cells, and also 
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suggests that ATM inhibitors must be evaluated further as an alternative 
synthetic lethality strategy in in vivo models. A model for synthetic lethality is 
shown in Figure 4.17. In brief, impaired expression of BER factors in BRCA1 
deficient cell lines leads to an increase accumulation of unrepaired SSBs which 
is followed by the formation of DSBs during DNA replication process. 
Therefore, it is suggested that cells are reliant on DSB pathway for cellular 
survival. Targeting the DSB pathway by ATM inhibition would lead to the 
observed synthetic lethality. In contrast, in cells that are proficient in DSB 
repair the DSBs would be repaired and cells would survive.   
A limitation of this chapter is that this synthetic lethality study was restricted 
to two ATM inhibitors. KU60019 is known as an improved analogue of 
KU55933 (Golding et al., 2009) although the current results did not show this. 
For example DFFXPXODWLRQRIȖ+$;IRFLZDV VLJQLILFDQWO\KLJKer in MDA-
MB-436 compared to untreated cells, though KU60019 was slightly toxic to 
MCF7 also. As a result more tests with KU60019 are needed using different 
cell lines. Another limitation was with cell cycle analysis which showed G2/M 
arrest increase with ATM treatment in BRCA1 HeLa cells, though MDA-MB-
436 cells increase was not significant. This could be because samples were 
analysed after 24 and 48 hours. However, more time points should be tested in 
the future to monitor cells response after different treatment. 
4.4.1. Conclusions  
 
     These in vitro studies demonstrate that a potential synthetic lethality 
relationship exists between BRCA1 deficiency and targeting the DSB pathway 
using ATM inhibitors (KU55933 or KU60019). The data suggests that ATM 
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inhibitors are selectively toxic to BRCA1 deficient cells. Also DNA DSBs 
accumulate following treatment with these inhibitors. In addition these data 
have shown a significant G2/M phase arrest in treated BRCA1 HeLa cells 
compared to untreated BRCA1 HeLa cells. As MDA-MB-436 cells showed a 
modest increase in G2/M arrest after 48 hours, this suggests that different time 
points should be tested in the future. Moreover, ATM inhibitor treatment 
triggers apoptosis in BRCA1 deficient cell lines. 
These findings represent an alternative synthetic lethality strategy in targeting 
BRCA1 deficiency, which can potentially overcome PARP inhibition 
challenges. On the other hand, the global defect in DNA repair proved in 
BRCA1 deficient cells in particular the impaired BER factors expression, gives 
a wider role for using ATM inhibitors in cancers defective in BER in the 
absence of germline BRCA1 mutations. However, investigations with more 
BER deficient cell lines are required.  
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Figure 4.17. Proposed model of synthetic lethality between ATM 
inhibitors and BRCA1-BER deficient system.  
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Chapter 5 
Targeting BRCA1 deficiency for 
personalized therapy using DNA-
PKcs inhibitors (NU7441 & 
NU7026) 
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5. Targeting BRCA1 deficiency in breast cancer for 
personalized therapy using DNA-PKcs inhibitors 
(NU7441 & NU7026) 
5.1. Introduction 
 
 
     BRCA1 facilitates the efficient resolution of DNA double-strand breaks 
(DSBs) through homologous recombination (HR) (Huen et al., 2010, 
Caestecker and Van de Walle, 2013). Cells lacking functional BRCA1 protein 
have impaired HR, and thus are suggested to depend on the more error-prone 
non-homologous end joining (NHEJ) pathway which is able to function at all 
stages of the cell cycle and does not require the presence of a homologous 
template. The NHEJ pathway is suggested to lead to chromosomal instability 
that leads to breast cancer development (Huen et al., 2010). It has been 
assumed that targeting the molecular machinery driving the DNA damage 
response, particularly the NHEJ pathway, with small molecule inhibitors will 
effectively enhance the efficacy of current cancer treatments that generate 
DNA damage (Kashishian et al., 2003, Davidson et al., 2013).  
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a key 
component of NHEJ pathway. DNA-PKcs has been shown to phosphorylate a 
large number of proteins, including NHEJ factors such as KU70/KU80, 
XRCC4, Lig3, XLF, WRN and Artemis along with other DNA damage 
response proteins including H2AX and p53. Recruitment of DNA-PKcs to the 
DNA-PK complex results in translocation of a heterodimer KU70/KU80 
inward on the DNA, this is more likely to allow DNA-PKcs to bind directly to 
the damage resulting in the activation of the catalytic activity of the enzyme 
(Davis and Chen, 2013). Studies show that even with the absence of 
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heterodimer KU70/KU80, DNA-PKcs has unlimited kinase activity (West et 
al., 1998, Hammarsten and Chu, 1998). In addition synthetic lethality has been 
observed with PARP deficient cells targeted with DNA-PKcs inhibitor 
NU7026 (Veuger et al., 2003).   
5.1.1. Rationale for study 
 
     Chapter 3 of this thesis suggested that BRCA1 deficiency is associated with 
reduced mRNA and/or protein expression of several factors involved in BER, 
HR and NHEJ. Data presented in Chapter 4 suggested a potential synthetic 
lethality relationship between BRCA1 deficiency and ATM inhibitors. In this 
chapter the aim was to investigate if BRCA1-BER deficient cells could be 
targeted by blockade of DNA-PKcs for personalized therapy. 
5.2. Aims 
 
The aims of this study were as follows: 
1. To investigate the effect of DNA-PKcs inhibitors (NU7441 and 
NU7026) on cell viability and growth using clonogenic cell survival 
and MTS assays.  
2. To test the hypothesis that DNA double strand breaks accumulate in 
cells after treatment with DNA-PKcs inhibitors in BRCA1 deficient 
cells.  
3. To determine the effect of DNA-PKcs inhibitors on cell cycle in 
BRCA1 deficient cells.  
4. To explore induction of apoptosis in BRCA1 deficient cells after 
treatment with DNA-PKcs inhibitors.  
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5.3. Results 
 
5.3.1. Clonogenic cell survival and Growth inhibition in response 
to DNA-PKcs inhibitors (NU7441 & NU7026)  
 
 
     Clonogenic survival assays were performed to test whether BRCA1 
deficient cells are sensitive to DNA-PKcs inhibition. BRCA1 mutated (MDA-
MB-436) and knockdown (BRCA1 HeLa cells) cell lines along with MCF7 
cells and Control HeLa cell lines were treated with increasing concentrations 
of NU7441 (C25H19NO3S) which is a potent, selective and competitive DNA-
PKcs kinase inhibitor. Results are shown in Figure 5.1.   
 
IC50 values were calculated using nonlinear regression, with the proviso that in 
BRCA1 proficient cell lines (Control HeLa and MCF7) cytotoxicity did not 
approach 50% in some cases, thus impairing extrapolation. Clonogenic assay 
demonstrated that BRCA1 HeLa cells, are more sensitive to NU7441 
compared to Control HeLa cells (mean IC50= 0.6 ± 0.16 vs. IC50 above the 
maximum level tested). Similarly, increased sensitivity was also demonstrated 
in BRCA1 mutated MDA-MB-436 cells compared to control MCF7 cells 
(mean IC50= 0.44 ± 0.12 vs. mean IC50= 0.64 ± 0.19). 
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In general, increasing concentrations of NU7441 inhibitor reduced the colony 
forming ability in BRCA1 deficient cells compared to the BRCA1 proficient 
cells. To validate further, an alternative clonogenic assay protocol was 
performed, where cells were treated with DNA-PKcs inhibitor for 24 hours 
then culture media was replaced with fresh media and the remaining assay was 
conducted as described in 2.3.4.3. Results are illustrated in Figure 5.2.  
    
 
 
Figure 5.1. Clonogenic survival assay of DNA-PKcs inhibitor (NU7441).  
Cell lines with reduced BRCA1 expression exhibited decreased colony forming 
ability after treatment with NU7441 inhibitor for 14 days, compared to BRCA1 
proficient cell lines. (A) BRCA1 HeLa cells compared to Control HeLa cells. (B) 
MDA-MB-436 cells compared to MCF7 cells. Plating efficiencies of cell lines 
with standard error were as follows: (A) Control HeLa- 79.22% ± 1.79%; 
BRCA1 HeLa- 66.44% ± 5.22% (B) MCF7- 51.21% ± 3.82%; MDA-MB-436- 
41.54% ± 4.33%. Clonogenic data are shown as the mean and SD values for each 
FRQFHQWUDWLRQIURP2 independent experiments.    
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Figure 5.2. Clonogenic survival assay of inhibitor NU7441 (24 hour 
treatment protocol).  
Cell lines with reduced BRCA1 expression exhibited decreased colony 
forming ability after treatment with NU7441 inhibitor for 24 hours. (A) 
BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-436 cells 
compared to MCF7 cells.  Plating efficiencies of cell lines with standard 
error were as follows: (A) Control HeLa- 90.30% ± 0.90%; BRCA1 HeLa- 
83.60% ± 2.40% (B) MCF7- 55.58% ± 0.02%; MDA-MB-436- 54.28% ± 
1.05%. Clonogenic data are shown as the mean and SD values for each 
concentration from 2 independent experiments.  
The alternative clonogenic assay results demonstrated that BRCA1 HeLa cells 
are more sensitive to NU7441 than Control HeLa cells. Similarly, sensitivity 
was demonstrated in BRCA1 mutated MDA-MB-436 cells compared to 
control MCF7 cells. However, data did not approach 50%, thus impairing 
extrapolation of IC50 values. Though, both the 24 hour NU7441 treatment 
protocol and the 14 day treatment protocol, provide evidence that increasing 
concentration of NU7441 inhibitor reduces the colony forming ability of 
BRCA1 deficient cell lines compared to the BRCA1 proficient cell lines. The 
14 day treatment protocol was used for all subsequent clonogenic assays 
described in the rest of the thesis.  
162 
 
 
     For additional validation, the proliferation assay (MTS assay) was used to 
determine cell growth in response to NU7441. As shown in Figure 5.3, 
BRCA1 deficient HeLa cells were more sensitive to NU7441 than the Control 
HeLa cells. Similar sensitivity was demonstrated in BRCA1 mutated MDA-
MB-436 cells compared to control MCF7 cells. 
  
 
 
  Figure 5.3. MTS cell growth inhibition assays of DNA-PKcs inhibitor 
(NU7441).  
Cell lines with reduced BRCA1 expression exhibited decreased cell growth 
after treatment with NU7441 inhibitor for 6 days, compared to BRCA1 
proficient cell lines. (A) BRCA1 HeLa cells compared to Control HeLa 
cells. (B) MDA-MB-436 cells compared to MCF7 cells. Data are shown as 
the mean and SD YDOXHV IRU HDFK FRQFHQWUDWLRQ IURP  2 independent 
experiments. 
163 
 
 
     For further validation NU7026 (C17H15NO3), another potent kinase inhibitor 
of DNA-PKcs, was investigated (Hollick et al., 2003, Veuger et al., 2003, 
Amrein et al., 2007). As shown in Figure 5.4 clonogenic cell survival assays, 
BRCA1 HeLa cells are more sensitive to NU7026 than Control HeLa cells. 
Similar sensitivity was also demonstrated in BRCA1 mutated MDA-MB-436 
cells compared to control MCF7 cells. Taken together, these data provide 
strong evidence that BRCA1 deficient cells are sensitive to DNA-PKcs 
inhibition.   
 
 
Figure 5.4. Clonogenic survival assay of DNA-PKcs inhibitor (NU7026). 
Cell lines with reduced BRCA1 expression exhibited decreased colony forming 
ability after treatment with NU7026 inhibitor for 14 days, compared to BRCA1 
proficient cell lines. (A) BRCA1 HeLa cells compared to Control HeLa cells. (B) 
MDA-MB-436 cells compared to MCF7 cells. Plating efficiencies of cell lines 
with standard error were as follows: (A) Control HeLa- 82.50% ± 0.50%; BRCA1 
HeLa- 76.00% ± 6.50% (B) MCF7- 58.21% ± 2.21%; MDA-MB-436- 41.50% ± 
2.25%. Clonogenic data are shown as the mean and SD values for each 
FRQFHQWUDWLRQIURP2 independent experiments.   
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5.3.2. Ȗ+$;IRFXVLPPXQRIOXRUHVFHQFHPLFURVFRS\DVVD\  
     To determine whether DSBs accumulate after treatment with NU7441, 
'6%V ZHUH PHDVXUHG XVLQJ WKH Ȗ+$; LPPXQRIOXRUHVFHQFH PLFURVFRS\
assay. As described in Chapter 2 section 2.3.5, cells were treated with 1.5 µM 
of NU7441 for 24 hours and 48 hours. A significant increase in foci formation 
was observed in BRCA1 deficient cells after 48 hours treatment. Cells were 
then treated with 1 µM of NU7441 for 48 hours, but no significant 
DFFXPXODWLRQRIȖ+$;IRFLLQ%5&$GHILFLHQWFHOOVZDVREVHUYHG7KHGDWD
support a dose response effect of DNA-PKcs inhibition in BRCA1 deficient 
cells.  
 
5.3.2.1. Ȗ+$;IRUPDWLRQLQUHVSRQVHWRDNA-PKcs 
inhibitors  
 
 
     BRCA1 proficient and BRCA1 deficient cell lines following treatment with 
1.5 µM of NU7441 for 48 hours are shown in Figure 5.5. The data 
demonstrates a statistically significant increase in the accumulation of Ȗ+$;
foci in treated BRCA1 HeLa cells compared to untreated BRCA1 HeLa cells 
(mean 62.50% ± 7.50 vs. mean 17.50% ± 0.50; p = 0.026) and compared to 
corresponding treated Control HeLa cells (mean 8.00% ± 3.00; p = 0.021). 
Similar results were also observed in treated MDA-MB-436 cells in which 
DFFXPXODWLRQRIȖ+$;IRFLZHUHsignificantly higher compared to untreated 
MDA-MB-436 cells (mean 81.00% ± 9 vs. 7% ± 2; p = 0.015) and compared 
to corresponding treated MCF7 cells (mean 4.50% ± 1.50; p = 0.013).  
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     For further validation NU7026, another DNA-PKcs inhibitor, was 
investigated. Treatment with 1.5 µM of NU7026 produced similar results to 
NU7441. As shown in Figure 5.6, a statistically significant increase in the 
accumulation of Ȗ+$; IRFL LQ WUHDWHG BRCA1 HeLa cells compared to 
untreated BRCA1 HeLa cells (mean 46% ± 4 vs. 11% ± 1.0; p = 0.013), and 
compared to corresponding treated Control HeLa cells (mean 6.00% ± 2; p = 
0.012) was observed. Similar results were also observed in treated MDA-MB-
436 celOV LQ ZKLFK DFFXPXODWLRQ RI Ȗ+$; IRFL ZDV significantly higher 
compared to untreated MDA-MB-436 cells (mean 80.50% ± 6.5 vs. 17.50% ± 
1.5; p = 0.011), and compared to the corresponding treated MCF7 cells (mean 
51% ± 1; p = 0.046). Even though MDA-MB-436 cells were more sensitive to 
NU7026 inhibitor, MCF7 cells showed similar changes (from 10% to 51%). 
Figure 5.5. ,PPXQRIOXRUHVFHQFHPLFURVFRS\VWDLQLQJIRUȖ+$;IRFL
formation   following NU7441 treatment for 48 hours. 
(A) BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-
436 cells compared to MCF7 cells. Data are shown as the mean and SD 
values for each cRQFHQWUDWLRQIURP2 independent experiments. * p<0.05, 
p value was assessed by a t-test comparing BRCA1 deficient cell lines to 
BRCA1 proficient cell lines. Graphs were produced and statistical analysis 
performed using GraphPad prism. 
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This result infers that NU7026 inhibitor maybe toxic to MCF7, especially as 
this increase was not seen with NU7441. 
 
 
Figure 5.6,PPXQRIOXRUHVFHQFHPLFURVFRS\VWDLQLQJIRUȖ+$;IRFL
formation   following NU7026 treatment for 48 hours. 
(A) BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-
436 cells compared to MCF7 cells. Data are shown as the mean and SD 
YDOXHVIRUHDFKFRQFHQWUDWLRQIURP2 independent experiments. * p<0.05, 
p value was assessed by a t-test comparing BRCA1 deficient cell lines to 
BRCA1 proficient cell lines. Graphs were produced and statistical analysis 
performed using GraphPad prism. 
 
 
5.3.3. Cell cycle analysis by propidium iodide flow cytometry after 
treatment with DNA-PKcs inhibitors 
 
     Cells were treated as described in Chapter 2, section 2.3.6 for 24 hours and 
48 hours with 1 µM or 1.5 µM of NU7441 (Figure 5.7). Although no 
significant difference was observed after 24 hours, at 48 hours in BRCA1 
deficient cells treated with 1.5 µM NU7441 exhibited a significant increase in 
G1 phase arrest compared to control was observed.  
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     Results for BRCA1 proficient and BRCA1 deficient cells following 
treatment with 1.5 µM (NU7441) for 48 hours are shown in Figure 5.8. The 
data demonstrate an increase in G1 arrest in treated BRCA1 HeLa cells 
compared with untreated BRCA1 HeLa cells (mean 60.6% ± 0.60 vs. 47.2% ± 
3.80; though not significant p = 0.07), and compared to corresponding treated 
Figure 5.7. Representative graphs of flow cytometric cell cycle analysis 
following NU7441 treatment. 
BRCA1 deficient HeLa cells and Control HeLa cells were treated with 1 µM 
or 1.5 µM for 24 hours or 48 hours. Y axis represents cell count and propidium 
iodides detected fluorescence is shown on the X axis. 
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Control HeLa cells (mean 32.4% ± 0.42; p = 0.0007). Results of treated MDA-
MB-436 cells demonstrate an increase in G1 arrest compared to MDA-MB-
436 untreated cells, though not significant (mean 49.4% ± 0.15 vs. mean 
37.8% ± 3.6; p = 0.08). The observed G1 arrest was significantly higher in 
treated MDA-MB-436 cells compared to treated MCF7 cells (mean 30.4% ± 
0.50; p < 0.0001). On the other hand, Control HeLa and MCF7 cells did not 
show the same rate of increase (i.e. ~12% increase like BRCA1 deficient cells) 
after treatment (Control HeLa and MCF7 cells, G1 arrest mean 41% to 32.4% 
and 25% to 30.4%, respectively). 
 
  
  
Figure 5.8. Flow cytometric cell cycle analysis following NU7441 
treatment for 48 hours.  
(A) BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-
436 cells compared to MCF7 cells. Data are shown as the mean and SD 
YDOXHV IRU HDFK FRQFHQWUDWLRQ IURP  2 independent experiments. *** 
p<0.001 and **** p<0.0001, p value was assessed by a t-test comparing 
BRCA1 deficient cell lines to BRCA1 proficient cell lines. Graphs were 
produced and statistical analysis performed using GraphPad prism. 
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     For further validation NU7026, another DNA-PKcs inhibitor, was 
investigated. Treatment with 10 µM of NU7026 produced similar results as 
with NU7441. As shown in Figure 5.9, increased G1 arrest in treated BRCA1 
HeLa cells was demonstrated as compared to untreated BRCA1 HeLa cells 
(mean 61% ± 1 vs. 54.5% ± 0.5; p = 0.028). A modest, although not 
statistically significant, G1 arrest was also observed in treated MDA-MB-436 
cells compared to untreated MDA-MB-436 cells (mean 40% ± 0.1 vs. 31.7% ± 
3.8; p = 0.1). A statistically significant increase in G1 arrest was observed 
when treated MDA-MB-436 cells were compared to treated MCF7 cells (mean 
27.25% ± 2.8; p = 0.04). In contrast, Control HeLa and MCF7 cells did not 
show the same increase. 
 
Figure 5.9. Flow cytometric cell cycle analysis following NU7026 
treatment for 48 hours. 
(A) BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-
436 cells compared to MCF7 cells. Data are shown as the mean and SD 
YDOXHV IRU HDFK FRQFHQWUDWLRQ IURP  3 independent experiments. * 
p<0.05, p value was assessed by a t-test comparing BRCA1 deficient 
cell lines to BRCA1 proficient cell lines. Graphs were produced and 
statistical analysis performed using GraphPad prism. 
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5.3.4. Apoptosis detection by annexin V-FITC flow cytometry 
after treatment with DNA-PKcs inhibitors 
 
 
     Following evaluation of cell cycle arrest in BRCA1 deficient cells treated 
with DNA-PKcs inhibitors, Annexin V was used in conjunction with a 
propidium iodide (PI) for identification of early and late apoptotic cells as 
described in Chapter 2, section 2.3.7.  
Arrest at the G1 phase of cell cycle may lead to apoptosis which could be the 
cause of the reduced survival observed in BRCA1 deficient cells in the 
clonogenic survival assay.  
Cells were treated for 24 hours and 48 hours with 1.5 µM of NU7441. 
Although no significant increase in apoptosis was evident after 24 hours, at 48 
hours in BRCA1 deficient cells treated with 1.5 µM of NU7441 significant 
increase in apoptosis compared to control cells was observed.   
 
     Results for BRCA1 proficient and BRCA1 deficient cells following 
treatment with 1.5 µM (NU7441) for 48 hours are shown in Figure 5.10, data 
were normalised against baseline apoptotic fraction (untreated cells) to 
determine the percentage increase in apoptosis. The data demonstrate a 
statistically significant increase in apoptosis with treated BRCA1 HeLa cells 
compared to untreated BRCA1 HeLa cells (mean 6.3% ± 0.36 vs. mean 3.6% ± 
0.68; p = 0.0057). Similar results were also observed in treated MDA-MB-436 
cells, in which a significant increase in apoptosis as compared to untreated 
MDA-MB-436 cells was observed (mean 13.5% ± 0.77 vs. 4.68% ± 0.07; p < 
0.0001). On the other hand, Control HeLa and MCF7 cells did not show the 
same rate of increase (mean 2.44% to 3.25% and 4.06% to 4.76%, 
respectively). 
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     For further validation NU7026, another DNA-PKcs inhibitor, was 
investigated. Treatment with 10 µM of NU7026 produced similar results as 
with NU7441. As shown in Figure 5.11, the data demonstrates a statistically 
significant increase in apoptosis in treated BRCA1 HeLa cells compared to the 
corresponding untreated BRCA1 HeLa cells (mean 8.71% ± 1.22 vs. mean 
4.72% ± 0.34; p = 0.034). A similar increase was also observed in treated 
MDA-MB-436 cells as compared to untreated MDA-MB-436 cells (mean 
9.13% vs. 4.67%; though was not significant p=0.06). On the other hand, 
  
Figure 5.10. Apoptosis detection by annexin V-FITC flow cytometry in 
NU7441 treated cells. 
Treatment with NU7441 inhibitor was associated with a significant increase 
in apoptotic cells. Data were normalised against baseline apoptotic fraction 
to determine the percentage increase in apoptosis. (A) BRCA1 HeLa cells 
compared to Control HeLa cells. (B) MDA-MB-436 cells compared to 
MCF7 cells. Data are shown as the mean and SD values for each 
FRQFHQWUDWLRQ IURP  3 independent experiments. ** p<0.01 and *** 
p<0.001, p value was assessed by a t-test comparing BRCA1 deficient cell 
lines to BRCA1 proficient cell lines. Graphs were produced and statistical 
analysis performed using GraphPad prism.   
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Control HeLa and MCF7 cells did not show the same rate of increase (mean 
3.11% to 3.16% and 3.15% to 5.6%, respectively). 
 
  
  
Figure 5.11. Apoptosis detection by annexin V-FITC flow cytometry in 
NU7026 treated cells. 
Treatment with NU7026 inhibitor was associated with a significant 
increase in apoptotic cells. Data were normalised against baseline apoptotic 
fraction to determine the percentage increase in apoptosis. (A) BRCA1 
HeLa cells compared to Control HeLa cells. (B) MDA-MB-436 cells 
compared to MCF7 cells. Data are shown as the mean and SD values for 
HDFKFRQFHQWUDWLRQ IURP  2 independent experiments. * p<0.05, p value 
was assessed by a t-test comparing BRCA1 deficient cell lines to BRCA1 
proficient cell lines. Graphs were produced and statistical analysis 
performed using GraphPad prism.   
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5.4. Discussion and conclusions 
 
 
     The aim of this chapter was to investigate whether targeting BRCA1 
deficiency by DNA-PKcs, a key player in NHEJ pathway, using NU7441 or 
NU7026 inhibitors, would be synthetically lethal.  
The role of BRCA1 in regulating the NHEJ pathway has been investigated for 
a number of years. The data have been conflicting with a number of studies 
showing a major role of BRCA1 in NHEJ and maintenance of genomic 
integrity (Zhong et al., 2002, Bau et al., 2004), while others did not show a role 
of BRCA1 in NHEJ (Moynahan et al., 1999, Merel et al., 2002). The lack of 
consistency between these results may be partly explained by the use of 
different assays, which may measure different sub-pathways of NHEJ (Bau et 
al., 2006). Several studies have confirmed the interaction between BRCA1 and 
NHEJ factors. For example, one study showed that BRCA1 interacts with a 
subunit of the DNA-PK complex (KU80). Another study showed that BRCA1 
is rapidly recruited to DSB and is dependent on its association with KU80 
(Wei et al., 2008). A more recent study has found that DNA-PKcs interacts 
with BRCA1 in the absence of KU70 and KU80 (Davis et al., 2014b).  
 
To test the importance of both BRCA1 and DNA-PKcs in the maintenance of 
cellular survival, clonogenic survival assays (inhibitor exposure for total assay 
period) were conducted to evaluate the cytotoxicity in BRCA1 knockdown 
HeLa cells and BRCA1 mutated MDA-MB-436 cells treated with DNA-PKcs 
inhibitors (NU7441 or NU7026), using Control HeLa and MCF7 cells as 
BRCA1 proficient controls, respectively. Then an alternative clonogenic assay 
protocol was performed (inhibitor exposure for 24 hours of assay period). 
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Results of both protocols showed high sensitivity in BRCA1 deficient cells 
compared to BRCA1 proficient cells. For additional validation, MTS assay 
was used to determine cell viability in response to DNA-PKcs inhibitor. Both 
NU7441 and NU7026 inhibitors induced significant cytotoxicity in BRCA1 
deficient cells compared to BRCA1 proficient cells. Taken together, these data 
suggest that BRCA1 deficient cells are reliant on DNA-PKcs to maintain 
cellular survival. For mechanistic insights, several functional studies were 
conducted. BRCA1 deficient cell lines treated with DNA-PKcs inhibitors for 
48 hours demonstrate a statistically significant increase in the accumulation of 
Ȗ+$; IRFL compared to untreated BRCA1 cell lines. This finding supports 
previous publications showing accumulation of Ȗ+$;IRFLwith inhibition of 
DNA-PKcs (Shaheen et al., 2011, Sultana et al., 2013a). Interestingly MCF7 
showed a slight increase after NU7026 inhibitor treatment but not with 
NU7441, this result infers that NU7026 may be toxic to MCF7 (Figure 5.6B); 
this could also be linked to the slight increase in apoptosis (Figure 5.11B). 
Results from Chapter 3 illustrate that ATM, ATR and DNA-PKcs are down 
regulated in BRCA1 deficient cells; these three enzymes are known to have a 
role in phosphorylation of H2AX (Podhorecka et al., 2010). Previously it had 
been shown that DSB deficient cells exhibited  reduced phosphorylation of 
H2AX after ionizing radiation treatment, however they conclude that 
inhibitions of DNA-PKcs and ATM reduce, but do not eliminate, the 
accumulation of Ȗ+$;IRFL (Paull et al., 2000). In the current study inhibition 
of DNA-PKcs or ATM in BRCA1 deficient cells have increased Ȗ+$;IRFL
formation around DSBs as compared to the untreated cells. The fact that 
Ȗ+$;was still forming in my study can have two explanations. Firstly, with 
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a low expression of ATM and ATR, in the absence of DNA-PKcs, other 
HQ]\PHVHJ&+.PD\DFWLYDWHȖ+$;DVKDVEHHQVKRZQLQDSUHYLRXV
study (Tu et al., 2013). Alternatively another signaling pathway may modulate 
Ȗ+$;OHYHOVfor example DNA-PKcs has been suggested to phosphorylates 
H2AX directly and modulate Ȗ+$; level indirectly through the Akt/GSK3ß 
signaling pathway (An et al., 2010). In the absence of DNA-PKcs it may be 
that the Akt/GSK3ß pathway can be activated by other factors. Secondly, the 
fact that ATM and ATR are down regulated in BRCA1 deficient cells does not 
mean it is completely silenced, and in the absence of DNA-PKcs low levels of 
ATM or ATR may be sufficient to phosphorylate H2AX. Taken together, these 
results support the hypothesis that DNA-PKcs inhibition in BRCA1-BER 
deficient cells causes DSB accumulation which cannot be repaired due to an 
actual defect in DSB pathway. 
Monitoring cell cycle progression in BRCA1 deficient cell lines after treatment 
with DNA-PKcs inhibitors for 48 hours was associated with a modest increase 
arrest at the G1 phase compared to untreated BRCA1 deficient cell lines. 
However, this increase was not always significant and different time points 
should be tested in the future. These modest increases in G1 arrest support 
those previously published showing that G1 arrest increases after inhibition 
with DNA-PKcs (NU7441) inhibitor, in colon cancer (Zhao et al., 2006), 
prostate cancer (Shaheen et al., 2011, Yu et al., 2012) and breast cancer cell 
lines (Ciszewski et al., 2014). A more recent study showed that BRCA1 
facilitates accurate repair during G1 phase through NHEJ (Jiang et al., 2013). 
To evaluate induction of apoptosis, a flow cytometry-based apoptosis detection 
assay was performed. Results demonstrated that BRCA1 deficient cell lines 
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treated with DNA-PKcs inhibitors for 48 hours exhibited increase in apoptosis 
rate compared to untreated BRCA1 deficient cell lines. These results support 
those previously published showing an increase in apoptosis after DNA-PKcs 
inhibition, in prostate cancer (Yu et al., 2012) and XRCC1 knockdown HeLa 
cell lines (Sultana et al., 2013a).  
Taken together, the data presented here demonstrated that a potential synthetic 
lethality relationship which exists between BRCA1 deficiency and DNA-PKcs 
inhibition. Also the present study highlights the important role of DNA-PKcs 
in maintaining cellular survival in BRCA1 deficient cell. A model for synthetic 
lethality is shown in Figure 5.12. In brief, impaired expression of BER in 
BRCA1 deficient cell lines leads to accumulation of unrepaired SSBs followed 
by the formation of DSBs during DNA replication process. Therefore, it is 
suggested that cells are reliant on backup DSB pathway for cellular survival. 
Targeting the DSB pathway by DNA-PKcs inhibition would lead to the 
observed synthetic lethality. In contrast, in cells that are proficient in DSB 
repair the DSBs would be repaired and cells would survive.  
It should be noted that these in vitro studies have limitations. Firstly, this 
investigation was restricted to two DNA-PKcs inhibitors. And a recent study 
has indicated that DNA-PKcs inhibitors currently available are limited by poor 
pharmacokinetics (Davidson et al., 2013). Secondly, cell cycle analysis 
showed modest G1 increase with DNA-PKcs treatment, this could be because 
samples were analysed after 24 and 48 hours. However, more time points 
should be tested in the future to monitor cells response after different 
treatments.  
 
177 
 
 
5.4.1. Conclusions 
 
     To conclude, this in vitro study has shown a potential synthetic lethality 
between BRCA1 deficiency and DNA-PKcs inhibition. Firstly, data have 
shown a selective toxicity in BRCA1 deficient cells to DNA-PKcs inhibitors 
(NU7441 or NU7026). Secondly, DNA DSB accumulation was observed after 
treatment with DNA-PKcs inhibitors in BRCA1 deficient cells compared to 
untreated cells. In addition modest increase in G1 phase arrest was detected, 
though this increase was not always significant and different time points 
should be tested in the future. Then again, DNA-PKcs inhibition was found to 
trigger apoptosis in BRCA1 deficient cells. Moreover, these findings present a 
potential new alternative synthetic lethality strategy in BRCA1 deficient cells. 
Finally, in agreement with previous studies this study shows the importance of 
DNA-PKcs in maintaining cellular survival. 
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Figure 5.12. Proposed model of synthetic lethality between 
DNA-PKcs inhibitors and BRCA1-BER deficient system. 
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Chapter 6 
Cisplatin in combination with Ataxia 
telangiectasia mutated (ATM) or DNA 
dependent protein kinase catalytic 
subunit (DNA-PKcs) inhibitor in 
BRCA1 deficient cells 
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6. Cisplatin in combination with Ataxia telangiectasia 
mutated (ATM) or DNA dependent protein kinase 
catalytic subunit (DNA-PKcs) inhibitor in BRCA1 
deficient cells  
 
6.1. Introduction 
 
 
     Cisplatin [cis-diamminedichloroplatinum(II)] is a platinating anticancer 
chemotherapeutic agent that acts by covalently binding to DNA and forming 
DNA damaging adducts. Cisplatin is effective in the treatment of many cancers 
including metastatic testicular cancers, bladder, cervical, ovarian, lung, head 
and neck cancers (Kelland, 2007, Ratanaphan, 2011).   
Several preclinical studies have shown that BRCA1 deficient cell lines are 
hypersensitive to cisplatin treatment compared to their wild type matched 
controls (Bhattacharyya et al., 2000, Tassone et al., 2003, Tan et al., 2008). In 
addition, clinical studies have demonstrated similar hypersensitivity to 
cisplatin (Byrski et al., 2009, Taron et al., 2004, Quinn et al., 2007, Font et al., 
2011, Silver et al., 2010).  
In the previous chapters, a potential synthetic lethality was demonstrated 
between BRCA1 deficiency and ATM inhibition or DNA-PKcs inhibition in in 
vitro cell culture system. In light of these data, cisplatin was investigated in 
combination with ATM or DNA-PKcs inhibitor in BRCA1 proficient and 
BRCA1 deficient cells.     
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6.1.1. Rationale for study 
 
The data presented in previous chapters suggested that BRCA1 deficiency is 
associated with low expression of BER. BRCA1-BER deficient cells are 
amenable to synthetic lethality targeting using ATM or DNA-PKcs inhibitors. 
As BRCA1 deficient cells are cisplatin sensitive, the potential of a combination 
strategy in BRCA1-BER proficient cells was investigated. 
 
 
6.2. Aims 
The aims of this study were as follows: 
1. To investigate the effect of cisplatin in combination with ATM 
inhibitor (KU55933) or DNA-PKcs inhibitor (NU7441) in clonogenic 
cell survival assay.  
2. To test the hypothesis that DNA double strand breaks accumulate in 
cells after treatment with cisplatin in combination with ATM inhibitor 
(KU55933) or DNA-PKcs inhibitor (NU7441) in BRCA1 deficient 
cells.  
3. To determine the effect of cisplatin / ATM inhibitor (KU55933) or 
DNA-PKcs inhibitor (NU7441) combination on cell cycle progression 
in BRCA1 deficient cells.  
4. To quantify apoptosis in BRCA1 deficient cells after treatment with 
cisplatin / ATM inhibitor (KU55933) or DNA-PKcs inhibitor 
(NU7441) combinations.  
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6.3. Results 
 
6.3.1. Clonogenic cell survival assay in response to Cisplatin  
 
 
     BRCA1 mutated (MDA-MB-436) cells and knockdown (BRCA1 HeLa) 
cell lines along with control cells MCF7 and Control HeLa cell lines 
respectively, were treated with increasing concentrations of cisplatin ranging 
from (0.25 µM to 1.25 µM). Clonogenic survival assay results are shown in 
Figure 6.1. No colonies were obtained at any dose for BRCA1 HeLa and 
MDA-MB-436, showing high sensitivity in these cell lines and that the IC50 
cannot be estimated from these data but must be below the minimum value 
tested. On the other hand, Control HeLa, mean IC50= 0.25 µM ± 0.6 and 
MCF7, mean IC50= 1.23 µM ± 0.9. 
 
Figure 6.1. Clonogenic survival assay of cisplatin.  
After exposure for 16 hours to cisplatin ranging from (0.25 µM to 1.25 µM), 
no colonies were obtained at any dose for BRCA1 HeLa and MDA-MB-436 
showing high sensitivity in these lines compared to BRCA1 proficient cell 
lines. (A) BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-
MB-436 cells compared to MCF7 cells. Plating efficiencies of cell lines 
were as follows: (A) Control HeLa- 75% ; BRCA1 HeLa- 75% (B) MCF7- 
56.5% ; MDA-MB-436- 49.75%. Clonogenic data are shown as the mean 
and SD values for each concentration from 2 experiments.    
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6.3.2. Clonogenic cell survival assay in cells treated with KU55933 
or NU7441 in combination with cisplatin  
 
 
     To evaluate the combination between cisplatin and ATM inhibitor 
(KU55933) or DNA-PKcs inhibitor (NU7441), cells were cultured with 
increasing concentrations of cisplatin. Cells were treated with increasing 
concentration of cisplatin ranging from (0.00001 µM to 0.1 µM) and KU55933 
(5µM, HeLa cell lines and 7.5 µM, breast cancer cell lines) or NU7441 
(0.5µM, HeLa cell lines and 0.75 µM, breast cancer cell lines). The 
concentration range for cisplatin in combination studies was lower as the cells 
were hypersensitive at higher concentrations and underwent profound cell 
death.  
 
Clonogenic survival assays results for the combination of ATM inhibitor and 
cisplatin are shown in Figure 6.2. BRCA1 knockdown cells are more sensitive 
to combination treatment than cisplatin alone (mean IC50= 0.00052 ± 0.00019 
vs. IC50 above the maximum level tested), and compared to BRCA1 proficient 
Control HeLa cells. Similar sensitivity was also demonstrated in combination 
treated MDA-MB-436 cells compared to cisplatin alone (mean IC50= 0.0003 ± 
0.00013 vs. IC50= 0.16 ± 0.026), and compared to control MCF7 cells.  
 
Clonogenic survival assays results for the combination of DNA-PKcs inhibitor 
and cisplatin are shown in Figure 6.3. BRCA1 knockdown cells are more 
sensitive to combination treatment than cisplatin alone (mean IC50= 0.09 ± 
0.098 vs. IC50 above the maximum level tested), and comparing to BRCA1 
proficient Control HeLa cells. Similar sensitivity was also demonstrated in 
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combination treated MDA-MB-436 cells compared to cisplatin alone (mean 
IC50= 0.005 ± 0.0047 vs. IC50= 0.16 ± 0.026), and compared to control MCF7 
cells.  
 
 
 
 
 
 
Figure 6.2. Clonogenic survival assay of ATM inhibitor (KU55933) in 
combination with cisplatin.  
BRCA1 deficient cells show decreased colony forming ability after exposure for 
16 hours to cisplatin ranging from (0.00001 µM to 0.1 µM) and then KU55933 (5 
µM, HeLa cells lines and 7.5 µM, breast cancer cell lines), compared to BRCA1 
proficient cell lines. (A) BRCA1 HeLa cells compared to Control HeLa cells. (B) 
MDA-MB-436 cells compared to MCF7 cells. Plating efficiencies of cell lines 
with standard error were as follows: (A) Control HeLa- 59.33% ± 1.69%; 
BRCA1 HeLa- 65.67% ± 0.60% (B) MCF7- 44.89% ± 0.72%; MDA-MB-436- 
24.53% ± 2.76%. Clonogenic data are shown as the mean and SD values for each 
FRQFHQWUDWLRQIURP2 independent experiments.    
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Figure 6.3. Clonogenic survival assay of DNA-PKcs inhibitor (NU7441) in 
combination with cisplatin.  
BRCA1 deficient cells show decreased colony forming ability after exposure 
for 16 hours to cisplatin ranging from (0.00001 µM to 0.1 µM) and then 
NU7441 (0.5µM, HeLa cell lines and 0.75 µM, breast cancer cell lines), 
compared to BRCA1 proficient cell lines. (A) BRCA1 HeLa cells compared 
to Control HeLa cells. (B) MDA-MB-436 cells compared to MCF7 cells. 
Plating efficiencies of cell lines with standard error were as follows: (A) 
Control HeLa- 60% ± 1.36%; BRCA1 HeLa- 64.83% ± 1.55% (B) MCF7- 
46.78% ± 2.61%; MDA-MB-436- 25.87% ± 2.36%. Clonogenic data are 
shown as WKH PHDQ DQG 6' YDOXHV IRU HDFK FRQFHQWUDWLRQ IURP  2 
independent experiments.   
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6.3.3. Ȗ+$;immunofluorescence microscopy in response to 
KU55933 or NU7441 in combination with cisplatin 
 
 
     To determine whether DNA double strand breaks (DSBs) accumulate after 
WUHDWPHQWZLWK.8DQGFLVSODWLQ'6%VZHUHPHDVXUHGXVLQJWKHȖ+$;
immunofluorescence microscopy assay. As described in Chapter 2 section 
2.3.5, cells were treated with cisplatin (0.1 µM) and KU55933 (for HeLa cell 
lines = 5 µM or breast cancer cell lines = 7.5 µM) for 24 hours and 48 hours. 
Although no significant changes were observed after 24 hours, at 48 hours a 
significant increase in foci formation was observed in BRCA1 deficient cells.  
As shown in Figure 6.4, the data demonstrates a statistically significant 
increase in the accumulation of Ȗ+$; IRFL LQ FRPELQDWLRQ WUHDWHG %5&$
HeLa cells compared to corresponding cisplatin alone treated BRCA1 HeLa 
cells and untreated BRCA1 HeLa cells (76.50% vs. 18%; p = 0.003 and 
76.50% vs. 11%; p = 0.0017, respectively) and compared to combination 
treated Control HeLa cells (15.00 %; p = 0.0019).  
Similar results were also observed in combination treated MDA-MB-436 cells 
in which DFFXPXODWLRQRIȖ+$;IRFLZHUHKLJKHUFRPSDUHGWRFRUUHVSRQGLQJ
cisplatin alone treated MDA-MB-436 cells and untreated MDA-MB-436 cells 
(60.50% vs. 36%; p = 0.06 and 60.50% vs. 17.50%; p = 0.012, respectively) 
and compared to combination treated MCF7 cells (31 %; p = 0.032). 
 
 
  
187 
 
 
 
 
Figure 6.4. Immunofluorescence microscopy staining for Ȗ+$; foci 
formation   following ATM inhibitor (KU55933) in combination with 
cisplatin for 48 hours exposure. 
(A) BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-
436 cells compared to MCF7 cells. Data are shown as the mean and SD 
YDOXHVIRUHDFKFRQFHQWUDWLRQIURP2 independent experiments. * p<0.05 
and ** p<0.01, p value was assessed by a t-test comparing BRCA1 
deficient cell lines to BRCA1 proficient cell lines. Graphs were produced 
and statistical analysis performed using GraphPad prism.  
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     Alternatively, cells were treated with cisplatin (0.1 µM) and NU7441 (for 
HeLa cell lines = 0.5 µM or breast cancer cell lines = 0.75 µM) for 24 hours 
and 48 hours. Although no significant changes were observed after 24 hours, at 
48 hours in BRCA1 deficient cells a significant increase in foci formation was 
observed. As shown in Figure 6.5, the data demonstrates a statistically 
significant increase in the accumulation of Ȗ+$;IRFLLQFRPELQDWLRQWUHDWHG
BRCA1 HeLa cells compared to corresponding cisplatin alone treated BRCA1 
HeLa cells and untreated BRCA1 HeLa cells (87% vs. 18%; p = 0.0017 and 
87% vs. 11%; p = 0.0009, respectively) and compared to combination treated 
Control HeLa cells (16%; p = 0.0026).  
Similar results were also observed in combination treated MDA-MB-436 cells 
LQZKLFKDFFXPXODWLRQRIȖ+$;IRFLZHUHKLJKHUFRPSDUHGWRFRUUHVSRQGLQg 
cisplatin alone treated MDA-MB-436 cells and untreated MDA-MB-436 cells 
(81.5% vs. 36%; p = 0.017 and 81.5% vs. 17.50%; p = 0.003, respectively) and 
compared to combination treated MCF7 cells (38.5%; p = 0.013). 
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Figure 6.5. Immunofluorescence microscopy staining for Ȗ+$; foci 
formation   following DNA-PKcs inhibitor (NU7441) in combination with 
cisplatin for 48 hours exposure. 
(A) BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-436 
cells compared to MCF7 cells. Data are shown as the mean and SD values 
IRU HDFK FRQFHQWUDWLRQ IURP  2 independent experiments. * p<0.05, ** 
p<0.01 and *** p<0.001, p value was assessed by a t-test comparing BRCA1 
deficient cell lines to BRCA1 proficient cell lines. Graphs were produced and 
statistical analysis performed using GraphPad prism.  
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6.3.4. Flow cytometric cell cycle analysis in response to ATM 
inhibitor (KU55933) or DNA-PKcs inhibitor (NU7441) in 
combination with Cisplatin  
 
 
     For cell cycle analysis, cells were treated with cisplatin (0.1 µM) and 
KU55933 (for HeLa cell lines = 5 µM or breast cancer cell lines = 7.5 µM) for 
48 hours. Results for BRCA1 proficient and BRCA1 deficient cells following 
combination treatment are shown in Figure 6.6. The data demonstrate an 
increase in G2/M arrest in combination treated BRCA1 HeLa cells compared 
to corresponding cisplatin alone treated BRCA1 HeLa cells and untreated 
BRCA1 HeLa cells (mean 37.6%, 29.5% and 25.8%; respectively). Similar 
results were also observed in combination treated MDA-MB-436 cells in 
which G2/M arrest were significantly higher compared to untreated MDA-
MB-436 cells (mean 38% vs. 32.4%). On the other hand, cisplatin alone 
treated MDA-MB-436 cells showed mean of 41.4% G2/M arrest.  
     Conversely, cells were treated with cisplatin (0.1 µM) and NU7441 (for 
HeLa cell lines = 0.5 µM or breast cancer cell lines = 0.75 µM) for 48 hours. 
As shown in Figure 6.7, the data demonstrates an increase in G2/M arrest in 
combination treated BRCA1 HeLa cells compared with corresponding 
cisplatin alone treated BRCA1 HeLa cells and untreated BRCA1 HeLa cells 
(mean 34.2%, 29.5% and 25.8%; respectively). Similar results were also 
observed in combination treated MDA-MB-436 cells in which G2/M arrest 
was significantly higher compared to untreated MDA-MB-436 cells (mean 
38.2% vs. 32.4%). On the other hand, cisplatin alone treated MDA-MB-436 
cells showed a mean G2/M arrest of 41.4%. Control HeLa and MCF7 cells did 
not show the same increase as BRCA1 deficient cells with both combination 
treatments.  
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Figure 6.6. Flow cytometric cell cycle analysis following ATM inhibitor 
(KU55933) in combination with cisplatin 
(A) BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-
436 cells compared to MCF7 cells. Data are shown as the mean and SD 
YDOXHVIRUHDFKFRQFHQWUDWLRQIURP2 independent experiments. * p<0.05 
and ** p<0.01, p value was assessed by a t-test comparing BRCA1 deficient 
cell lines to BRCA1 proficient cell lines. Graphs were produced and 
statistical analysis performed using GraphPad prism. 
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Figure 6.7. Flow cytometric cell cycle analysis following DNA-PKcs inhibitor 
(NU7441) in combination with cisplatin 
(A) BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-436 
cells compared to MCF7 cells. Data are shown as the mean and SD values for 
HDFKFRQFHQWUDWLRQIURP2 independent experiments. * p<0.05 and ** p<0.01, 
*** p<0.001, p value was assessed by a t-test comparing BRCA1 deficient cell 
lines to BRCA1 proficient cell lines. Graphs were produced and statistical 
analysis performed using GraphPad prism. 
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6.3.5. Apoptosis detection by annexin V-FITC flow cytometry in 
response to KU55933 or NU7441 in combination with cisplatin  
 
 
     Cells were treated with cisplatin (0.1 µM) and KU55933 (for HeLa cell 
lines = 5 µM or breast cancer cell lines = 7.5 µM) for 48 hours. Results for 
BRCA1 proficient and BRCA1 deficient cells following combination treatment 
are shown in Figure 6.8, data were normalised against baseline apoptotic 
fraction (untreated cells) to determine the percentage increase in apoptosis. The 
data demonstrate a statistically significant increase in combination treated 
BRCA1 HeLa cells compared to corresponding cisplatin alone treated BRCA1 
HeLa cells and untreated BRCA1 HeLa cells (mean 20.6%, 15.9% and 5.3%; 
respectively). Similar results were also observed in combination treated MDA-
MB-436 cells in which the increase in apoptosis was significantly higher 
compared to cisplatin alone treated MDA-MB-436 and compared to untreated 
MDA-MB-436 cells (mean 17.6%, 7.4% and 4.9%; respectively). On the other 
hand, Control HeLa and MCF7 cells did not show the same high increase (i.e. 
around 14% increase with BRCA1 deficient cells) after cisplatin and KU55933 
treatment (mean 4.35% to 7.49% and 3.17% to 9.25%, respectively). 
     Conversely, cells were treated with cisplatin (0.1 µM) and NU7441 (for 
HeLa cell lines = 0.5 µM or breast cancer cell lines = 0.75 µM) for 48 hours. 
As shown in Figure 6.9, the data demonstrates a statistically significant 
increase in combination treated BRCA1 HeLa cells compared to corresponding 
cisplatin alone treated BRCA1 HeLa cells and untreated BRCA1 HeLa cells 
(mean 25%, 15.9% and 5.3%; respectively). Similar results were also observed 
in combination treated MDA-MB-436 cells in which the increase in apoptosis 
was significantly higher compared to cisplatin alone treated MDA-MB-436 
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and compared to untreated MDA-MB-436 cells (mean 19.2%, 7.4% and 4.9%; 
respectively). On the other hand, Control HeLa and MCF7 cells did not show 
the same high increase (i.e. around 17% increase with BRCA1 deficient cells) 
after cisplatin and NU7441 treatment (mean 4.35% to 4.13% and 3.17% to 
11%, respectively). 
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Figure 6.8. Apoptosis detection by annexin V-FITC flow cytometry in 
response to ATM inhibitor (KU55933) in combination with cisplatin 
Treatment with combination KU55933 and cisplatin was associated with a 
significant increase in apoptotic. Data were normalised against baseline 
apoptotic fraction to determine the percentage increase in apoptosis. (A) 
BRCA1 HeLa cells compared to Control HeLa cells. (B) MDA-MB-436 cells 
compared to MCF7 cells. Data are shown as the mean and SD values for each 
concentration from 3 independent experiments. * p<0.05, ** p<0.01, *** 
p<0.001 and **** p<0.0001, p value was assessed by a t-test comparing 
BRCA1 deficient cell lines to BRCA1 proficient cell lines. Graphs were 
produced and statistical analysis performed using GraphPad prism.   
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Figure 6.9. Apoptosis detection by annexin V-FITC flow cytometry in 
response to DNA-PKcs inhibitor (NU7441) in combination with cisplatin 
Exposure to combination NU7441 and cisplatin was associated with a 
significant increase in apoptotic. Data were normalised against baseline 
apoptotic fraction to determine the percentage increase in apoptosis. (A) 
BRCA1 HeLa cell line compared to Control HeLa. (B) MDA-MB-436 
compared to MCF7. Data are shown as the mean and SD values for each 
concentration from 3 independent experiments. ** p<0.01 and **** p<0.0001, 
p value was assessed by a t-test comparing BRCA1 deficient cell lines to 
BRCA1 proficient cell lines. Graphs were produced and statistical analysis 
performed using GraphPad prism.   
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6.4. Discussion and conclusions 
 
 
     In previous chapters (Chapter 4 and Chapter 5), it was suggested that there 
was a synthetic lethality relationship between BRCA1 deficiency and targeting 
DSB repair pathway by blockade of ATM or DNA-PKcs. ATM and DNA-
PKcs modulation has been shown to enhance cisplatin cytotoxicity (Yoshida et 
al., 2008, Dejmek et al., 2009). Therefore, in this section of the study, the 
efficacy of combining cisplatin with ATM or DNA-PKcs inhibitor in BRCA1 
proficient and BRCA1 deficient cells was investigated. To achieve this, 
clonogenic survival assay was conducted first to evaluate the cytotoxicity of 
cisplatin alone followed by combination studies using ATM (KU55933) or 
DNA-PKcs (NU7441) inhibitors. In agreement with previous studies, BRCA1 
showed hypersensitivity to platinum therapy (Husain et al., 1998, 
Bhattacharyya et al., 2000, Tassone et al., 2003, Tan et al., 2008, Byrski et al., 
2009, Taron et al., 2004, Quinn et al., 2007, Font et al., 2011, Silver et al., 
2010). The dose of cisplatin used for the combination treatment in this study 
was 1/10th the dose used in previous preclinical studies. The results of both 
combination treatments (cisplatin/ATM inhibitor and cisplatin/DNA-PKcs 
inhibitor) induced hypersensitivity in BRCA1 deficient cells compared to 
BRCA1 deficient cells treated with cisplatin alone. )RUPDWLRQRIȖ+$;IRFL
in BRCA1 deficient cells following combination treatments increased 
compared to cisplatin alone and compared to either inhibitor alone. Whereas 
BRCA1 knockdown cells showed 76.5% increase in the accumulation of 
Ȗ+$;IRFLfollowing ATM inhibitor/cisplatin treatment (Figure 6.4A) and an 
87% increase with DNA-PKcs inhibitor/cisplatin treatment (Figure 6.5A), 
ATM inhibitor alone showed 66.5% (Figure 4.9A) and DNA-PKcs inhibitor 
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alone showed 62.5% (Figure 5.5A). Interestingly, this increase in Ȗ+$;IRFL
formation was not seen following combination treatments in the BRCA1 
mutated cells (Figure 6.4B and 6.5B) compared to each inhibitor alone (Figure 
4.9B and 5.5B). This observation may be because MDA-MB-436 cells were 
found to be hypersensitive to the combination treatments and exhibited 
profound cell death. It should be noted that IRUPDWLRQ RI Ȗ+$; IRFL ZDV
analyzed after 48 hours with both single and combination treatments and to 
follow the damage after combination treatments different time points should be 
tested in the future.    
The flow cytometry assay showed that BRCA1 deficient cells arrested 
significantly at G2/M phase after combination treatments compared to either 
inhibitor alone. Whereas BRCA1 deficient cell lines showed 37.6% and 38% 
increase in G2/M arrest following ATM inhibitor/cisplatin treatment (Figure 
6.6), ATM inhibitor alone showed 26.6% and 32.45% (Figure 4.12), 
respectively. A similar increase was observed following DNA-PKcs 
inhibitor/cisplatin treatment with 34.25% and 38.25% (Figure 6.7), compared 
to 21.8% and 26.55% following DNA-PKcs inhibitor alone (Figure 5.8), 
respectively. In previous studies, G2/M arrest was demonstrated when 
combining KU55933 and NU7441 with Doxorubicin or Neocarzinostatin or 
Ionizing radiation (Zhao et al., 2006, Yu et al., 2012, Shaheen et al., 2011, 
Ciszewski et al., 2014). Cisplatin has been suggested to activate CHK1 and 
CHK2 which then leads to G2 arrest. Previous studies have also showed the 
selectivity of cisplatin in the killing of p53 defective tumor cells (Fan et al., 
1995, Lee et al., 1999). Interestingly, targeting DNA-PKcs alone in BRCA1 
deficient cells showed G1 arrest, whereas in the combination study G2/M 
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arrest was observed. This current study suggests that in combination treatments 
cisplatin activates G2/M arrest independent of DNA-PKcs inhibition. After 
G2/M arrest, BRCA1 deficient cells were unable to repair the DSBs and hence 
initiate apoptosis. A significant accumulation of apoptosis was observed in 
ATM inhibitor/cisplatin combination treatment, showing 20.6% and 17.6% 
(Figure 6.8) compared to 11.12% and 13.1% following ATM inhibitor alone 
(Figure 4.15) in BRCA1 HeLa and MDA-MB-436 cells, respectively. A 
similar increase in apoptosis was observed following DNA-PKcs 
inhibitor/cisplatin treatment with 25% and 19.2% (Figure 6.9) compared to 
6.3% and 13.5% following DNA-PKcs inhibitor alone (Figure 5.10) in BRCA1 
HeLa and MDA-MB-436 cells, respectively.  
Taken together, several important observations have emerged from this 
chapter: firstly, the platinum anticancer drug cisplatin is selectively toxic to 
BRCA1 deficient cells. Cisplatin sensitivity in BRCA1 deficient cells observed 
here is consistent with previous publications. Secondly, inhibition of ATM or 
DNA-PKcs in combination with cisplatin enhances the cytotoxicity compared 
to either inhibitor alone. However, it should be noted that investigating drug 
combination interactions is an important area to study and it is one of the 
limitations in this chapter. For future studies in order to evaluate the interaction 
between ATM inhibitors and cisplatin or DNA-PKcs inhibitors and cisplatin, 
number of published methodologies can be used to evaluate the nature of drug-
drug combination, e.g. isobologram, combination index, curve shift analysis 
(Evaluation of drug interaction methods are listed with more details in 
APPENDIX D). Thirdly, combination treatments increase DSB accumulation 
in BRCA1 deficient cells. Finally, combination treatments increase G2/M cell 
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cycle arrest, followed by an increase in apoptosis. A model for synthetic 
lethality is shown in Figure 6.10. In brief, impaired BER factors in BRCA1 
deficient cell lines leads to accumulation of unrepaired SSBs followed by the 
formation of DSBs during DNA replication process. Therefore, it is suggested 
that cells are reliant on backup DSB pathways for cellular survival. Targeting 
DNA-PKcs or ATM along with cisplatin could induce extensive DSBs and 
over whelm BRCA1 deficient cells. This could lead to the observed synthetic 
lethality. In contrast, cells that are proficient in DSB repair (BRCA1-BER 
proficient), the DSBs would be repaired and cells would survive.   
 
6.4.1. Conclusions  
 
     To conclude, this chapter of the study suggests that ATM and DNA-PKcs 
inhibition enhances cisplatin sensitivity in BRCA1 deficient cells. Firstly, data 
have shown that inhibition of ATM or DNA-PKcs in combination with 
cisplatin enhances the cytotoxicity compared to cisplatin alone. Secondly, 
combination treatments increase DSBs accumulation in BRCA1 deficient cells 
compared to cisplatin alone. In addition, combination treatments increase 
G2/M cell cycle arrest, followed by an increase in apoptosis. Finally, 
combination data were compared with corresponding cells treated with 
inhibitors alone (data presented in chapter 4 and chapter 5); the results 
generally suggested improved outcomes in combination treatments compared 
to each inhibitor alone. The data implies that the combination therapy could be 
an attractive strategy in BRCA1 cancer cells. However, advanced preclinical 
investigations with more cell lines and inhibitors are required. 
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Figure 6.10. Working model for cisplatin and ATM or DNA-PKcs inhibitor 
as a synthetic lethality strategy in BRCA1-BER deficient cells.  
(A) Inhibitors alone. (B) Cisplatin in combination with inhibitors.  
(BRCA1+/BER+) BRCA-BER proficient cells and (BRCA-/BER-) BRCA1-
BER deficient cells.    
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7. General Discussion and suggestions for future 
studies 
 
     Maintenance of genome stability is of primary importance for living 
organisms. However, DNA is under constant attack from numerous 
endogenous and exogenous DNA damaging agents. The accumulation of DNA 
damage can induce permanent changes that lead to carcinogenesis and could 
promote aggressive cancer biology. To counteract the deleterious effects of 
DNA damage, all organisms are equipped with DNA repair machinery to 
process DNA damage and maintain genomic integrity. Cancer cells on the 
other hand acquire defects in a certain DNA repair pathway and become 
dependent on a compensatory repair pathway in order to survive. More 
recently, inhibitions of the compensatory DNA repair (backup repair) pathway 
has emerged as a promising target for anticancer therapy. This strategy of 
selective killing of cancer cells is known as synthetic lethality (Abbotts et al., 
2014b, Rassool and Tomkinson, 2010, Lord and Ashworth, 2008). Synthetic 
lethality is defined as a genetic combination of mutations in two or more 
genes/pathways that leads to cell death, whereas a mutation in only one of 
them does not. This represents a new approach of targeting DNA repair 
pathways with cancer therapies based on the genetic background of the tumour 
(Lord and Ashworth, 2008). The well known synthetic lethality relationship to 
date is targeting BRCA mutation with PARP inhibitors. BRCA/PARP synthetic 
lethality model proposes that targeting BRCA deficient tumours, which are HR 
deficient, with PARP inhibitor leads to the accumulation of SSBs. This is 
followed by the formation of DSBs during DNA replication, leading to cell 
death (Farmer et al., 2005, Bryant et al., 2005). On 23 October 2014, PARP 
204 
 
 
inhibitor (Olaparib, AstraZeneca©) has moved a step closer to being available 
for patients in the UK, after receiving a positive recommendation from the 
Committee for Medicinal products for Human Use (CHMP), which is part of 
the European Medicines Agency (EMA). The CHMP recommended that 
Olaparib (known as Lynparza) be used as monotherapy for adult patients 
with relapsed, platinum sensitive epithelial ovarian, fallopian tube or primary 
peritoneal cancer with mutations in one of two genes BRCA1 or BRCA2, and 
who have responded to platinum-based chemotherapy (EMA, 2014). This 
makes Lynparza the first in class drug depending on synthetic lethality 
strategy.     
Clinical data provide compelling evidence that alterations in expression of 
DNA repair factors may have prognostic and predictive significance in 
patients. Germ-line mutations in BRCA1 predispose to breast and ovarian 
cancer development. BRCA1 mutation carriers have an 80% lifetime risk of 
developing breast cancer and 40-50% risk of developing ovarian cancer (Risch 
et al., 2001). In addition, BRCA1 mutations has been found to increase the risk 
of pancreatic and prostate cancers (Thompson and Easton, 2002). A more 
recent study suggested that BRCA1 mutation increases the risk of other types 
of cancer such as kidney, leukemia, lung, colorectal, myeloma, melanoma, 
stomach, thyroid and uterine cancers (Mersch et al., 2014). BRCA1 functions 
to maintain genomic stability through the assembly of multiple protein 
complexes involved in DNA repair pathways. BRCA deficiency on the other 
hand has been linked to genomic instability related to a defect in double strand 
break repair (Moynahan et al., 1999, Kass et al., 2013).  
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Alternative synthetic lethality target is an area of intense research. Our group 
has shown that targeting APE1, a central component of the BER pathway is 
synthetically lethal in HR deficient cells (Mohammed et al., 2011, Sultana et 
al., 2012). Similarly, targeting APE1 in PTEN deficient melanoma cell lines 
also shows synthetic lethality (Abbotts et al., 2014a). In addition, targeting 
XRCC1 deficient cell lines by ATM, DNA-PKcs or SSB repair inhibitor of 
ATR also induces synthetic lethality (Sultana et al., 2013a, Sultana et al., 
2013b). Recently, BRCA1 has been suggested to be involved in the 
transcriptional regulation of three BER enzymes; OGG1, NTH1 and APE1 
(Saha et al., 2010). A more recent study supports these observations and 
demonstrated down-regulation of APE1, NTH1, OGG1 and XRCC1 in BRCA1 
mutated and sporadic breast cancers (De Summa et al., 2014). Therefore 
impaired BER in BRCA1 deficient cell lines may be an opportunity for novel 
synthetic lethality strategy. The primary aim of the work described in this 
thesis was to investigate whether targeting BRCA1-BER deficient cells using 
ATM or DNA-PKcs inhibitors will be synthetically lethal. In order to achieve 
the aim, firstly DNA repair gene and protein expression in BRCA1 deficient 
and BRCA1 proficient cells were investigated (Chapter 3). Secondly, BRCA1 
deficient cells were targeted by ATM inhibitors (KU55933 and KU60019) to 
investigate whether they would be synthetically lethal compared to BRCA1 
proficient cells (Chapter 4). Then, BRCA1 deficient cells were targeted by 
DNA-PKcs inhibitors (NU7441 and NU7026) to investigate if they would also 
be synthetically lethal (Chapter 5). Finally, BRCA1 deficient cells were 
targeted by ATM or DNA-PKcs inhibitor in combination with cisplatin to 
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investigate whether it would enhance the observed synthetic lethality (Chapter 
6).    
Initially the RT² Profiler DNA Repair PCR Array was used to scan 84 DNA 
repair genes. Data demonstrated down-regulation of several DNA repair 
mRNAs in BRCA1 mutant/knockdown cell lines as compared to BRCA1 
proficient cell lines. Low mRNA expression was demonstrated for APE1, 
OGG1 and NTHL1, which is consistent with previous observations (Saha et al., 
2010, De Summa et al., 2014). However RT² Profiler Array results did not 
always give statistical significance. Further assessments of the results were 
carried out using quantitative real time PCR (RT-qPCR) for a panel of selected 
DNA repair genes (APE1, XRCC1, SMUG1, Pol ß, Lig3, ATM and DNA-PKcs) 
which had previously be linked to BRCA1 (Abdel-Fatah et al., 2013, Masaoka 
et al., 2013, De Summa et al., 2014). RT-qPCR demonstrated statistically 
significant down-regulation of the selected genes. Protein expression was then 
analyzed for this selected group by western blot, which showed down-
regulation consistent with the mRNAs expression. Taken together, these 
results suggest that BRCA1 deficiency may associate with a global defect in 
BER pathway. Interestingly, BRCA1 expression was also associated with a 
global reduction in HR (see section 3.4.2), NHEJ (see section 3.4.3), NER and 
MMR pathways (see section 3.4.4). However, further investigation is needed 
to measure the efficiency of these pathways. 
As BRCA1 deficient cells were suggested to be BER deficient, cells may be 
amenable to synthetic lethality approach by targeting additional DSB repair 
targets. To examine this, clonogenic survival assays were conducted first to 
evaluate the cytotoxicity of ATM inhibitors (KU55933 and KU60019) against 
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BRCA1 knockdown HeLa cells and BRCA1 mutated MDA-MB-436 cells, 
using Control HeLa and MCF7 cells as BRCA1 proficient controls, 
respectively. Data demonstrated significant cytotoxicity in BRCA1 
mutant/knockdown cell lines. For additional validation, the proliferation assay 
(MTS assay) was used to determine cell growth in response to ATM inhibitor, 
which showed consistent results with the clonogenic assay. Several functional 
studies were conducted to understand the mechanism behind this selective 
cytotoxicity. Ȗ+$; LPPXQRIOXRUHscence microscopy assay showed that 
BRCA1 deficient cell lines treated with ATM inhibitors (KU55933 or 
KU60019) for 48 hours were associated with statistically significant increase 
in the accumulation of '6%V Ȗ+$; IRFL compared to untreated BRCA1 
deficient cells. Cell cycle progression was arrested significantly at G2/M phase 
in treated BRCA1 HeLa cells compared to untreated BRCA1 HeLa cells. On 
the other hand, MDA-MB-436 cells showed a modest increase in G2/M arrest 
after 48 hours treatments which suggests a disturbance in cell cycle 
progression, though different time points should be tested in the future. 
Increases in G2/M arrest supports previously published data showing G2/M 
arrest after ATM inhibition (Sultana et al., 2013a, Lee et al., 2013, Nadkarni et 
al., 2012, Jazayeri et al., 2006). A flow cytometry-based apoptosis detection 
assay was performed after that and results demonstrated an increase in 
apoptosis rate in treated BRCA1 deficient cells compared to untreated BRCA1 
deficient cells. These results support those previously published showing ATM 
inhibitor KU55933 treatment triggers apoptosis in different cancer cell lines 
(Sultana et al., 2013a, Li and Yang, 2010, Korwek et al., 2012) which again 
highlighted the importance of ATM in DNA repair and cell survival. 
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Altogether, these results support the hypothesis of BRCA1/ATM synthetic 
lethality and suggest that ATM plays a vital and irreplaceable role in genomic 
stability in BRCA1 deficient cells.       
In light of the observed BRCA1/ATM synthetic lethality relationship, targeting 
BRCA1 deficiency by DNA-PKcs inhibitors (NU7441 and NU7026) was also 
carried out to investigate if there was a synthetically lethal relationship. 
Clonogenic survival assays results in Chapter 5 demonstrated that upon DNA-
PKcs inhibition, BRCA1 mutant/knockdown cell lines showed increased 
cellular toxicity compared to BRCA1 proficient cell lines. For additional 
validation, MTS assay was used to determine cell viability in response to 
DNA-PKcs inhibitor. Both NU7441 and NU7026 inhibitors induced consistent 
results with the clonogenic assay. DSBs formation increased significantly after 
DNA-PKcs inhibition in BRCA1 mutant/knockdown cell lines. This finding 
supports previous publications showing accumulation of Ȗ+$; IRFL ZLWK
inhibition of DNA-PKcs (Shaheen et al., 2011, Sultana et al., 2013a). 
Monitoring cell cycle progression in BRCA1 deficient cell lines after treatment 
with DNA-PKcs inhibitors for 48 hours was associated with a modest arrest at 
G1 phase compared to untreated BRCA1 deficient cell lines. This suggests 
further investigation with different time points is required. The data 
demonstrate that a potential synthetic lethality relationship which exists 
between BRCA1 deficiency and DNA-PKcs inhibition, and highlights the role 
of DNA-PKcs in the maintenance of genomic stability of BRCA1 deficient 
cells.  
Finally, combination strategy was investigated to demonstrate if targeting 
BRCA1 deficiency by ATM or DNA-PKcs inhibitor in combination with 
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cisplatin would enhance this synthetic lethality. Clonogenic combination 
results in Chapter 6 of both treatments (cisplatin/ATM inhibitor and 
cisplatin/DNA-PKcs inhibitor) induced hypersensitivity in BRCA1 deficient 
cells compared to BRCA1 deficient cells treated with cisplatin alone. 
Functional studies demonstrated that cisplatin enhanced cell death by increased 
accumulation of DSBs, G2/M cell cycle arrest and increased induction of 
apoptosis compared to either inhibitor alone. These data suggest that cisplatin 
can enhance the observed synthetic lethality effect.     
Interestingly, it has always been assumed that cells lacking functional BRCA1 
protein have impaired HR, and thus are suggested to depend on the more error-
prone non-homologous end joining (NHEJ) pathway (Huen et al., 2010). In 
this thesis BRCA1 deficiency has been associated with a global impairment of 
expression of HR and NHEJ factors. Targeting NHEJ by DNA-PKcs inhibitors 
or HR by ATM inhibitors in BRCA1 deficient cells showed synthetic lethality. 
This observation supports that both DSB sub-pathways play an important role 
in maintaining chromosomal stability (Takata et al., 1998). Moreover, in 
BRCA1 proficient cells with functional BER, despite ATM or DNA-PKcs 
inhibition, DSBs may be rapidly repaired in backup DNA repair pathways and 
cells may continue to survive. The backup repair could operate through the 
complex overlap between HR, NHEJ and alternative non-homologous end 
joining (A-NHEJ) pathways (Schipler and Iliakis, 2013, Chapman et al., 2012). 
On the other hand, in BRCA1 deficient cells with low BER, ATM or DNA-
PKcs inhibitors may lead to accumulation of DSBs which beyond a threshold, 
leading cells to cell cycle arrest and apoptosis. Recently our group has shown 
that ATM or DNA-PKcs inhibitors are synthetically lethal in XRCC1 deficient 
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cells (Sultana et al., 2013a). Given the potential role of XRCC1 in the A-NHEJ 
(Mladenov and Iliakis, 2011, Brandsma and Gent, 2012, Dueva and Iliakis, 
2013), BRCA1 deficient cells with low XRCC1 may have impaired A-NHEJ 
in addition to BER resulting in an increased genomic instability and enhanced 
synthetic lethality when cisplatin was added in the current study. Moreover, 
ATM and DNA-PKcs modulation has been shown to enhance cisplatin 
cytotoxicity (Yoshida et al., 2008, Dejmek et al., 2009). 
A limitation of my study is that this investigation was restricted to a few cell 
lines only. For future work, use of positive control drugs (e.g. several PARP 
inhibitors) in the functional studies will validate the results further. As with 
most research, the data presented here have thrown up as many questions as 
answers. Future in vivo studies are required to test these new findings and to 
evaluate the toxicity in normal tissue, which will validate the potential 
therapeutic benefit in clinical use. Another important area of investigation 
would be to evaluate potential biological mechanisms of resistance to ATM 
and DNA-PKcs inhibition. Moreover, the findings described here would also 
need further validation using pharmaceutical grade ATM and DNA-PKcs 
inhibitors that are currently under development. Also, to investigate if BRCA1 
overexpression increases enzymatic activities related to DNA repair pathways 
(e.g. BER) a knock-in method using a BRCA1 expression plasmid created by 
cloning the BRCA1 cDNA into a vector could be used. In addition, ATM and 
DNA-PKcs knockdown cell lines can be targeted by BRCA1 small interfering 
(si) RNA to study the synthetic lethality relationship further.   
This study suggests that BRCA1 deficiency may be associated with a global 
defect in DNA repair pathways, in particular base excision repair. The study 
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also provides proof that BRCA1 deficient cells could be targeted by inhibitors 
of the double strand break repair pathway, proposing that drug targets other 
than PARP can also be used for personalized cancer therapy.  
7.1. Summary of key findings 
9 Loss of BRCA1 expression is associated with reduction in mRNA and 
protein expression of factors involved in Base excision repair. 
9 In cell lines, loss of BRCA1 expression is also associated with reduction in 
the expression of factors involved in Homologous recombination and Non-
homologous end joining. 
9 BRCA1 mutated and knockdown cell lines are sensitive to ATM inhibitors 
(KU55933 & KU60019). 
9 ATM inhibitors treatment is associated with DNA double strand break 
accumulation and induction of apoptosis in BRCA1 deficient cells.  
9 BRCA1 mutated and knockdown cell lines are sensitive to DNA-PKcs 
inhibitors (NU7441 & NU7026). 
9 DNA-PKcs inhibitors treatment is associated with DNA double strand 
break accumulation and induction of apoptosis in BRCA1 deficient cells. 
9 Cisplatin in combination with ATM inhibitor (KU55933) or DNA-PKcs 
inhibitor (NU7441) enhances cytotoxicity in BRCA1 deficient cells. 
9 ATM inhibitor (KU55933) or DNA-PKcs inhibitor (NU7441) in 
combination with cisplatin treatment is associated with DNA double strand 
break accumulation, G2/M arrests and induction of apoptosis in BRCA1 
deficient cells.  
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APPENDIX A. ǻǻ&t Method 
 
     ǻǻ&t method is a convenient way to analyze the relative changes in gene 
expression from real-time quantitative PCR experiments. This involves 
comparing the Ct values of the samples (BRCA1 deficient cells) of interest 
with a control (BRCA1 proficient cells). The Ct values of both the control and 
the samples of interest are normalized to a housekeeping gene (GAPDH). The 
ǻǻ&t method is also known as the comparative Ct method and 2±
[delta][delta]Ct method (Livak and Schmittgen, 2001), where 
ǻ&W &Wtarget, control sample) ± Ct (ref, control sample) 
ǻ&W &Wtarget, deficient sample) ± Ct (ref, deficient sample) 
ǻǻ&t  ǻ&W- ǻ&W 
Where 
Ct (target, control sample) = Ct value of gene of interest in BRCA1 proficient 
sample 
Ct (ref, control sample) = Ct value of housekeeping gene in BRCA1 proficient 
sample 
Ct (target, deficient sample) = Ct value of gene of interest in BRCA1 deficient 
sample 
Ct (ref, deficient sample) = Ct value of housekeeping gene in BRCA1 deficient 
sample 
 
Then calculate the ratio of our target gene in our deficient sample relative to 
our control sample by taking 2ǻǻ&7. 
Example: 
 
control sample deficient sample 
BRCA1 31.7 35.50 
GAPDH 24.14 21.847 
 
ǻǻ&t = (31.7 - 24.14) ± (35.50 - 21.847)  
ǻǻ&t = (7.56) ± (13.653)  
ǻǻ&t = - 6.093 
2ǻǻ&7= 2 (0 - 6.093) = 0.02 (Fold Change) 
 
So BRCA1 gene is decreased by 0.02 times in BRCA1 deficient sample versus 
BRCA1 proficient sample. 
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APPENDIX B.  DNA repair genes assayed in Qiagen 
RT2 Profiler DNA Repair 
Symbol Description 
APE1 APEX nuclease (multifunctional DNA repair enzyme) 1 
APE2 APEX nuclease (apurinic/apyrimidinic endonuclease) 2 
ATM Ataxia telangiectasia mutated 
ATR Ataxia telangiectasia and Rad3 related 
ATXN3 Ataxin 3 
BRCA1 Breast cancer 1, early onset 
BRCA2 Breast cancer 2, early onset 
BRIP1 BRCA1 interacting protein C-terminal helicase 1 
CCNH Cyclin H 
CCNO Cyclin O 
CDK7 Cyclin-dependent kinase 7 
DDB1 Damage-specific DNA binding protein 1, 127kDa 
DDB2 Damage-specific DNA binding protein 2, 48kDa 
DMC1 DMC1 dosage suppressor of mck1 homolog, meiosis-specific homologous recombination 
(yeast) 
ERCC1 Excision repair cross-complementing rodent repair deficiency, complementation group 1 
ERCC2 Excision repair cross-complementing rodent repair deficiency, complementation group 2 
ERCC3 Excision repair cross-complementing rodent repair deficiency, complementation group 3  
ERCC4 Excision repair cross-complementing rodent repair deficiency, complementation group 4 
ERCC5 Excision repair cross-complementing rodent repair deficiency, complementation group 5 
ERCC6 Excision repair cross-complementing rodent repair deficiency, complementation group 6 
ERCC8 Excision repair cross-complementing rodent repair deficiency, complementation group 8 
EXO1 Exonuclease 1 
FEN1 Flap structure-specific endonuclease 1 
LIG1 Ligase I, DNA, ATP-dependent 
LIG3 Ligase III, DNA, ATP-dependent 
LIG4 Ligase IV, DNA, ATP-dependent 
MGMT O-6-methylguanine-DNA methyltransferase 
MLH1 MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) 
MLH3 MutL homolog 3 (E. coli) 
MMS19 MMS19 nucleotide excision repair homolog (S. cerevisiae) 
MPG N-methylpurine-DNA glycosylase 
MRE11A MRE11 meiotic recombination 11 homolog A (S. cerevisiae) 
MSH2 MutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) 
MSH3 MutS homolog 3 (E. coli) 
MSH4 MutS homolog 4 (E. coli) 
MSH5 MutS homolog 5 (E. coli) 
MSH6 MutS homolog 6 (E. coli) 
MUTYH MutY homolog (E. coli) 
NEIL1 Nei endonuclease VIII-like 1 (E. coli) 
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NEIL2 Nei endonuclease VIII-like 2 (E. coli) 
NEIL3 Nei endonuclease VIII-like 3 (E. coli) 
NTHL1 Nth endonuclease III-like 1 (E. coli) 
OGG1 8-oxoguanine DNA glycosylase 
PARP1 Poly (ADP-ribose) polymerase 1 
PARP2 Poly (ADP-ribose) polymerase 2 
PARP3 Poly (ADP-ribose) polymerase family, member 3 
PMS1 PMS1 postmeiotic segregation increased 1 (S. cerevisiae) 
PMS2 PMS2 postmeiotic segregation increased 2 (S. cerevisiae) 
PNKP Polynucleotide kinase 3'-phosphatase 
POLB Polymerase (DNA directed), beta 
POLD3 Polymerase (DNA-directed), delta 3, accessory subunit 
POLL Polymerase (DNA directed), lambda 
DNA-PKcs Protein kinase, DNA-activated, catalytic polypeptide 
RAD18 RAD18 homolog (S. cerevisiae) 
RAD21 RAD21 homolog (S. pombe) 
RAD23A RAD23 homolog A (S. cerevisiae) 
RAD23B RAD23 homolog B (S. cerevisiae) 
RAD50 RAD50 homolog (S. cerevisiae) 
RAD51 RAD51 homolog (S. cerevisiae) 
RAD51B RAD51 homolog B (S. cerevisiae) 
RAD51C RAD51 homolog C (S. cerevisiae) 
RAD51D RAD51 homolog D (S. cerevisiae) 
RAD52 RAD52 homolog (S. cerevisiae) 
RAD54L RAD54-like (S. cerevisiae) 
RFC1 Replication factor C (activator 1) 1, 145kDa 
RPA1 Replication protein A1, 70kDa 
RPA3 Replication protein A3, 14kDa 
SLK STE20-like kinase 
SMUG1 Single-strand-selective monofunctional uracil-DNA glycosylase 1 
TDG Thymine-DNA glycosylase 
TOP3A Topoisomerase (DNA) III alpha 
TOP3B Topoisomerase (DNA) III beta 
TREX1 Three prime repair exonuclease 1 
UNG Uracil-DNA glycosylase 
XAB2 XPA binding protein 2 
XPA Xeroderma pigmentosum, complementation group A 
XPC Xeroderma pigmentosum, complementation group C 
XRCC1 X-ray repair complementing defective repair in Chinese hamster cells 1 
XRCC2 X-ray repair complementing defective repair in Chinese hamster cells 2 
XRCC3 X-ray repair complementing defective repair in Chinese hamster cells 3 
XRCC4 X-ray repair complementing defective repair in Chinese hamster cells 4 
XRCC5 X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-
break rejoining) 
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APPENDIX C. Other related DNA repair genes under-
expressed in BRCA1 deficient cell lines compared to 
BRCA1 proficient cell lines.   
 
 
 Fold Change P Value Fold Change P Value 
Other related DNA repair genes  
 BRCA1 knockdown cell 
compared to Control cells 
MDA-MB-436 cells compared 
to MCF7 cells 
ATR 0.8129 0.622017 0.1521 0.00402 
EXO1 0.7888 0.572304 0.143 0.002984 
MGMT 0.3817 0.022209 0.2671 0.043123 
RAD18  0.7589 0.511457 0.2366 0.02729 
RFC1  0.7687 0.531243 0.4667 0.242016 
TOP3A  0.7281 0.450213 0.2772 0.049293 
TOP3B 0.6541 0.312452 0.3977 0.1571 
MRE11A 0.7363 0.466241 0.1613 0.005307 
MMS19 0.7137 0.422161 0.3424 0.100227 
TDG 1.1639 0.717939 0.147 0.003411 
 
APPENDIX D. Evaluation of drug interaction 
 
     Isobologram, combination index and curve shift analysis are useful methods 
for analyzing drug-drug interaction, and provide complimentary information. 
 
Isobologram analysis: The isobologram analysis provides a graphical 
presentation of the nature of interaction of two drugs (e.g. drug A and drug B). 
Firstly, in a two-coordinate plot with one coordinate representing concentration 
of drug A (IC50(A)) and the other representing concentration of drug B (IC50(B)), 
the concentrations of drugs A and B required to produce a defined effect x, 
XRCC6 X-ray repair complementing defective repair in Chinese hamster cells 6 
XRCC6BP1 XRCC6 binding protein 1 
 Statistical significance determined using the Bonferroni correction for 
multiple testing, with p values less than 0.05 (threshold p < 0.000595 = 
0.05/84).   
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when used as single agents, are placed on the X and Y axes, respectively. The 
line of additivity is constructed by connecting these two points. Secondly, the 
concentrations of the two drugs used in combination to provide the same effect 
x, denoted by point (C (A, X), C (B, X)), are placed in the same plot. Synergy, 
additivity, or antagonism is indicated when this point is located below, on, or 
above the line, respectively. 
 
Combination index analysis: Combination index (CI) provides a quantitative 
measure of the extent of drug interaction at a given effect level. That is, the 
combination concentrations of first drug (A) and second drug (B) to produce 
an effect (D), combination drugs are normalized by their corresponding 
concentrations that produces the same effect as a single agent (Chou and 
Talalay, 1984). This is a useful method for analysing drug-drug interactions 
(Zhao et al., 2010). The effect of the combined treatment is analysed for the 
combination of drugs by applying the following CI equation: (Ac/Ae) + 
(Bc/Be) = D, where Ac and Bc correspond to the concentrations of drugs used 
in the combination treatment, and Ae and Be corresponds to the concentrations 
of drugs able to produce the same effect by themselves. CI is considered 
synergistic if D (combination index) is < 1, whereas considered additive if D = 
1 or antagonistic if D is > 1.  
 
Curve shift analysis: Curve shift analysis allows simultaneous presentation of 
the studied concentration-effect curves of single agent and combination 
treatments in a single plot. The effects of combination therapy can be analysed 
by applying the following equation: 
 
 
Where Emax is the full range of drug effect; CA,x or CB,x is the IC50-equivalent 
concentration of drug A or B in combination; IC50 is the drug concentration 
producing the median effect of 50%; and n is the curve shape parameter 
describing the steepness of the concentration-effect relationship; IC50, X is the 
IC50 value of drug X; IC50,combo and ncombo are the values for the combination 
therapy. 
Plotting the effects of both single agents and combinations against (IC50-
equivalent drug concentrations) enables the simultaneous presentation of these 
concentration effect curves in a single plot. Due to the normalization, the 
curves for the single agents will have an IC50 value of one, while synergistic 
combinations will have a lower IC50 value resulting in a leftward shift, and 
antagonistic combinations will show a rightward shift (Zhao et al., 2010). 
